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Sažetak
Kao važan dio urođenog imunološkog sustava svih živih bića, antimikrobni peptidi, smatraju se
možebitnim riješenjem u brobi protiv bakterija otpornih na standardne antibiotike. Važna osobina dobrog
kandidata za budući lijek njegova je selektivnost, koja se određuje kao omjer koncentracije pri kojoj se
opaža 50%-tna hemolitična aktivnost prema eritrocitima i minimalne inhibitorne koncentracije pri kojoj se
opaža 100%-tna inhibicija rasta bakterije Escherichije coli. Algoritmom „Designer“ dizajnirani su adepantini
– veoma selektivni umjetni peptidi u konformaciji  uzvojnice, bogati glicinom i lizinom, a sličnost njihovih
sekvenci s poznatim antimikrobnim peptidima manja je od 50%. Algoritam je koristio našu bazu podataka
antimikrobnih peptida iz anura s poznatim indeksom selektivnosti.
Eksperimentalnim i računalnim metodama istražene su strukture i aktivnosti monomera, dimera i
fluorescentno označenih oblika adepantina. Eksperimentalna istraživanja provedena na različitim sojevima
bakterija pokazala su visoku selektivnost adepantina prema Gram-negativnim bakterijama (MIC = 0.5 - 4
µM), naročito prema E. coli. U mjerenju propusnosti membrana rabljeni su različiti modeli membrana, a
pokazalo se da adepantini vrlo brzo povećavaju propusnost obje membrane E. coli. Time je dobiven uvid u
mehanizme djelovanja adepantina. Svi monomeri adepantina imaju izrazito malu hemolitičnost prema
eritrocitima, dok su dimeri pokazali određenu toksičnost prema ljudskim stanicama. Dokazano je da se
adepantini vežu na staničnu površinu ljudskih stanica bez popratnog oštećenja membrane. Prikupljeni
rezultati potvrdili su adepantine kao jako selektivne umjetne peptidne antibiotike.
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As an important part of the innate immune system of all organisms, antimicrobial peptides, are
considered as a possible solution for fighting bacteria resistant to standard antibiotics. Crucial
characteristic of peptide antibiotic, as drug candidate is its high selectivity, parameterized as the ratio of
concentration causing 50% haemolysis (HC50) against erythrocytes and the minimal inhibitory
concentration (MIC) against the reference bacterium Escherichia coli. Using the “Designer” algorithm
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helical conformation, having less than 50% homology of primary sequence to any known sequence of
antimicrobial peptides. The algoritham used our database of anuran antimicrobial peptides with known
selectivity index.
Structure and activity of adepantins were experimentally and computationally tested in their
monomeric, dimeric and fluorescently labelled form. Experimental investigations performed on different
bacteria strains showed high selectivity of adepantins for Gram-negative bacteria (MIC = 0.5 - 4 µM),
especially E. coli. In membrane permeabilization measurements, different membrane models were used
and adepantins showed rapid permeabilization of both membranes of E. coli. These tests provided insight
in their mode of action. All monomeric adepantins have exceptionally low haemolytic activity, while
dimers expressed certain toxicity against host cells. It is proven that adepantins bind efficiently to the cell
surface of the host cell membranes without subsequent membrane damage. Gathered results confirmed
that adepantins are indeed highly selective artificial peptide antibiotics.
Number of pages: 145
Number of figures: 36
Number of tables: 20
Number of references: 97 + 15
Number of appendices: 8
Original in: English
Thesis deposited at The National and University Library in Zagreb, Croatia, University Library in Split,
Croatia, Library of Faculty of Science of the University of Split, Croatia.
Keywords: antimicrobial peptides, computational design, selectivity index, adepantins, helical peptides,
Escherichia coli, membrane permeabilization, low toxicity, anuran
Supervisors: Prof.Dr. Davor Juretić, full profesor, Faculty of Science, University of Split, Croatia
Prof.Dr. Alessandro Tossi, associate professor, University of Trieste, Italy
Reviewers: Prof.Dr. Jasna Puizina, associate professor, Faculty of Science, University of Split, Croatia
Dr. Bono Lučić, higher research associate, Ruđer Bošković Institute, Zagreb, Croatia
Doc.Dr. Stjepan Orhanović, assistant profesor, Faculty of Science, University of Split, Croatia
Thesis accepted: 12. 06. 2013.

Sveučilište u Splitu, Prirodoslovno-matematički fakultet
Odjel za fiziku, Poslijediplomski sveučilišni doktorski studij Biofizika
“Dizajn i testiranje adepantina – novih peptidnih antibiotika”
Doktorski rad autorice Nade Ilić kao dio obaveza potrebnih da se dobije doktorat znanosti
_______________________ godine.
Dobiveni akademski naziv i stupanj: doktorica prirodnih znanosti iz polja kemije.
Povjerenstvo u sastavu:
1. prof.dr.sc Jasna Puizina, predsjednik
2. prof.dr.sc. Davor juretić, mentor
3. prof.dr.sc. Alessandro Tossi, komentor
4. dr.sc. Bono Lučić, član
5. doc.dr.sc. Stjepan Orhanović, član
prihvatilo je izrađeni doktorski rad dana ____________________________.
Obrana disertacije održati će se ____________________________.
Predsjednik povjerenstva:
________________________
prof.dr.sc Jasna Puizina
Voditelja studija:
________________________
prof.dr.sc. Davor Juretić
Predsjednik vijeća studija:
________________________
prof.dr.sc. Vlasta Bonačić-Koutecky

Sveučilište u Splitu, Prirodoslovno-matematički fakultet
Odjel za fiziku, Poslijediplomski sveučilišni doktorski studij Biofizika
Povjerenstvo za obranu doktorskog rada u sastavu:
1. prof.dr.sc Jasna Puizina, predsjednik ______________________________
2. prof.dr.sc. Davor juretić, mentor ______________________________
3. prof.dr.sc. Alessandro Tossi, komentor ______________________________
4. dr.sc. Bono Lučić, član ______________________________
5. doc.dr.sc. Stjepan Orhanović, član ______________________________
Potvrđuje da je disertacija obranjena dana 12. srpnja 2013. godine.
Dekan
_____________________
prof.dr.sc Marko Rosić

ITable of Contents
Table of Contents .....................................................................................................................................I
List of Figures..........................................................................................................................................III
List of Tables......................................................................................................................................... VII
List of appendices.................................................................................................................................. IX
List of abbreviations ............................................................................................................................... X
List of bacteria used .............................................................................................................................. XI
1. Introduction.........................................................................................................................1
1.1. Antimicrobial peptides – basic information ........................................................................ 1
1.1.1. Hydrophobicity and hydrophobic moment..................................................................... 3
1.1.2. AMP mode of action........................................................................................................ 4
1.2. New approaches in AMP research – databases and algorithms construction.................... 6
1.3. About the thesis .................................................................................................................. 8
1.4. Hypothesis and goals of the thesis...................................................................................... 8
2. Materials and methods .....................................................................................................11
2.1. Construction of an AMP activity database (AMPad) and relevant algorithms ................. 11
2.1.1. The AMPad database..................................................................................................... 11
2.1.2. Sets of peptides from the AMPad database.................................................................. 11
2.1.3. „PredictorSelector“ algorithm....................................................................................... 12
2.1.4. „Designer“ algorithm..................................................................................................... 14
2.2. SPPS (solid phase peptide synthesis) of designed peptides.............................................. 15
2.2.1. Selection of peptides for synthesis................................................................................ 15
2.2.2. Synthesis difficulty prediction ....................................................................................... 16
2.2.3. Solid phase synthesis..................................................................................................... 16
2.2.4. Cleavage and workup .................................................................................................... 18
2.3. Peptide characterization and purification......................................................................... 19
2.3.1. ESI-MS (electro spray ionization mass spectrometry)................................................... 20
2.3.2. RP - HPLC ....................................................................................................................... 22
2.3.3. Peptide modification (acetamidation, dimerization, bodipylation) .............................. 22
2.3.3.1. Blocking of cysteine by iodoacetamidation........................................................... 22
2.3.3.2. Covalent dimerization ........................................................................................... 24
2.3.3.3. Bodipylation - Fluorescent labelling with BODIPY maleimide............................... 25
2.3.4. Quantification................................................................................................................ 27
II
2.4. Structure analysis .............................................................................................................. 29
2.4.1. CD spectroscopy in different solvents........................................................................... 30
2.4.2. Preparation and use of liposomes................................................................................. 31
2.5. Antimicrobial activity assays ............................................................................................. 33
2.5.1. MIC assays ..................................................................................................................... 33
2.5.2. MBC assays .................................................................................................................... 35
2.5.3. Effect of AMPs on bacterial growth kinetics and IC50.................................................... 36
2.5.4. Barrier effect of outer membrane – permeabilization kinetics .................................... 37
2.6. Bacterial membrane permeabilization assays................................................................... 38
2.6.1. Spectroscopic analysis of permeabilization to chromogenic substrates ...................... 39
2.6.2. Flow cytometric analysis of permeabilization to PI....................................................... 40
2.7. Interaction of peptides with host cells .............................................................................. 41
2.7.1. Haemolysis assay........................................................................................................... 41
2.7.2. Flow cytometric analysis of cellular AMP uptake.......................................................... 43
3. Results ...............................................................................................................................45
3.1. Peptide sets derived from the AMPad database............................................................... 45
3.2. From designed to synthesized peptides............................................................................ 54
3.3. High yields and purity of the adepantins and modified analogues................................... 57
3.4. Confirmed secondary structure......................................................................................... 62
3.5. Effects of adepantins on bacterial cells............................................................................. 67
3.6. Effects of adepantins on host cells.................................................................................... 75
4. Discussion ..........................................................................................................................81
5. Conclusion .........................................................................................................................85
6. References (alphabetical order) ........................................................................................87
6.1. Web link references (in order of appearance) .................................................................. 95
CV and list of publications .....................................................................................................................97
Abstracts ...........................................................................................................................................99
Acknowledgements .............................................................................................................................101
Appendices .........................................................................................................................................103
III
List of Figures
Figure 1. Helical AMP interaction with biological membranes; in bulk solution peptides are
random coil, while in the presence of membrane they structure as amphipathic
 helices; the peptides’ subsequent insertion into the membrane is then more
likely to result in toroidal pore formation than in a classical barrel-stave pore. ................5
Figure 2. Example preparative HPLC chromatogram for ADP2(AM) peak showing fractions
expected to contain pure targeted peptide, in this case fractions 5 - 7; X axes –
time in minutes, Y axes – absorbance inmAU (milli absorbance units). ..........................21
Figure 3. Adepantins 2 and 3 in amidated form; cysteine on C-terminus is blocked. AA
coloured in red represent difference from the ADP1 sequence. Note that by
amidating the C-terminus, a negative charge is removed, so that the overall
charge increases by +1. .....................................................................................................23
Figure 4. Adepantins 2 and 3 in dimerised form, connections achieved with disulphide
bridge between cysteines on C-terminus. AA coloured in red represent difference
from the ADP1 sequence...................................................................................................25
Figure 5. Adepantins 2 and 3 labelled with BODIPY maleimide on cysteines at the C-
terminus. AA coloured in red represent difference from the ADP1 sequence. ................26
Figure 6. BODIPY molecule and its reaction with SH group in the Cysteine side chain. ..................27
Figure 7. Scheme for vesicles in different sizes; MLV = multi lamellar vesicles are large
“onion-like” structures, SUV = small unilamellar vesicle, 15-30 nm in diameter,
unstable and tending to fuse spontaneously at temperatures below phase
transition temperature; LUV = large unilamellar vesicles, 100-200 nm or larger in
diameter, stable on storage. .............................................................................................31
Figure 8. Scheme of mini-extruder (Avanti Polar Lipids, Alabaster, AL) (as in Web link [13]) .........33
Figure 9. Lipopolysaccharide (LPS) structure in E. coli with genes involved in its synthesis; *
predicted activity of the waaP gene product (as in Yethon and Whitfield, 2001)............38
Figure 10. Propidium iodide (IP) molecule (as in Web link [14])........................................................40
Figure 11. Relationship between peptide length and number of peptide entries in the whole
AMPad database, “training” and “testing” sets and “set of the best peptides”
(SBP). .................................................................................................................................47
Figure 12. Distribution of the peptides in the AMPad database divided in three sets
considering peptide length by number of AA and experimental TI value; SBP („set
of the best peptides“) constructed from peptides included in both sets that have
TI greater than 20. .............................................................................................................48
Figure 13. Example of the results given by Virginia university helical wheel application (Web
link [1]) and HydroMCalc tool (Web link [8]); Aschapin1 was used for
experimental testing, as very selective antimicrobial peptide. Separation
between hydrophilic and hydrophobic AA is clearly visible..............................................52
IV
Figure 14. Sequence moments for adepantins 1, 2 and 3; small arrows are calculated by
using amino acids index scales (Appendix 2, Appendix 3, Appendix 4), red for
Janin’s (Janin 1979) scale and blue for Guy’s (Guy 1985) scale; sum of the small
vectors result in sequence moments presented by the large vectors; angle
between sequence moments is used to calculate D-descriptor as the cosine of
that angle...........................................................................................................................53
Figure 15. Cladogram tree from Clustal W tool showing sequence alignment of 7 resulting
peptides from the „Designer“ algorithm; Seq4 was later called adepantin 2 and is
most similar to adepantin 1; Seq1 later called adepantin 3 and is most different
from adepantin 1...............................................................................................................55
Figure 16. Prediction of the synthesis difficulty for ADP1 by Peptide companion tool. Most
AA are between upper two lines indicating difficult synthesis. ........................................56
Figure 17. ESI-MS analysis of adepantins, A) ADP2, B) ADP3.............................................................58
Figure 18. ESI-MS molecular weight analysis of A) ADP2(AM) and B) ADP3(AM) .............................59
Figure 19. ESI-MS molecular weight analysis of A) [ADP2]2 and B) [ADP3]2 ......................................60
Figure 20. ESI-MS molecular weight analysis of A) ADP2(BY) and B) ADP3(BY). Graphs
contain two peaks where lower peek represents correct one for bodipylated
peptide while higher one is a “shadow peak” that can often be noticed during
MS analysis of fluorescently labelled peptides possibly due to loss of one fluorine
under ESI conditions..........................................................................................................61
Figure 21. CD spectra of ADPs (20 M of peptide) measured in A) H2O and B) sodium
phosphate buffered (SPB, 10 mM); ADP1(); ADP2(AM) (  ); [ADP2]2
(); ADP2(BY) (-----); ADP3(AM) ( - - -); [ADP3]2 (); ADP3(BY) ()..................63
Figure 22. CD spectra of ADPs (20 M of peptide chain) measured in A) phosphate buffered
saline (PBS, pH7.4), B) 50% trifluoroethanol (TFE) and C) 50% isopropanol
(iPrOH); ADP1(); ADP2(AM) (  ); [ADP2]2 (); ADP3(AM) ( - - -);
[ADP3]2 ().................................................................................................................63
Figure 23. Helix % with increasing TFE; ADP1 ; ADP2(AM) ; [ADP2]2 :
ADP3(AM); [ADP3]2 . ..................................................................................65
Figure 24. CD spectra of ADPs (20 M of peptide chain) measured in A) 1:1
phosphatidylglicerol/ diphosphatidtylglicerol LUVs in PBS (PG/dPG) and B) 2:2:1
phosphatidylcholine/ sphingomyelin/cholesterol LUVs in PBS (PC/SM/Ch);
ADP1(); ADP2(AM) (  ); [ADP2]2 (); ADP3(AM) ( - - -); [ADP3]2
(). .............................................................................................................................67
Figure 25. Example of MIC results for E. coli all ADPs; rows: ADP1, ADP2(AM), [ADP2]2,
ADP2(BY), ADP3(AM), [ADP3]2, ADP3(BY), empty; columns: 1st – 11th peptide +
bacteria + MH starting with concentration 128 µM and decreasing by two-fold
dilution method, 12th negative control = bacteria + MH; white dots on the
bottom of the well is grown bacteria. ...............................................................................68
Figure 26. Example of MIC results for S. aureus all ADPs; rows: ADP1, ADP2(AM), [ADP2]2,
ADP2(BY), ADP3(AM), [ADP3]2, ADP3(BY), empty; columns: 1st – 11th peptide +
Vbacteria + MH starting with concentration 128 µM and decreasing by two-fold
dilution method, 12th negative control = bacteria + MH; white dots on the
bottom of the well is grown bacteria. ...............................................................................69
Figure 27. A) Curves from data collected after growth kinetics for E. coli monomers at
concentration 1 M and dimers at concentration 0.5 M; B) inhibition
percentage at 210 min extracted from growth curves; Bacteria control ();
adepantins ADP1 (, ); ADP2(AM) (  , ); ADP3(AM) (- - -,
); [ADP2]2 (,); [ADP3]2 (,)............................................70
Figure 28. Effect of A) ADP2(AM) and B) [ADP2]2 on growth kinetics of E. coli (1), P.
aeruginosa (2), K. pneumoniae (3) and S. typhimurium (4), experiments were
done three times in triplicates. .........................................................................................71
Figure 29. Effect of ASC1, PSEU2 and ADP1 on growth kinetics of E. coli; PSEU2  ;
ASC1  ; ADP1  ; mean of two experiments performed in triplicates
(Juretić et al., 2009). ..........................................................................................................72
Figure 30. Growth kinetics of A) E. coli BW 25113 strain and B) E. coli BW 25113 waaP
strain affected by adepantins (ADP1 ; ADP2(AM) ; [ADP2]2  ;
ADP3(AM) ; [ADP3]2 ). ................................................................................73
Figure 31. Permeabilization of the inner and outer membrane of E. coli ML-35 pYC by ADPs
determined by following the hydrolysis of the impermeant chromogenic
substrate A) Gal-ONp by a cytoplasmic -galactosidase and B) CENTA® by the
periplasmic enzyme -lactamase respectively (no peptide  ; ADP1 ;
ADP2(AM) ; [ADP2]2 ; ADP3(AM) ; [ADP3]2). ......................74
Figure 32. Permeabilization of E. coli ATCC 25922 (106 cells/ml) inner membrane caused by
ADPs (0.25 M) and determined by % of PI-positive bacterial cells by flow
cytometric analyses; (ADP1  ; ADP2(AM)  ; [ADP2]2  ;
ADP2(BY) ; ADP3(AM) ; [ADP3]2 ; ADP3(BY)). ....................75
Figure 33. Adepantin-induced haemolysis on 0.5% RBC; ADP1  ; ADP2(AM)  ;
[ADP2]2  ; ADP3(AM)  ; [ADP3]2  ; Results are from four
experiments carried out in triplicate.................................................................................76
Figure 34. Pseudin and ascaphin-induced haemolysis on 0.5% RBC; PSEU2  ; PSEU2
A9  ; ASC1  ; ASC1 I2  ; Results are from two experiments
carried out in triplicate......................................................................................................78
Figure 35. ADPs interaction with U937 cells, as measured by flow cytometry, presented on
monoparametric histograms; A) ADP2(BY) and B) ADP3(BY) demonstrates the
effect after 5 minutes where the black line is control, the green line is peptide at
concentration 0.1M and the red line is peptide at concentration 1M; C)
ADP2(BY) and D) ADP3(BY) where empty curve is for U937 cells in the absence
and filled curve in presence of ADPs (1M) while dashed line represents U937
cells with ADPs and the impermeant, extracellular quencher Trypan blue added...........79
Figure 36. Fluorescence dot plots expressing results of monitoring fluorescence at 525 nm
(BODIPY) and 610 nm (PI) on the flow cytometer for human leukemic monocytes
VI
(U937, 106 cells/ml) treated with peptides (1 M) A) ADP2(BY) or B) ADP3(BY)
and PI for 30 min at room temperature before treating cells with Trypan blue. .............80
VII
List of Tables
Table 1. Resulting sequences (seq) of the „Designer“ algorithm with original restrictions;
sequences are ordered as „Designer“ algorithm offered; adepantin 1 (ADP1),
adepantin 2 (ADP2), adepantin 3 (ADP3); red letters represent amino acid (AA)
residues that are different considering adepantin 1; the complete result with
calculated parameters is presented in Table 9, on page 53................................................7
Table 2. Peptides and their variations used to test an early version of the „Mutator“
algorithm as well as to be referent peptides to the study of adepantins. ..........................8
Table 3. Cleavage mixtures for different types of peptides (Web link [11])...................................17
Table 4. Calculation for the volume of TFE to be added to the peptide in order to
calculate percentage of  helix. ........................................................................................31
Table 5. Example of microtiter plate preparation for MIC assay; a) 100 l MH – x l of
peptide; b) 50 l of MH where peptide was later added; c) 50 l of MH without
peptide that serves as a bacterial growth control; concentrations in B row
represents final peptide concentration in those wells achieved by serial two-fold
dilution. .............................................................................................................................35
Table 6. Example of microtiter plate preparation for bacterial growth kinetic; First column
is negative control containing bacteria with medium without peptide; each
peptide has 3-5 concentrations in triplicates; well 12H contains only 200 l 100 %
MH as a blank to avoid any possible background noise....................................................37
Table 7. “Set of the best peptides” (SBP) where the first 15 peptides are from the
“testing” set and the last 11 peptides from the “training” set, in both cases
ordered by descending value of TI. ...................................................................................46
Table 8. Three descriptors with the highest correlation found by „PredictorSelector“.
Although D-descriptor (in the second row) has slightly lower correlation than the
first one, it was chosen because it is much simpler than the first one. For codes
of the used scales see Appendix 5. Correlation is among descriptor values and
experimentally determined TI values for peptides in the “training” set. .........................50
Table 9. Output adepantin sequences from the „Designer“ algorithm. .........................................54
Table 10. Theoretical and measured yields of ADP2 and ADP3 with and without resin. .................57
Table 11. Theoretical and measured MW and yields of ADP1, unmodified ADP2 and ADP3,
ASC1 and ASC1 I2, PSEU2 and Pseu2 A9. ..........................................................................58
Table 12. ADP2 and ADP3 modifications with its theoretical versus measured MW and
their yields; for ADP2(AM) and [ADP2]2 modification reaction was performed
twice, therefore, the yields are higher. .............................................................................59
Table 13. Mass concentration of peptides tested in the first set of tests. .......................................62
Table 14. Results of methods used for determining concentration of adepantins. .........................62
Table 15. % helicity of ADPs in different environments according to the method of Reed
and Reed 1997. Peptides were 20 M in H2O, 50% trifluoroethanol (TFE), anionic
VIII
LUV (PG/dPG = phospatidylglycerol/diphospatidylglycerol; 95:5) and neutral LUV
(PC/SM/Ch = phospatidylcholine/sphingomyelin/cholesterol; 2:2:1) in PBS buffer.
Dimerization was taken into account by normalising ellipticity per residue. (1)No
corrections for the presence of the BODIPY chromophore were made (% helicity
shown in parentheses). .....................................................................................................66
Table 16. MIC values for adepantins, pseudins and ascaphins; (1)assays were carried out in
100% (v/v) MH broth using 5x105 cells/ml bacteria in the logarithmic phase; each
value is the mean of at least 3 independent determinations carried out in
duplicate. ...........................................................................................................................68
Table 17. MBC (minimal bactericidal concentration), (1) Concentration resulting in no
bacterial growth, 2 independent determinations carried out in duplicate. .....................70
Table 18. IC50 value of peptides; (1) Concentration resulting in 50% growth inhibition of
bacteria, calculated from data in figure (Figure 27)..........................................................71
Table 19. IC50 value of ADP2(AM) and [ADP2]2 measured for the following bacteria: E. coli,
P. aeruginosa, K. pneumoniae and S. typhimurium; (1) Concentration resulting in a
50% growth inhibition of bacteria, calculated from data in figure (Figure 28).................72
Table 20. Haemolytic, MIC and TI values for tested peptides; Haemolytic activity tested for
peptides, expressed as HC50 value; (1) determined from Figure 33 and Figure 34;
MIC values from Table 16; TI value calculated from experimental data (TI
calculated) and predicted one (TI predicted); (2) For ADP1, the first value is from
second set of tests together with other ADPs, while the second value is from the
first set of tests when only ADP1 was tested along with PSEU2 and ASC1. (3)
Values are for original peptide sequence not iodoacetamidated one..............................77
IX
List of appendices
Appendix 1. “Set of AMPad peptides” (SAP) that forms AMPad database.........................................105
Appendix 2. Contribution to the sequent moment of each AA for Janin and Guy scale - ADP1.........107
Appendix 3. Contribution to the sequent moment of each AA for Janin and Guy scale - ADP2.........108
Appendix 4. Contribution to the sequent moment of each AA for Janin and Guy scale - ADP3.........109
Appendix 5. Table of amino acid scales from Split 3.5 algorithm [7] used for finding D-
descriptor ........................................................................................................................110
Appendix 6. Preparative RP-HPLC spectra for ADP2(AC) (both synthesis), [ADP2]2 (both
synthesis), ADP2(BY), ADP3(AC), [ADP3]2, ADP3(BY) ......................................................115
Appendix 7. Analytical RP-HPLC for ADP1 (first testing name was DESC1) ADP2(AC), [ADP2]2,
ADP2(BY), ADP3(AC), [ADP3]2, ADP3(BY), all graphs overlapped for comparison. .........123
Appendix 8. ESI - MS and Analytical RP-HPLC for ADP1 (first testing name was DESC1), PSEU2
(first testing name was PSEU2B), PSEU2 A9 (first testing name was PSEU2A),
ASC1 (first testing name was ASC1B), ASC1 I2 (first testing name was ASC1A)..............131
XList of abbreviations
AA(s) – amino acid(s)
ADP(s) – adepantin(s)
AMP(s) – antimicrobial peptide(s)
Cfu – colony forming units /ml
Conc. or c. - concentration
HC50 – concentration that causes 50% haemolysis of RBC
MilliQ H2O - ultrapure laboratory grade water
HPD(s) – host defence peptide(s)
IC50 – half maximal inhibitory concentration (for bacterial growth)
LPS - Lipopolysaccharides
MLV - multi lamellar vesicles, large “onion-like” structures
LUV - large, unilamellar vesicles
M – Mol (mM – milli mol; M – micro mol)
MIC – minimal inhibitory concentration
MW – molecular weight
OD – optical density
PG/dPG – Phosphatidylglicerol/Diphosphatidylglicerol
PC/SM/Ch – Phosphatidylcholine/Sphingomyelin/Cholesterol
Pbf – 2,2,4,6,7-pentamethyldihydrobenzofuran-5-sulfonyl
RBC – red blood cells, erythrocytes
SPPS - solid phase peptide synthesis
SUV - small, unilamellar vesicles or sonicated, unilamellar vesicles
TI - therapeutic index
XI
List of bacteria used
Escherichia coli
 ATCC25922
 BW2553
 Waap-BW2553
 ML-35pYC
Staphylococcus aureus
 ATCC25923
Pseudomonas aeruginosa
 ATCC27853
Salmonella typhimurium
 ATCC14082
Klebsiella pneumoniae
 clinical isolate

Introduction Nada Ilić
1
1. Introduction
In the never ending battle against microbes, only recently has the ancient weapon
been rediscovered. Antimicrobial peptides (AMPs) have existed in nature for millions of
years and are still very functional in defending their producers against bacteria, fungi and
viruses (Bullet et al., 2004; Yeaman and Yount, 2007). Natural antimicrobials are produced by
unicellular and multicellular organisms to act directly on microbes or to profoundly
modulate innate immune system response. In the case of direct action, the suggested term
for this agents is “antimicrobial peptide”, while in the case of modulating or enhancing the
host immune response to infectious agents, the term “host defence peptide” has been
suggested (Fjell et al., 2012). Antibiotics in current use present a negative side effect: the
explosion of the resistant bacteria that do not respond to any kind of antimicrobial
treatment (Taubes, 2008; McKenna, 2011). Therefore, a new kind of antibiotics is desired.
Antimicrobial peptides present one of the possible solutions showing promising results.
Natural AMPs are however not sufficiently selective for direct use on humans. To improve
this, most AMP alterations have been made according to experts’ experience or just plain
guessing. Even so, the increase in antibacterial activity, measured as a reduction in MIC
(minimal inhibitory concentration), has in most instances increased toxicity as well measured
as an increase in HC50 (peptide concentration that causes 50% haemolysis of erythrocytes).
This effect has discouraged the pharmaceutical industry, where the requirement for good
drugs with low side effects and toxicity is of the utmost importance.
AMPs are interesting research material due to low probability for bacteria to gain
resistance to them; they tend to be fairly selective in killing bacteria cells. They mantain this
ability also against pathogens, multidrug resistant to conventional antibiotics, having a
predominantly nonstereospecific mechanism of action against bacterial membranes
(Hancock and Lehrer 1998; Glukhov et al., 2005; Marr et al., 2006). Due to these advantages
of AMPs, many laboratories have engaged in AMP research over the past decades (Hancock
and Sahl 2006; Bommarius and Kalman 2009; Zhang and Falla 2010). The growing amount of
data available on several interesting characteristics of AMPs, has led to the necessity for
constructing databases and computational tools for predicting novel and improving existing
AMPs (Juretić et al., 2009; Juretić et al., 2011; Aoki et al., 2012; Hammami and Fliss 2010;
Novković et al., 2012).
1.1. Antimicrobial peptides – basic information
Our body uses several ways to defend itself against pathogens that are constantly
attacking its integrity. An interesting and very efficient way of the body to protect itself is by
using AMPs (antimicrobial peptides) and HDPs (host defence peptides). Both have
extraordinary molecular diversity, differing in length from 12 to hundreds of AA residues and
belonging to several structural classes.
HDPs are natural and endogenous, gene-encoded polypeptides and are widely
distributed among all known kingdoms: animal, plant and bacteria. The fact that they are
gene encoded connects their evolution with that of their microbial targets. This, and the fact
that they are evolutionary very ancient components of the innate immune system of many
species (Zasloff, 2002), has resulted in such molecular diversity. Some HDPs are active
against eukaryotic micro- and macro-predators as well.
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Unlike HDP notation, which is reserved for endogenous molecules of host defence,
the term AMP is used to describe both natural and synthetic peptides showing antimicrobial
activity. They therefore have even greater variety in their structure (Yeaman and Yount,
2003) but generally tend to be shorter in length than HDPs, consisting of 10 to approximately
46 AA. HDPs and natural ADPs not only differ widely in their primary structure within and
among the different producer organism, but there is also a great diversity in their secondary
structure. Those found so far are forming  helices,  sheets,  hairpins, random coil or
combine more than one of the mentioned structures. The most abundant and widespread in
nature are probably those with a linear  helical structure that appears to be particularly
successful in defending their producing organism. These AMPs are invariably positively
charged (+2 to +9), with the possibility to spatially organise cationic and hydrophobic amino
acids (AA) on the opposite faces of the helix, a hydrophobic side and a polar side. This effect
is nicely visible in an Edmundson or “helical wheel” projection (Schiffer and Edmundson
1967) (Web link [1]). This results in a transversal amphipathicity, and enables peptides to
interact with both water and biological membranes. Change in the amphipathicity influences
change in antimicrobial activity, but can increase toxicity towards mammalian cells with
neutral membranes (Dathe and Wieprecht 1999). All those characteristics have placed 
helical AMPs amongst the most studied antimicrobial peptides.
Possible modes of action AMPs use to defend the host organism are:
 Disruption of the microbial membranes, which are negatively charged and
selectively attract positively charged AMPs (primary antimicrobial
mechanism).
 Interaction with secondary targets in the cells by interrupting vital metabolic
processes, when translocated in the cell.
 Interference with external molecular targets on the microbial envelope and
causing severe damage. Targets can be lipids involved in cell-wall synthesis
and autolytic enzymes required for cellular division.
 Creating pores in the cytoplasmic membrane without disrupting it, but
provoking a decrease in the membrane potential, electrical field and proton-
motive force, which in turn blocks the ATP synthesis.
Outside the membrane, in aqueous bulk solution, many AMPs are in random coil or
extended conformation (Figure 1), while in the presence of phospholipid membrane or
membrane mimetic solvent they tend to assume more regular structures. As AMPs are
active when folded in their final secondary structure (Tam et al., 2001; Unger et al., 2001),
the mode of action is also defined by the membrane that peptides interact with. Cells,
depending on which organism they belong to, have differences in their membrane
composition, but peptides interact with all of them on the basis of electrostatic interactions.
AMPs selectivity is based on the difference between bacterial and mammalian cell
membranes (Aoki et al., 2012). Bacterial cells have anionic character, depending on
membrane components, and therefore attract cationic AMPs (Glukhov et al., 2005;
Umeyama et al., 2006). Along with membrane phospholipids, in Gram-negative bacteria,
important negative components of the surface are phosphate groups of membrane
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lipopolysaccharides in the outer membrane, while in Gram-positive bacteria negative
charges are contributed by lipoteichoic acids of the peptidoglycan. In mammalian cells
negative charge of the membrane is not strongly expressed, and the membrane is
additionally stabilized with an abundance of cholesterol reducing its susceptibility to AMPs
(Matsuzaki et al., 1995). Negatively charged phospholipids are much more abundant at the
external side of cytoplasmic membrane in bacteria than in human cells. This is one of the
main reasons why peptides act differently on various membranes, and is also the fact
researchers are trying to use in adjusting peptides for medical use.
The membrane electrochemical gradient is the result of unequal distribution of ions
inside and outside the cell membrane. Unequal ion distribution creates transmembrane
potential. Potential measured in bacterial cells is -130 to -150 mV, while in mammalian cells
it is -90 to -110 mV. This more highly negative transmembrane potential of bacterial
membrane can drive cationic peptide in the cell through the membrane, reducing their
concentration on the surface. The difference in membrane electrochemistry can contribute
to selective toxicity of AMPs targeting microbial and avoiding human cells, which would be
the perfect case. Considering differences of the membranes, it can be noticed that AMPs can
be selective for bacterial with respect to eukaryotic cells, as well as selective for Gram-
negative with respect to Gram-positive bacteria. Those variations can make AMPs potential
drugs with specific targets in possible future medical use.
1.1.1. Hydrophobicity and hydrophobic moment
Beside conformation and charge, other functionally important AMP properties are
hydrophobicity and hydrophobic moment.
Hydrophobicity (H) is the numerical value quantifying a dislike for water for each
amino acid side-chain. There are more than 100 hydrophobicity scales in the literature
differing in these values. Examples of the scales are Eisenberg consensus scale (Eissenberg at
al. 1984), Tossi CCS scale (Tossi at al. 2002), Janin (Janin 1979) and Guy (Guy 1985) scale. The
mean hydrophobicity (H) of the peptide is defined as the sum of hydrophobicity values of
each AA averaged over the total length of the peptide. Percentage of hydrophobic AA in the
peptide can also be defined as peptide hydrophobicity. For most AMPs approximately 50%
are hydrophobic AA that makes them moderately hydrophobic but quite amphipathic and
optimized against the membranes of the microbes (Yeaman and Yount 2003). A change in
the percentage of hydrophobicity can lead to a change in their specificity, as well as a change
in membrane permeabilization. The effect was tested on magainin2 and its analogues with
slight changes in hydrophobicity (Wieprecht et al., 1997).
Hydrophobic moment (H) is a quantitative measure of amphipathicity (Eisenberg
1984). It is defined for each AA residue as a vector, starting from the symmetry axis of the
helix and pointing towards C atom of the given AA residue, with the value of scalar
hydrophobicity parameter of the same residue. Mean hydrophobic moment of the peptide
is, then, the vectorial sum of the individual AA hydrophobicities, averaged over the helix
length. In some cases, it can be normalized to an ideal, perfectly amphipathic  helix.
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1.1.2. AMP mode of action
Helical AMPs are likely to be membrane active if: they have about 50% hydrophobic
AA residues in the primary structure, if they have a net positive charge deriving from at least
20% of charged AA in the sequence, and if they are amphipathic. Those characteristics
enable peptides to come into initial contact with the targeted membrane. Once bound to
the membrane, different AMPs have different modes of actions, but all are based on
membrane permeabilization and passage through the membrane. To activate any of the
processes, peptides need to reach threshold concentrations of the peptide, accumulated on
the outer leaflet of the membrane that enables peptides to damage the membrane itself,
following a conformational transition, and/or peptide aggregation. Peptide aggregation can
lead to formation of the pores in the membrane, enabling molecular transfer in the
damaged cell. Many AMPs act in this manner, as described by the Shai-Matsuzaki-Huang
(SHM) model (Zasloff 2002).
In the pores, the hydrophobic part of the peptide faces and inserts itself into the
membrane. The hydrophilic part initially faces the extracellular medium. After the pore is
formed, it faces the centre of the pore. There are many models of peptide permeabilization
through the membrane. This is the result of peptide diversity which leads to diversity in their
mode of action (Epand and Vogel 1999). Until now there is no consensus on the exact
mechanism, although three of them are most commonly used (Yeaman and Yount 2003, Shai
1999, Brogden 2005): barrel-stave, toroidal pore and carpet mechanism (Figure 1, carpet
mechanism is not shown). The name of each mechanism is derived from the shape of the
pore or type of lesion formed in the membrane.
Barrel-stave is formed when peptides (Oren and Shai 1998),  helical or  sheet, with
threshold concentration, bridge the membrane perpendicularly in the form of the barrel like
ring, while they are parallel among themselves. Toroidal pore or wormhole mechanism is the
most accepted one. Peptides are interlaced with phospholipids in the form of a toroid
through the whole pore (Figure 1), while the pores are slightly bigger than those of barrel-
stave. In the carpet mechanism, peptides act as detergents while “carpeting” the outer
membrane (Shai 1999, Epand and Vogel 1999, Brogden 2005). A particularity of this model is
that peptides cover the membrane like a carpet, whether locally by self-association or by
covering the whole membrane with monomers. Permeabilization starts with the threshold
concentration of the peptide reached, disrupting membrane to peptide covered micelles.
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bulk solution
membrane
hydrophobic
hydrophylic
Figure 1. Helical AMP interaction with biological membranes; in bulk solution peptides are random coil, while in
the presence of membrane they structure as amphipathic  helices; the peptides’ subsequent insertion
into the membrane is then more likely to result in toroidal pore formation than in a classical barrel-stave
pore.
Membrane penetration is not the only way AMPs can affect bacteria. There are
several other mechanisms. One of the mechanisms is targeting intercellular components,
similar to some classical antibiotics. Most of those mechanisms are based on inhibition, such
as inhibition of: enzymatic activity, cell wall synthesis, nucleic acids or protein synthesis, but
they also affect protein folding, key cellular processes, metabolic turnover (Nguyen et al.,
2011).
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1.2. New approaches in AMP research – databases and algorithms
construction
The field studying AMPs is relatively new and constantly developing. In order to
render peptide research easier and reduce the cost of further laboratory work it is
convenient to develop databases and computational tools as knowledge-based methods. As
every tool development in bioinformatics and data-mining, research starts with an extensive
data collection. In fact, several databases have been created collecting thousands of AMP
sequences, listed along with their characteristics (Hammami and Fliss 2010). Each database
has a different number of peptides depending on what it was collected for. AMPad database
(Juretić et al., 2009), has 73 AMPs of amphibian origin, with  helical structure, while DADP
database (Web link [2]) created later has 2571 amphibian AMPs (Novković at al. 2012). On
the other hand, AMSDb database (Web link [3]) has 895 eukaryotic antimicrobial peptides
(Tossi and Sandri 2002). There are several other databases such as: CAMP (Thomas et al.,
2010), APD (Wang et al., 2009) (Web link [4]), AMPer (Fjell et al., 2007), that all cover diverse
origin AMP sequences. Most sequences represent common biophysical parameters such as
molecular size, cationicity and amphipathicity, which can be essential for AMPs activities
(Hammami and Fliss 2010). Those databases are later used for all types of research, including
creation of computational tools for AMP design, prediction or predicting certain parameters
relevant for peptides activity, like TI. So far, several algorithms have been developed from
the AMPad database: “PredictorSelector”, „Designer“ (Juretić at al. 2009) and „Mutator“
(Kamech et al., 2012).
Peptides, which are the main subject of this thesis, are artificial AMPs proposed by
„Designer“ algorithm, named adepantins (ADPs) from Automatically Designed Peptide
Antibiotic Number 1, 2 and 3. The algorithm was created using a collected set of 73 peptides
(described in 2.1 and 3.1) effective against Escherichia coli, extracted from anurans (mainly
frogs) and that have preference for  helix conformation in hydrophobic environment. The
constructed database was named AMPad (Juretić et al., 2009) and it lists peptide name,
sequence, MIC and HC50 value expressed in M, and therapeutic index (TI) value for each
peptide. The TI is a ratio of HC50 and MIC, and it represents the measure of selectivity of the
peptide.
TI= HC50/MIC (1)
where TI is therapeutic index representing selectivity, HC50 is peptide concentration
causing 50% of haemolysis of red blood cells, and MIC is minimal inhibitory concentration.
From the AMPad database, three sets were formed: the „training“ set, the „testing“
set and the „set of the best peptides“ (SBP) (described in 2.1 and 3.1). The „training“ set
consists of 36 non-homologous peptides with less than 70% pairwise identity, „testing“ set
consists of the remaining 37 peptides, while SBP contains all peptides from AMPad database
with TI > 20. Non-homologous peptides were chosen for the „training“ set with the intention
of using data-mining procedures for extracting general rules for highly selective AMPs with
measured TI. The concept of sequence moments (constructed by Prof. Davor Juretić)
facilitated the data-mining-procedure and the selection of optimal parameters for TI
prediction by using the „PredictorSelector“ algorithm (constructed by Prof. Damir Vukičević).
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Sequence moments were presented as vector summation of chosen set of amino acid
attributes for a peptide sequence bent into right angle arc of 90° (Juretić et al., 2009.). The
cosine of the angle between sequence moments is called D-descriptor and it leads to the
predicted TI value by using linear one-parameter model expressed with the equation TI =
50.126 – 44.803D. Hydrophobicity values used to calculate sequence moments are
associated with the scales of Guy (Guy 1985) and Janin (Janin 1979) (see Figure 14, str. 53,
Appendix 2, Appendix 3, Appendix 4). The maximal predicted TI value in this model is 95,
while the measured value for the same peptide can be significantly higher. When
constructed, the „Designer“ algorithm contained certain restrictions. By selecting a certain
range of mean physicochemical parameters, a peptide length of 23 AA, net positive charge
of 4 or 5 and TI > 85, such restrictions were enforced to reduce the number of proposed
peptides. The algorithm then proposed 7 peptides (Table 1) (see in 2.1.4, 3.2).
Table 1. Resulting sequences (seq) of the „Designer“ algorithm with original restrictions; sequences are
ordered as „Designer“ algorithm offered; adepantin 1 (ADP1), adepantin 2 (ADP2), adepantin 3
(ADP3); red letters represent amino acid (AA) residues that are different considering adepantin 1; the
complete result with calculated parameters is presented in Table 9, on page 54.
Abbreviation of peptide name Sequence
ADP3 (seq1) GLKGLLGKALKGIGKHIGKAQGC
seq2 GLKGLLGKALGEAKGLLGKHKGC
seq3 GITQGVLKGIGKHVGKALKGIGC
ADP2 (seq4) GIGKHVGKALKGLKGLLKGLGEC
seq5 GIGKHVGKALKGVKGLLKGLGEC
seq6 GIGKHVGKALGELKGLLKGLKGC
ADP1 GIGKHVGKALKGLKGLLKGLGES
Adepantin 1 was the first AMP from this group of 7 to be tested (see 2.2.1 and 3.1). It
is the only AMP from the proposed group that ends with S (Serine) at the C-terminus. All
others end with C (Cysteine) AA which has a reactive sulphydryl group. That reactivity, in the
following experimental tests, was used to label the peptides with fluorescent label and to
construct adepantin dimers. In the case of adepantin monomers with C-terminal Cys the
cysteine was blocked by iodoacetamidation. From the same series of ADPs two additional
peptides, the most similar one (ADP2) and one with highest molecular diversity to ADP 1
(ADP3), were chosen to undergo further testing.
The „Mutator“ algorithm is a bioinformatical tool, designed by prof. Damir Vukičević
with the help of Prof. Davor Juretić, to improve AMPs by suggesting possible point mutations
one by one, with constant increase of the peptides’ TI value. Recently, it was improved and
tested (Kamech et al., 2012). Its construction began in the same time as development of the
„Designer“ and the „Predictor“ algorithm. Preliminary laboratory experiments on two
peptides were done to prove the results in the early stage of the algorithm development.
Since this algorithm was still under construction, the chosen peptides were not only
supposed to test early „Mutator“ algorithm but, more importantly, to serve as referent
peptides in the adepantin testing study. In the end, one good and one mediocre
antimicrobial peptide, considering their TI values, were selected. They were synthesized
along with their versions with one point mutations proposed by the preliminary version of
the „Mutator“ algorithm (Table 2).
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Table 2. Peptides and their variations used to test an early version of the „Mutator“ algorithm as well as to be
referent peptides to the study of adepantins.
Peptide name abbreviation sequence
Ascaphin 1 ASC1 GFRDVLKGAAKAFVKTVAGHIAN
Ascaphin 1 I2 ASC1 I2 GIRDVLKGAAKAFVKTVAGHIAN
Pseudin 2 PSEU2 GLNALKKVFQGIHEAIKLINNHVQ
Pseudin 2 A9 PSEU2 A9 GLNALKKVAQGIHEAIKLINNHVQ
The results gathered in the first tests of the „Mutator“ algorithm confirmed
improvements in peptides TI. However, improvements were not significant enough to
exclude human error while performing tests. Therefore, „Mutator“ algorithm was left for
further development. The results were recently published in (Kamech et al., 2012), and the
algorithm can be tested at corresponding Web address (Web link [5]). Acsaphin 1 and
pseudin 2 were left as referent peptides in the first sets of experiments on adepantins, more
precisely, by testing of adepantin 1 (Juretić et al., 2009).
1.3. About the thesis
In the methods and results of the thesis the whole process will be described, from
data gathering to the collecting of the results after adepantins are tested. The description
will follow all steps of the process, although some parts of it were not done by me. Firstly,
the database construction will be described, which is the part I participated in. The next step
is its division into desired sets of peptides adapted for further managing (also mainly my part
of the work), and will be described as the next step of the work. This will be followed by the
algorithms construction process, which was the part of the work performed by Prof. Davor
Juretić and Prof. Damir Vukičević, and will be described as the relevant part of the process
on how adepantins were constructed. In the following paragraph, there will be a
presentation of why we chose adepantin 1, 2 and 3 for the testing, as well as what peptides
we took as referent ones and why. At this point, I must point out that laboratory testing of
the peptides were performed in two set of assays, one where ADP1 and referent peptides
were used, and the second where ADP1 was the referent peptide while ADP2 and 3 were
under testing. In subsequent paragraphs, all laboratory experiments carried out by me
during this process will follow a logical order, starting from synthesis, purification,
modification and characterization, through quantification and structural analysis.
Antimicrobial activity and bacterial membrane permeabilization assays will show how ADPs
react when in contact with bacterial strains of interest. To be able to determine selectivity of
ADPs, their interaction with host cells was tested. In the discussion part of the thesis results
will be discussed and some future prospective will be given. Thesis will end with the
conclusion.
1.4. Hypothesis and goals of the thesis
The lack of sophisticated methods capable of improving natural and known AMPs
initiated the idea for constructing algorithms that could assist laboratory work by performing
in-silico peptide design. One of the algorithms constructed was named “Designer”, a
software created by prof. Damir Vukičević with the sequence moment concept at its core,
which suggests the primary structures of novel AMPs. „Designer“ algorithm proposed AMPs
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named adepantins (ADP) (Automatically Designed Peptide Antibiotic Number 1, 2 and 3).
Their subsequent experimental testing was the main objective of this thesis.
The main hypothesis of the thesis was that adepantins should be highly selective for
Gram-negative bacteria and have very low haemolytic activity. This was substantially proved,
except for modifications (dimerization) that resulted in an interesting increase in toxicity (a
sort of exception that proves the rule).
In order to confirm this hypothesis several more specific factors were addressed:
 ADPs are predicted to be alpha helical peptides (proved).
 ADPs were designed to have high selectivity against Escherichia coli, against which
„Designer“ parameters are trained, but not necessarily against other Gram-negative
bacteria or the Gram-positive Staphylococcus aureus (proved).
 ADPs are expected to have high HC50 values (50% haemolysis of erythrocytes),
resulting in low haemolytic activity (proved).
 ADPs should permeabilize both the inner and outer membrane of E. coli (proved).
 Dimerization might improve ADPs antimicrobial activity due to double alpha helix and
therefore improve selectivity (proved to be true for antimicrobial activity but not for
selectivity).
 Fluorescently labelled ADPs should help reveal the mode of action (partly proved).
To confirm the hypothesis made, two kinds of methods were used. The first set was
mainly theoretical, required in constructing the algorithm, while the second set of methods
represents the major part of the thesis, and was mainly experimental.
The goals of the work described in the thesis were thus:
 Construction of a new database consisting of antimicrobial peptides with certain
characteristics addressing data collected for AMPs against E. coli (participating in the
process of collecting, verifying and sorting data).
 Dividing the gathered database in „training“ and „testing“ sets, and an additional “set
of the best peptides” (SBP), consisting of the peptides with TI > 20 from both sets.
 Prediction of at least one peptide with the required characteristics that was later
called adepantin 1 (ADP1) (participating in the process).
 Testing hypothesis about ADPs presented above.
 Collected data that can later be included into another database for possible
construction of additional bioinformatical tools.
The accomplishment of the first and the second goal enabled the construction of
three new bioinformatical tools named “PredictorSelector”, „Designer” and “Predictor”. The
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main contribution in creating these tools came from Prof. Dr. Davor Juretić and Prof. Dr.
Damir Vukičević. The tools were later used to accomplish the third and the fourth goal.
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2. Materials and methods
2.1. Construction of an AMP activity database (AMPad) and relevant
algorithms
2.1.1. The AMPad database
To be able to create any software for AMP construction, the crucial step was to
create a proper and representative database of natural AMPs with the data we considered
useful at that time. The data were values for the minimal inhibitory concentration (MIC) and
for 50% haemolysis of human red blood cells (HC50). The values have been chosen as those
which represent AMP selectivity through the Therapeutic index (TI). In a recent article (Ilić et
al., 2013), the TI index was renamed selectivity index (SI) as the same group of scientists
suggested in their earlier works (Juretić et al., 2009; Juretić et al., 2011). The TI index is given
by expression (1).
The search for required data throughout the literature consisted mostly of scanning
the PubMed application (Web link [6]) using their search tool. The keywords applied to the
search tool were: antimicrobial, peptides, AMP, peptide antibiotics, MIC, HC50, selectivity,
amphibian, anuran, frog, TI or therapeutic index, α helix, helical, and different combinations
of these. At that time, the PubMed search tool proposed a limited number of articles
containing required data. Research results on AMPs, aldough abundant, were not published
with the type and amount of data we required for forming a big AMP database with data of
interest. Later, our group constructed a large database named DADP: the database of anuran
defence peptides (Novković et al., 2012).
Peptides considered for the entry into the AMPad database were of amphibian origin
and had propensity to form α helix in membrane mimetic solvent (predicted and/or
experimentally verified propensity). Furthermore, only data representing MIC and HC50
values, expressed in µM, measured by performing the same type of assay with the same
concentrations of the target cells, were extracted and listed in the database. MIC values
used had to be determined by the serial dilution method. Furthermore, if values for several
E. coli strains were present, the value for the most sensitive strain was selected. A criterium
for selecting HC50 values was that they had to be measured with fresh human blood from
healthy donors. Also, articles not containing all the required data for the same peptide were
omitted, as well as articles containing data for peptides for which the same data were
measured later. Artificial peptides or peptides with more than two point mutations were
also excluded from the database.
2.1.2. Sets of peptides from the AMPad database
To be able to construct any kind of bioinformatical tool we needed a minimum of two
sets of peptides with certain characteristics. AMPad database is a relatively small database
with only 73 AMPs, which was divided into „training“ and „testing“ sets. For that purpose,
bioinformatical multiple alignment tool Clustal V (version used in 2008) was used. Database
was divided by the rule that the „training“ set must consist of nonhomologous peptides with
less than 70% pairwise identity. This was a necessary criterium for extracting rules as general
as possible. All other peptides formed the „testing“ set. The „training“ set than was
Materials and methods Nada Ilić
12
subjected to various analyses in order to extract rules and logic needed for software
construction. (Appendix 1; Juretić et al., 2009).
An additional set of peptides was required for algorithm construction. In order to
construct an algorithm able to offer good and selective antibiotics, a set of the best AMPs
from the AMPad database needed to be extracted. For that purpose, all peptides in the
AMPad database were sorted by decreasing TI value, and then all peptides with TI values
greater than 20 were extracted to form a set called the „set of best peptides“ (SPB). TI value
20 was chosen to be the threshold, because in literature AMPs with TI ≥ 20 are still
considered to be good antibiotics as well as selective ones (Juretić et al., 2009).
AMPs not listed as α helical in the original article were examined by using SPLIT
algorithm version 3.5 (Juretić et al., 1998) (Web link [7]). For all peptides also the distribution
of the polar/hydrophilic and nonpolar/hydrophobic amino acids (AA) was observed either by
using the Virginia university helical wheel application (Web link [1]) or HydroMCalc tool
(Web link [8]).
2.1.3. „PredictorSelector“ algorithm
Peptides, in the primary structure, are represented as a sequence of AA. Each of
those AA has certain characteristics expressed as position-dependent attributes, presented
mostly as smoothed values. All AA attributes are presented as two-dimensional plots for
sequence profiles. Such a profile is for example the Kyte-Doolittle hydrophobicity profile
(Kyte and Doolitle 1982). For the „Designer“ algorithm construction, the whole sequence
profile for the chosen set of AA attributes is converted into one vector with two
components, named sequence moment. That was possible by summation of all vectors
representing AA attributes in chosen sequence, when the sequence was bent into right angle
arc. The „PredictorSelector“ found the best descriptors when sequence was bent in the first
quadrant of coordinate system. N-terminal of the peptide is located then at the positive y-
axes, while the C-terminal is located on positive x-axes (Figure 14, page 53). AA attributes
vectors are defined in length and orientation by direct or smoothed attribute value. The
results showed that smoothed attribute values with omitted attribute of a central residue in
a sliding window (used for smoothing) produced the best descriptors. In this case too, the
criterion for choosing descriptors was the correlation with measured TI values of the
„training“ data set peptides. The inclination of resulting vector, named the sequence
moment vector, is given with respect to the x-axis. The sequence moment vector is
therefore an indicator of the lengthwise asymmetry of the peptide for the chosen attribute
profile, and is not associated with secondary structure of the peptide. Lengthwise
asymmetry is different from sidewise asymmetry or amphipathicity. Sidewise asymmetry is
associated with secondary structure of the peptide, and measured by Eissenberg’s
hydrophobic moment (Eissenberg et al., 1982). Lengthwise asymmetry of the peptides is
additionally emphasized with the observation that AAs closer to the N-terminus are more
relevant for AMP activity (Tossi et al., 1997; Tossi et al., 2000), and that is included in
calculation of the sequence moments as optimized weighting factor (Juretić at al. 2009). To
be more specific, for the job of converting sequence profiles of AA attributes into sequence
moments the following was necessary:
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 144 different scales of AA attributes obtained from studies describing protein
folding and integral membrane proteins (Juretić at al. 1998 (b), Gromiha 2005,
Yuan et al., 2006)
 Finding sequence profiles from AA attributes by considering three simple
methods: direct usage, smoothing with central AA in a sliding window (mean
values), smoothing with central AA in sliding window but not taking into account
the attribute for the central AA itself (sequence environment values).
 Determining peptide bending angle between 15 possible ones from /15, /14...
to .
 Determining weighting values among 0, 1, 1/2, 1/3, 1/4.
These characteristics were applied at the „training“ set of 36 nonhomologous
peptides, to obtain sequence moments, for all pairs of sequence profiles corresponding to
the same angle and weighting value. In practice, this means that „PredictorSelector“
algorithm examined all pairs of AA attributes (all pairs of AA scales), all weighting values, all
bending angles and each of the three methods for creating sequence profiles to find the best
descriptors.
Finding frequent motives of the best peptide antibiotic was also of great interest. For
this purpose, the „set of the best peptides“ (SBP) extracted from AMPad database was used
and two indices were introduced: AA selectivity index and motif regularity index.
Incorporation of the motives, found in the peptides of SBP, in new designed peptides is
estimated by means of a motif regularity index (Juretić et al., 2009; Juretić et al., 2011). The
lower the motif regularity index value is, the greater regularity associated with the new
peptide is. The statistical analysis behind motif regularity index combines:
 definition of the AA selectivity index scale,
 definition of the succeeding AA for each AA residue extracted from the SBP set in
a manner that it is one of the five most common successors of required AA,
 definition of the AA placed in the i + 4 position with respect to any AA, which is
the AA spatially close in an  helical conformation, also extracted from the SBP
set in the manner that it is one of the five most common successors in that
position.
AA selectivity index selects AA with high frequency among most effective frog-
derived antibiotics (Juretić et al., 2009; Juretić et al., 2011). It must be noticed that selectivity
index scale reflects selectivity but not necessarily the antimicrobial potency. Fifth possible
most common successor in both groups was chosen among glutamic acid (E), aspartic acid
(D), glutamine (Q) and histidine (H), in that way additionally favouring AA most significant for
selective frog-like peptide antibiotics.
A hydrophobicity index scale CCS was used for global hydrophobicity and
amphipathicity calculation for each synthesized peptide sequence (Tossi et al., 2000; Tossi at
al. 2002). Hydrophobicity index scale was derived from the normalized and filtered
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consensus of 163 published scales with values that arbitrarily ranges between +10 for
phenylalanine (F) and -10 for arginine (R). Hydrophobicity of the peptide was calculated as
the mean value by dividing sum of hydrophobicity indices for AA in the given peptide, with
length of the peptide, while mean hydrophobic moment was calculated as described in
Eisenberg et al., 1982. A perfectly amphipathic, 18 residue peptide, consists of only two AA,
most hydrophilic Arg and most hydrophobic Phe, with maximum hydrophobic moment of 6.4
when CCS scale is used as the reference scale. For each predicted peptide relative
amphipathicity was determined with respect to already mentioned perfect amphipathic
peptide.
2.1.4. „Designer“ algorithm
All the above mentioned characteristics of the peptides were used in the
„PredictorSelector“ algorithm that led to choosing the D-descriptor, as the simplest
descriptor extracted from position dependent physicochemical properties. The D-descriptor
is defined as a cosine of the angle between sequence moments vectors (see Section 3.1,
page 45, for the D-descriptor definition too). A linear one-descriptor fit for predicted TI was
then obtained: TI = 50.126 – 44.803D, such that correlation between predicted and
measured TI was r2 = 0.83. The second goal of this process was the creation of the
“Designer“ algorithm. D-descriptor was a good base but it has its limitations, for example the
range of predicted TI is limited to 5 < TI < 95, while that of measured ones ranges from less
than 0.5 to well over 100. The intent was to create an algorithm that distinguishes between
good and mediocre peptides when considering TI, but not to predict the exact TI itself.
Furthermore, for designing peptides an algorithm has to be taken into account, apart from
the high predicted TI value:
 appropriate net positive charge
 hydrophobic moment
 hydrophobicity
 the peptide length
all of which are relevant to its antimicrobial potency.
If these characteristics were applied to a peptide with approximately 20 AA, the
algorithm could not work, because the number of possibilities needed to be checked would
be extremely large. Therefore additional physicochemical and rational data mining derived
restrictions were applied along with a recursive algorithm, all based on the structural and
chemical characteristics of the peptides from the SBP set. The peptide length chosen for the
initial peptide design was 23 AA. The following restrictions were applied following the most
frequently found characteristics in natural AMPs, especially in SBP (Juretić et al., 2009):
1. TI > 85 predicted (for D-descriptor model maximal TI = 95),
2. 4 or 5 for net positive charge, counting Lys and Arg as +1, Glu and Asp as -1,
His as neutral and not taking the N- or C-termini into account,
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3. 0.0 to – 1.2 for mean hydrophobicity using CCS scale (Tossi et al., 2002),
4. separation of polar (E, D, Q, N, G, K, R) from nonpolar (A, L, M, V, I, F, W) AA
residues in helical wheel projection (design was limited to helix-forming
amphipathic peptides, where Gly residues are part of polar helix face, and Hys
are not),
5. limits to two neighbouring identical AA,
6. three C-terminal AA residues as in at least one good natural peptide antibiotic,
7. Gly for the first AA residue,
8. Leu or Ile on the second position,
9. minimum of nine residues E, D, Q, H, G, having high AA selectivity index, must
be present in a designed paptide,
10. motif regularity index lower than 2.5 (Juretić et al., 2011).
These precise rules for peptide design were such to result in an algorithm executable
in reasonable time and a workable load of suggested AMPs expected to have high TI value as
well as good antimicrobial activity against Escherichia coli. Recursive algorithm eliminated
partial peptide sequences as soon as they violated one of the proposed restrictions.
All files connected to „Designer“ algorithm including AMPad database, are available
at (Web link [9]). TI values can be calculated for any query sequence using the tool
“Predictor” available at Web link [10], with full name “Therapeutic index estimator for frog-
derived helical antimicrobial peptides”. The “Predictor” is incorporated in the “Designer”
algorithm.
2.2. SPPS (solid phase peptide synthesis) of designed peptides
An easy and rapid way to produce peptides needed for testing is solid phase
synthesis. Adepantins were synthesised on the CEM Liberty synthesizer.
2.2.1. Selection of peptides for synthesis
Restrictions implemented in the algorithm were strict enough to predict a small
number of peptides, only 7 of them. Among them, the only peptide in the group ending with
S (Ser; Serine) at the C terminus was chosen to be tested first. It was called adepantin 1
(ADP1). The remaining peptides from the group end with C (Cys; Cysteine). For additional
testing, two more peptides from the same group were selected: having the most and the
least similar primary sequence to adepantin 1, later called adepantin 2 (ADP2) and adepantin
3 (ADP3) respectively. Sequences were aligned and compared using bioinformatical tool
Clustal V (version used in 2008). As the Cys at the C terminus has a reactive sulphydryl group,
its reactivity was exploited in for experimental testing, such as for labelling the peptides with
a fluorescent molecule, constructing dimers, or just blocking the Cys by iodoacetamidation.
Another two peptides of natural origin were used as reference peptides in the first sets of
Materials and methods Nada Ilić
16
experiments: ascaphin 1 (ASC1) (Conlon et al., 2004) and pseudin 2 (PSEU2) (Olson et al.,
2001). These had also been used for the first tests of the „Mutator“ algorithm, ASC1 as an
example of a “good” antimicrobial peptide, with high TI, and PSEU2 as a mediocre one.
2.2.2. Synthesis difficulty prediction
The first step in the laboratory testing was preparing for the synthesis, using a
software connected to the Liberty peptide synthesizer to calculate AA weights as well as
those for other necessary reagents, solvent volumes etc. The Liberty PepDriver software
controls all aspects of the synthesis automatically. A separate software, PeptideCompanion
from CoshiSoft can be used to predict difficult coupling sequences in the peptide and help
decide whether it is necessary to apply longer coupling cycles, double coupling and/or
increased deprotection cycles. For adepantins, most of the couplings were predicted to be
difficult so double-coupling reactions were carried out at most positions.
2.2.3. Solid phase synthesis
There are two techniques for synthesizing peptides in the laboratory. The classical
approach is the liquid phase peptide synthesis which is mostly replaced by widely accepted
solid phase peptide synthesis (SPPS) (Merrifield, 1963; Kent, 1988). The liquid phase peptide
synthesis is a classical method still used for industrial purposes in large scale production.
SPPS was pioneered by Merrifield, and is used for producing peptides:
 that are natural but cannot be obtained recombinantly from bacteria,
 that have unnatural AA,
 that have altered backbone characteristics,
 for synthesizing peptides and proteins from D-amino acids (D-AA).
The solid support must be treated with a linker to allow “hosting” the growing
peptide chain during its construction, so that the peptide is not washed away when other
reagents are removed during washing in synthesis cycles. Using SPPS result in good yields at
each coupling cycle, and consequently also of the final product. For this purpose, each
incoming AA is added in a large excess (at least 4x), and in combination with appropriate
activating agents. While ribosomic peptide synthesis starts from the N-terminus and
proceeds towards the C-terminus, SPPS creates peptide from C to N- terminus. There are
widely used chemistries, Fmoc and Boc. The t-Boc (tert-butyloxycarbonyl) chemistry was the
originaly proposed version by Merrifield, in 1963, where t-Boc is the -amino protecting
group and it is removed from the growing peptide using neat trifluoroacetic acid (TFA), while
side chain protecting groups and cleavage from the resin at the end of synthesis requires
hydrofluoric acid, and is dangerous. In Fmoc (9-Fluorenylmethoxycarbonyl) SPPS, basic
conditions are required to remove the -amino protecting group (20% piperidine in DMF),
while side chain deprotection and resin cleavage require TFA. For adepantins synthesis we
used the Fmoc group.
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Two groups of compounds are normally used for activations: triazoles and
carbodiimides (very reactive with high probability for causing AA racemisation). Triazoles
most commonly used are:
 HOBt (1-hydroxy-benzotriazole), an organic compound used both as coupling
reagent and racemisation suppressor, that can improve peptide yields in
synthesis,
 PyBOP (Benzotriazol-1-yl-oxytripyrrolidinophosphonium hexafluorophosphate),
another coupling reagent used as a substitute for the originally used but
carcinogenic BOP,
 HCTU (2-(6-Chloro-1H-benzotriazole-1-yl)-1,1,3,3-tetramethylaminium hexafluoro
phosphate) activating group that speeds up reaction.
There are several types of resins and linkers used in SPPS. One of those is commonly
used because of its characteristic of not swelling too much in DCM (Dichloromethane), a
solid gel type support called Polyoxyethylene glycol polystyrene based resin in combination
with Polyamide linker (PAL). The PEG hybrid polystyrene resin is used in synthesis of long
and difficult peptides and ADPs were predicted to have difficult synthesis by synthesis
software. During the synthesis, the side chains in the growing peptide must be protected.
For this purpose Fmoc-AA are commercially available with appropriate protecting groups.
The link of the peptide with the resin, as well as its side chain protection, remains unaltered
throughout synthesis. Only when the peptide is completed, is it cleaved using Trifluoroacetic
acid (TFA) scavenger mixture. Scavengers are used along with TFA to prevent reattaching the
cleaved side-chain protecting groups. DMF is removed from peptide with the resin by
washing with Diclormethane (DCM) in order to prevent TFA acidolysis inhibition. The TFA –
scavenger cleavage mix depends on the variety of AA side chain protecting groups, for
instance those in Table 3:
Table 3. Cleavage mixtures for different types of peptides (Web link [11])
Peptides Cleavage mix (v/v)
Any peptide TFA/thioanisole/water/phenol/EDT(82.5/5/5/5/2.5)
Any except Arg(Pbf) or unprotected Trp TFA/TIS/water/EDT (94/1/2.5/2.5)
Any except Arg(Pbf), Cys(Trt), Met, or unprotected Trp TFA/TIS/water (95/2.5/2.5)
The SPPS is based on repeated cycles of reactions consisting of coupling,
deprotection and washing in-between those two steps. Peptide is built from its C-terminus
that is attached to resin, leaving the N-terminus of the last AA in the peptide chain free to
react. Each AA N-terminus needs to be deprotected before each coupling by using 20%
Piperidine in Dimethylformamide (DMF). Washing with DMF is performed after both
coupling and deprotection in order to remove excess reagents.
When the synthesis is performed, it is desireable to have peptides with high yields
and low racemisation. Microwave irradiation (MWR) helps in coupling acceleration and
prevents peptide aggregation. In order to catalyze AA coupling, activation reagents are used,
as well as an increase in reaction temperature the alternating electromagnetic radiation. The
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disadvantage of this kind of synthesis is a possible racemisation when a Cys or His coupling
occurs.
All peptides synthesized in the thesis were amidated at the C-terminal. This peptide
version is easier to synthesize as the amide is already present in the linker and the C-
terminal AA can be coupled directly as in a normal cycle.
After the test AMPs were chosen, all peptides were synthesized in solid phase as C-
terminal amides on CEM Liberty automated microwave peptide synthesizer (CEM
corporation, Matthews, NC) using Fmoc-PAL-PEG-PS resin (substitution 0.34 mmol/g) (Juretić
et al., 2009; Ilić et al., 2013). Couplings were carried out with PyBob as activator, at 75°C in
DMF, with a fourfold excess of AA. During the first C-terminal coupling, preactivated Fmoc-
Cys(-Trt)OPfp was used at 45°C to reduce racemisation of the cysteine.
The scale for peptide amount that can be synthesized on CEM Liberty microwave
assisted automated synthesizer is from 0.1 to 1.0 mmol. For ADPs 0.1 or 0.5 mmol was used.
Masses and volumes of all reagents needed were calculated using PepDriver program. All
amounts of AA were dissolved in calculated volumes of NMP (N-Methyl-2-pyrrolidone).
Further, for ADP2 and ADP3 synthesis:
 13.5 g of HOBt was dissolved in 80 ml DMF,
 15 g PyBOP in 115 ml NMP,
 2 x 0.15 g of resin in 5ml DCM each,
 12.2 ml of DIPEA (N,N-diisopropylthylamine) in 57.8 ml NMP,
 0.5ml of Collidine in 9.5ml NMP.
Prepared HOBt in DMF was mixed with 720 ml of additional DMF and 200 ml
Piperidine (20%). All reagents were added to the machine to perform synthesis.
When reference peptides were synthesized, synthesis was performed until points
where wild type peptide differed from mutated one. Then, the resine was removed from the
synthesizer, washed, dried and weighed. This amount was split into two halves, swelled
again, replaced in the synthesizer to finish the synthesis. In this manner, the common parts
of the peptides were synthesised together, while the variant parts were synthesised
separately.
2.2.4. Cleavage and workup
Peptide synthesizer delivers synthesized peptides attached to resin. To separate
peptide from the resin, it was necessary to use one of the cleavage methods. For all
peptides, cleavage was done using trifluoroacetic acid (TFA) – scavenger mixture consisting
of TFA with thioanisol (TA), phenol (PhOH), water (H2O), 3,6-dioxa-1,8-octanedithiol (DoDt)
and triisopropylsilane (TIPS). Ratio of the chemicals was 83 : 3 : 2 : 2 : 8 : 2, respectively. The
process is published on the Web (Web link [12]) and will be described only for one peptide.
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The tubes with peptide attached to resin were taken out of the peptide synthesizer,
washed with DMF (Dimethylformamide) and transferred to the weighted plastic syringes.
The syringes were placed on a vacuum station where DMF was removed from the peptide-
resin. DCM (Dichloromethane) was added and resin was left in DCM for few minutes to
swell, and then it was pumped out. To thoroughly wash the resin in the syringe before
cleavage, isopropanol was used several times and afterwards, cold Petroleum ether.
Peptide-resin was the dried with nitrogen in syringe protected with parafilm, to eliminate
any remaining washing compound, until constant mass was achieved. Weighing peptide-
resin enabled determining the exact yield and comparing it with the theoretical one.
At this point, resin was cleaved from the peptide. Syringe with dried peptide-resin
was once again placed on the vacuum station and DCM was added for resin to swell for a
few minutes. After DCM was pumped out, TFA-scavenger mixture was added (4 ml for each
peptide), the syringe was sealed and left for 3 hours at room temperature on easy shake.
The peptide dissolved in the cleaving mixture was pumped out into a new weighted test
tube, while the resin remained in the syringe. Additional 1 ml of TFA-scavenger mixture was
added to the resin and drained to the new test tube with peptide.
Precipitation of the peptide from the mixture was accomplished by adding tert-Butyl
methyl ether (TBME) at -20°C and centrifugation at 3000 rpm for 5 minutes. TBME was
decanted from the tube with peptide sediment, and another aliquot of 15 ml TBME was
added. This process was repeated three times to promote peptide precipitation. The peptide
was dried with nitrogen for approximately 30 minutes until its mass remained constant. This
process produced peptide in the solid state allowing to measure peptide yield and compare
it with theoretical one.
2.3. Peptide characterization and purification
After synthesis and cleavage peptides were checked on a mass spectrometer to
distinguish if the peptides were synthesized correctly, and if they were pure. Since all
peptides were synthesized with excellent yields the peptides were quite pure, purification by
preparative RP-HPLC was not always necessary to separate fractions that contained desired
peptide. Peptide purity were confirmed by ESI-MS on an Esquire 4000 mass spectrometer.
Cleaved, dried and weighted peptides were dissolved in 200 l of solvent A (0,05%
TFA in H2O), vortexed and centrifuged at 1300 rpm (round per minute) for 3 minutes. That
solution is used later for mass spectrometry and analytical HPLC.
Counterions and impurities in the peptide solution after cleavage and nitrogen drying
were eliminated with the mixture HCl (10mM) and Diethyl ether (DEE) in the ratio 50 : 50. In
the falcons with dried peptides 5 – 10 ml of 10 mM HCl was added and vortexed to dissolve
the peptide. Then the same volume of DEE was added to extract impurities, vortexed and
centrifuged at 2500 rpm for 5 minutes. The ether fraction was then removed, and the
process was repeated 3 to 5 times. After the last ether elimination the peptide solution in
HCl was divided into weighted eppendorf tubes and lyophilized. This is the process usually
performed after preparative RP-HPLC, but since ADPs had high purity it was performed
directly on the crude peptides, before analytical HPLC testing, since preparative HPLC was
skipped not to lose peptide.
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2.3.1. ESI-MS (electro spray ionization mass spectrometry)
Mass spectrometry instrument used for this experiment was a Bruker Daltonics
Esquire 4000 and on it molecular weight (MW) of each peptide was tested. Later measured
MW was compared with theoretically calculated one by the synthesis protocol software.
10 l aliquot of each peptide fraction to be tested on ESI-MS was mixed with 90 l of
mass solvent (H2O : Acetonitrile (ACN) : formic acid, 50 : 50 : 0,1 %), injected into
spectrometer and measured.
ESI-MS was also used to test purity of fractions of each peptide collected during HPLC
run. Fractions expected to contain desired peptide were analysed, which are those fractions
collected when the main peak was visible on the HPLC chromatogram for each peptide
(Figure 2).
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Figure 2. Example preparative HPLC chromatogram for ADP2(AM) peak showing fractions expected to contain
pure targeted peptide, in this case fractions 5 - 7; X axes – time in minutes, Y axes – absorbance in mAU
(milli absorbance units).
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2.3.2. RP - HPLC
RP-HPLC of ADPs can be divided in two different sets: analytical HPLC and preparative
HPLC purification.
Preparative HPLC for ADPs, if required, was carried out with 2 ml/min flux on a
preparative reversed phase Waters RadialPak C18 column (21 mm x 150 mm, 5 µm, 300 Å)
using a 20-55% gradient of acetonitrile (solvent B) in 70 minutes. The loop used for
bodipylated peptides was 10 ml and for dimerised peptides 2 ml. Absorbance was followed
at 215 nm where absorbance of the peptide bonds can be monitored and at 280 nm where
absorbance of the Tryptophan (W) and Tyrosine (Y) can be observed (Aguilar, 2003). The
third wavelength monitored, 254 nm where Phenylalanine (F) has maximum absorbance,
was not important for ADPs. For the first set of HPLC runs, smaller quantities of ADP1, PSEU2
and ASC1 were purified on a semipreparative Waters column (XTerra C18, 7 µm, 300 Å, 19 x
300mm) using a 25 – 45% gradient of solvent B in 60 minutes with 5ml/min flow.
For the second set of synthesis (ADP2 and 3), analytical RP-HPLC was carried out after
cleaving, drying, weighing and dissolving peptides in 200 ml of solvent A. Since synthesized
ADPs were exceptionally pure, preparative HPLC was skipped in order not to lose peptide
but analytical RP-HPLC was performed. Preparative RP-HPLC, on the other hand, was
performed after all peptides modifications such as Bodipylation, dimerization etc.
For analytical RP-HPLC, adepantins were eluted with a flow rate of 2 ml/min and a
gradient of 15 – 60% of solvent B in 45 to 70 minutes. Column used for analysis was
Phenomenex C18 column (Jupiter size 100 x 10.00 mm, 5, 300 Å,) with 2 ml loop. For
confirming purity another analytical RP-HPLC was performed. 50 g of each peptide (5l
peptide stock + 85l solvent A (H2O + 0.05l TFA)) was injected in RP-HPLC using analytical
column and 100l loop.
In both types of RP-HPLC adepantins were expected to elute at 25-35% of solvent B.
Fractions expected to contain desired peptide were collected and left aside for further
testing.
2.3.3. Peptide modification (acetamidation, dimerization, bodipylation)
ADP2 and 3 have cysteine as the last AA on the C-terminus which is very reactive and
enabled usage of this feature to create more testing possibilities of the same peptides.
When ADP 2 and 3 were synthesized and lyophilised, a certain amount of the crude peptides
were split into three aliquots and each aliquot was treated differently as described below.
After each procedure purity and correct mass of the peptides were checked by RP-HPLC and
ESI-MS followed by lyophilisation.
2.3.3.1. Blocking of cysteine by iodoacetamidation
In the first aliquot of both peptides, reactive sulphydryl group on C-terminal cysteine
was blocked by iodoacetamidation (Creighton, 2002) (Figure 3) to avoid interference when
peptides were used as monomers in further tests. This peptide modification was prepared
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twice for ADP2 due to numerous experiments done with it. The preparation will be
described only for 10 mg aliquot.
GIGKHVGKALKGLKGLLKGLGE-Cys – AM ADP2(AM)
GLKGLLGKALKGIGKHIGKAQG-Cys – AM ADP3(AM)
Figure 3. Adepantins 2 and 3 in amidated form; cysteine on C-terminus is blocked. AA coloured in red represent
difference from the ADP1 sequence. Note that by amidating the C-terminus, a negative charge is removed,
so that the overall charge increases by +1.
For reaction of iodoacetamidation following reagents had to be prepared:
a) 0.5M Tris8 buffer with 2mM EDTA in 10ml MilliQ H2O and pH 8
 600mg TRIS (Tris(hydroxymethyl)aminomethane, C4H11NO3, MW = 121.14 g/mol)
 3.72 mg Na2-EDTA (Ethylenediaminetetraacetic acid, [CH2N(CH2COOH)CH2COONa]2 ∙
2H2O, MW = 372.24 g/mol)
 all dissolved in 10 ml MilliQ H2O
 pH 10 was corrected with 37% HCl to reach 8 pH
 purged with N2 (nitrogen) for 2-5 minutes
b) 100mM Ascorbic acid solution in TRIS8 buffer
 88mg Ascorbic acid (C6H8O6, MW = 176.1 g/mol)
 5ml of Tris8 buffer
 All done in dark, protected with aluminium foil and freshly prepared before starting
reaction.
 Used as iodine traces scavenger.
Prepared mixture was centrifuged to avoid reactants loss on the sides of falcon.
c) Acid quench solution is 0.5 M Citric acid
 480mg Citric acid (HOC(COOH)(CH2COOH)2, MW = 192.13 g/mol)
 5ml ofMilliQ H2O
d) 100 mg Iodoacetamide (C2H4ION, MW = 184.86 g/mol) dissolved in 300 l Tris8 buffer
(for adepantins in total 600 l was used due to their difficult dilution) under nitrogen to
achieve 2.2 M solution always prepared fresh and kept in dark. To be able to dissolve
Iodoacetamide, water bath on 65°C was used. (IAc MW = 56.7 g/mol)
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e) 10 mg of each peptide ADP2 and ADP3 dissolved in 200 l ofMilliQ H2O (in assay peptide
can be dissolved in 100 – 300 l of water).
Product of the reaction is collected in 2 ml eppendorf tube. Most of the steps require
dark surroundings because of the light sensitivity of some chemicals and is done under hood.
The whole reaction requires time precision.
After weighing chemicals and preparing all laboratory equipment, including HPLC, the
reaction can be started. All needed chemicals must be dissolved and mixed following assay
steps.
The procedure starts with TRIS8 buffer preparation, see a) above. TRIS8 is then added
to Iodoacetamide, see d) above, vortexed and put in water bath on 65°C until the solid is
completely dissolved. 10 l of ascorbic acid solution, preparation see b) above, is added to
the solution as iodine scavenger. The mixture is then transferred in the eppendorf with
dissolved peptide, see e), and vortexed for 30-60 seconds. Adepantins needed little longer to
dissolve and extra 300 l of TRIS8 buffer, but since they don’t have Tyrosine they are not so
sensitive and the time before the next step can be slightly prolonged. To stop the reaction
500 l of acid quench solution is added, see c) above. The final mixture is diluted with 400 l
of the solvent A (0.05% TFA in H2O), pH is adjusted at 2-3, centrifuged and injected in RP-
HPLC for purification where semipreparative column (Phenomenex C18) and 2 ml loop is
used. HPLC fractions from the main peeks were examined with ESI-MS to determine purity
and molecular weight on the iodoamidated modification of the peptides. Pure fractions were
combined together for each peptide and lyophilized during the night. Than we add 1 ml 10
mM HCl to the tube (if there is several tubes the same solution is transferred from one to
another) and then transferred to the weight eppendorf tube. Additional wash was
performed by adding 0.5 ml ACN : (10mM) HCl (50:50) to tubes in which lyophilisation
occurred and transferring once again everything to the marked and weight eppendorf.
This mixture was lyophilized once more for 5 - 6 hours after eppendorf tube was
protected with parafilm, and cooled at -80°C for 15 minutes. Finally, the crude peptide was
weighted on analytical balance so that exact yields of each peptide could be determined.
2.3.3.2. Covalent dimerization
In the second aliquot of both peptides covalent dimerization was performed (Figure
4). Dimerization was achieved by formation of an intermolecular disulfide bridge as
described in Tam et al., 1991. The reason for creating this peptide form was to probe the
effect of AMPs aggregation often noticed on the microbial surface that can also affect
cytotoxicity to host cells membranes.
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GIGKHVGKALKGLKGLLKGLGE-Cys [ADP2]2
GIGKHVGKALKGLKGLLKGLGE-Cys
GLKGLLGKALKGIGKHIGKAQG-Cys [ADP3]2
GLKGLLGKALKGIGKHIGKAQG-Cys
Figure 4. Adepantins 2 and 3 in dimerised form, connections achieved with disulphide bridge between
cysteines on C-terminus. AA coloured in red represent difference from the ADP1 sequence.
Each of two ADPs were prepared using 20 mg of crude peptide, but ADP2 had to be
prepared once more for 10 mg. Procedure will be explained for 20mg aliquot.
Aliquots of 20 mg for each peptide was measured and dissolved in 1 ml MilliQ H2O
with 20% DMSO (Dimethyl sulfoxide). As we used 1 mM DMSO the mixture was 800 l H2O +
200 l DMSO. Reaction starts the moment the mixture is combined with peptide, but to be
sure of its completion it must be allowed to proceed for at least 24 hours, while adepantins
were left during the weekend (~ 48 hours).
To confirm that the dimerization occurred, mixtures from both eppendorf tubes were
brought to pH 6 (must be in between 6 – 6.5) using NaOH 0.5 M or HCl 10 mM and then
examined on ESI-MS. After confirmation, peptides were prepared for HPLC by lowering pH to
2 – 3. This time we used Phenomenex semipreparative column with precolumn (Jupiter 5
C18 300A, size 100 x 10 mm 5 micron), loop of 2 ml, and the flux of the solvent B (0,05% TFA
in ACN (acetonitrile)) was brought from 20 – 45% in 45 minutes. Fractions from the main
peeks were tested for purity of the peptides and pure fractions combined together for each
peptide. Combined pure fractions of both peptides were lyophilized during the night. We
later added 1 ml 10 mM HCl to the tube and then transferred it to the weighted eppendorf
tube. Additional wash was performed by adding 0.5 ml ACN : (10 mM) HCl (50:50) to tubes in
which lyophilisation occurred and transferring once again everything to the marked and
weighted eppendorf tube.
This mixture was lyophilized once more for 5 - 6 hours after eppendorf tube was
protected with parafilm, and cooled at -80°C for 15 minutes. Finally, the crude peptide was
weighted on analytical balance so that exact yields of each peptide can be determined.
2.3.3.3. Bodipylation - Fluorescent labelling with BODIPY maleimide
The third aliquot of both peptides was labelled on C-terminal cysteine (Figure 5) with
fluorescent dye BODIPY-N-(2-aminoethyl)maleimide (BY) (Figure 6) as described in (Scocchi
et al., 2008). BY was chosen to fluorescently label peptides because of its stability, strong
fluorescence, lack of charge and relatively small dimensions. It enabled following the
peptides’ interaction with membranes as well as internalization into cells by monitoring
fluorescence at 525 nm.
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GIGKHVGKALKGLKGLLKGLGE-Cys – BODIPY ADP2(BY)
GLKGLLGKALKGIGKHIGKAQG-Cys – BODIPY ADP3(BY)
Figure 5. Adepantins 2 and 3 labelled with BODIPY maleimide on cysteines at the C-terminus. AA coloured in
red represent difference from the ADP1 sequence.
The whole reaction was performed in the dark due to BODIPY’s photosensitivity. For
the reaction 6 mg aliquot of each crude peptide was weighted in two different eppendorf
tubes (3+3 mg). Aliquot of 2 mg BODIPY (MW = 414 g/mol) was also weighted for each
peptide. Reaction will be described for one peptide, but was performed for both of them
separately.
BODIPY was dissolved in total 3ml Acetonitrile (ACN, CH3CN) in the way that ACN was
added to the eppendorf tube with BODIPY, vortexed until it turned yellow and then
transferred in a larger falcon tube in several smaller amounts (1+1+1 ml). This way, all
BODIPY residues were transferred. To this mixture 7 ml of 10 mM Sodium phosphate buffer
(SPB) at pH 7.5 was gradually added, vortexed each time and saturated with N2 gas by
bubbling for 1 – 2 minutes. The next step was adding peptide by transferring a small amount
of the resulting solution to one of the eppendorf tubes with crude weighted peptide,
vortexing and transferring it back to falcon tube with the rest of the mixture and vortexing
again. It was important to adjust pH to 6 – 7 because overly acidic surrounding prevents
BODIPY to attach to peptide. This last step initiated the labelling reaction. Mixture was put
on shake for 2 hours in the dark. After that, the second aliquot of the peptide was added
following the same steps as before and again put on shake for 2 hours. The mixture is left in
the fridge overnight.
The next step was to stop the reaction and block any unbound BODIPY from further
interaction with the peptide. For this purpose, 10 mg of L-Cys hydrochloride monohydrate
(Cys-SH, MW = 175.63 g/mol) in eppendorf tube was prepared and then transferred to the
tube with peptide BODIPY-mixture and vortexed. At that point, pH was adjusted to 2-3 using
1 M HCl, 10 ml solvent A (0.05% TFA in H2O) was added and everything injected to RP-HPLC.
For extracting pure peptide, Phenomenex semipreparative column (Jupiter 5 C18 300A, size
100x10.00 mm 5 micron) with precolumn was used with loop of 10 ml, and the flux of the
solvent B (0,05% TFA in ACN (acetonitrile)) was brought from 15 – 50% for ADP2 and 20 –
55% for ADP3 in 60 minutes (20 – 80 min). Fractions from the main peeks were tested for
purity of the peptides and pure fractions combined together for each peptide. Combined
pure fractions of both peptides were lyophilized during the night. 1 ml 10 mM HCl were
added to the tube and then transferred to the weighted eppendorf tube. Additional wash
was performed by adding 0.5 ml ACN : (10 mM) HCl (50:50) to tubes in which lyophilisation
occurred and everything was transferred once again to the marked and weighted eppendorf.
This mixture was lyophilized once more for 5 - 6 hours after eppendorf tube was
protected with parafilm, and cooled at -80°C for 15 minutes. Finally, the crude peptide was
weighted on analytical balance so that exact yields of each peptide could be determined.
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Figure 6. BODIPY molecule and its reaction with SH group in the Cysteine side chain.
2.3.4. Quantification
For all subsequent analysis peptide solutions were prepared from purified and
lyophilized peptides dissolved in water and then quantified by at least two independent
methods.
Exact concentration of each peptide was determined by using following methods:
a) Mass concentration - accurately weighting peptides used to prepare solutions and
dividing it with the volume of the solution,
b) Waddell method (Waddell, 1956) – spectrophotometrical method,
c) Quantification by molar extinction coefficient of peptide bond (Kuipres & Gruppen,
2007),
d) Quantification by molar extinction coefficient of BODIPY [79000 M-1 cm-1 at 504 nm in
MeOH, Molecular Probes Handbook, Invitrogen, 10th Ed. p. 107],
e) Kaiser test (ninhidrin test) (Kaiser at al. 1970).
Ad a) Mass concentration was calculated by dividing weight of the peptide with the
volume of the solvent peptide was dissolved in, in adepantin case MilliQ H2O. Mass
concentration was taken as reference concentration, later confirmed by another method.
The most important step in this method was to determine exact yield of each peptide
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purified and lyophilized by weighing it on analytical balance. Furthermore, on the baseis of
the peptide weight and its molecular weight it was decided which volume of the solvent to
use. In the first set of tests there were more than enough peptides for all experiments, so it
was decided to target specific concentration by dissolving calculated peptide weight in
corresponding volume of water (Table 13). Targeted concentrations were 10 mg/ml for
ADP1, PSEU2 and PSEU2 A9, while it was 5 mg/ml for ASC1 and ASC1 I2. To maintain a
relatively high peptide concentration, in the second set of tests on adepantins, peptides
were dissolved in 500 l MilliQ H2O. This is the way stock solution was created.
Ad b) Waddell method (Waddell, 1956) is a method used to estimate peptide
concentration based on the difference between spectrophotometric absorption at
wavelengths 215 and 225 nm. To perform this method, it was necessary to have a peptide
that needed quantification, a reference peptide with similar characteristics and known
concentration, and a solution for testing. In the second set of tests adepantin 1 was taken as
the reference peptide, as the peptide most similar to other adepantins. For bodipylated
modifications Bac7(1-13)CysBy (3.5 mg/ml) was used. Measurements were performed on
Ultrospec 2100 Pro (Amersham Bioscience) spectrophotometer using quartz 1 cm (1 ml)
cuvette. The measuring range of the instrument is 0.05 – 0.5 nm. The solution used as a
blank solution is the mixture of MilliQ H2O and 1/150 N NaOH 500 µl each. This was also the
control sample used to reduce background noise in the measurements. When the blank
measurement was made in the same solution, peptide was added 3 times 2 l and
measurement performed after each adding. The same procedure was made for reference
peptide as well as for the peptide needed to be quantified. Here the absorbance values were
obtained in the way that volume of the peptide added to the blank solution, 2, 4 and 6 l,
was multiplied with appropriate dilution factor, 500, 250 and 166.6 respectively, and the
results were averaged for each peptide. Concentration of the desired peptide was then
extracted by using the simple method of comparing ratio of the concentration and
absorbance between reference and desired peptide.
Ad c) Quantification by molar extinction coefficient (direct measure of a dye’s ability
to absorb light) (Kuipers and Gruppen, 2007) is the method that measures peptide bond
contribution in the quantified peptide along with the sum of each present AA contribution at
214 nm. The solution used for blank probe and later as a buffer to dissolve peptide is a
mixture of MilliQ H2O and AcCN in the ratio 80 : 20 with 0.1% Trifluoroacetic acid (TFA).
Peptide concentration was calculated after measuring absorbance of the peptide, calculating
its molar extinction coefficient and taking into account that cuvette used was 1 cm in width.
Cuvette is filled with the aliquot of 1 ml buffer for the blank probe and measured.
After that, in the 990 l buffer, peptide is added to the cuvette in each step (the volume of
2.5 l). Concentration values are obtained by averaging the products of absorbance
measured for following peptide volumes: 2.5, 5, 7.5 and 10 l and their belonging dilution
factors 397, 199, 133 and 100 respectively.
Ad d) Extinction coefficient of BODIPY was used for quantifying bodipylated peptides
(79000 M-1 cm-1 at 504 nm in MeOH, Molecular Probes Handbook, Invitrogen, 10th Ed. p.
107). Once again buffer solution was prepared from the methanol, inserted in 1 ml cuvette
and measured at 504 nm. Measurements were performed for buffer without peptide to
exclude any background noise. Afterwards, peptide was added. Absorbance for peptide
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aliquots of 2 and 4 I was measured and multiplied with appropriate dilution factors, 500
and 250 respectively, and then divided by cuvette width and BODIPY extinction coefficient.
Ad e) Kaiser test (ninhydrin test) (Kaiser at al. 1970) measures absorbance at 570 nm
and is usually used for determination of completeness of AA coupling at each step in SPPS. It
is a fast and sensitive colour test based on reaction of ninhydrin reagents with small samples
of resin + peptide.
For performing this test a kit with the already prepared solutions was used:
 Phenol, ~ 80% in ethanol (30 I),
 Potassium cyanide (KCN) in H2O / pyridine (30 I),
 Ninhydrin, 6% in ethanol (30 I).
Additionally 905 I of 70% ethanol in MilliQ H2O was used as well as 5 I of desired
peptide dissolved in MilliQ H2O. Peptide is mixed with all 3 solutions from the kit and heated
to 110°C in water baths as the assay requires. Ethanol is added last and the solution is
heated to 110°C for 5 minutes until it turns dark blue indicating that free primary amine is
present. In the same routine the blank probe was prepared to avoid any background noise,
but with 910 I of ethanol without peptide. The solution was then transferred into 1 ml
cuvette and measured in spectrophotometer. Peptide concentration was obtained using the
ratio of measured absorbance at 570 nm multiplied by the dilution factor 500 and extinction
coefficient (15700M-1 cm-1).
In the end, the concentrations determined by the various spectroscopic methods
were used to correct the calculated mass concentration. Stock solutions of all peptides with
concentration 1.28 M were prepared.
2.4. Structure analysis
Adepantins were expected to be  helical peptides taking into consideration that the
AMPad database was created from  helical peptides. To be sure that „Designer“ algorithm
is really constructing  helical peptides circular dichroism (CD), spectroscopy was performed,
which is a method normally used in determining secondary structure of the peptides (Kelly
et al., 2005).
The same amplitudes of two components of an electrical field acting orthogonally
and 90° out of phase cause circular polarization. Depending on point of view or source there
are two cases of circular polarization right-handed (clockwise) and left-handed
(anticlockwise). Determination of the peptides’ secondary structure is based on optical
activity of amino acids that absorb polarized light differently. Secondary structures of
peptides such as  helix and  sheet or hairpin are asymmetric themselves which is also the
characteristic used when the structure is determined by absorbance difference (A = AL - AR)
measured using CD-spectropolarimeter. The measure, in this case, is molar ellipticity in
degrees correlated with absorbance difference by equation:
 = 32.98 A (2)
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Wavelengths below 240 nm are used to determine peptides’ secondary structure, in
ADPs experiments in range 200 – 240 nm, while peptide bonds absorb at 214 nm. Specific
secondary structures have characteristic CD spectra in shape and magnitude in the
mentioned far UV spectral region.
Peptides are detected to be random coil in aqueous solutions in most cases, while in
organic solvents or in liposome solution they tend to structure. The instrument used for
these experiments was J-715 Spectropolarimeter (Jasco, Tokyo, Japan).
2.4.1. CD spectroscopy in different solvents
Analyses of adepantins secondary structure was carried out with CD spectrometry at
wavelengths from 200 nm to 240 nm (far-UV spectral region). For each of the tests the blank
probe was measured in order to eliminate any possible background noise, and the probe
was of the solvent later used for testing peptides. The volume of the blank probes was 400
l, and when the peptide was added the targeted peptide concentration was 20 M (393.75
l MilliQ H2O + 6.25 l peptide). Later, the adepantin dimers were also measured with the
concentration of 10M to achieve 20 M with respect to the peptide chains. The cuvette
used was the narrow one of 0.2 cm.
First inorganic solvents were tested:
 MilliQ H2O
 PBS 150mM with NaCl
 SPB 10 mM
Later two organic solvents were used:
 Isopropanol in SPB 10 mM (50:50%)
 TFE in different concentrations 10-50%; with SPB 10 mM
These two organic solvent were used because they are compatible with far UV
spectral region unlike ACN, DCM and chloroform. Unlike normal aqueous solvents they
induce secondary structure formation in peptides and proteins. TFE in particular is known to
strongly induce conformational transition of peptides and proteins to α-helical structure
(Hirota et al., 1997). The helical content was estimated from the molar ellipticity at 222 nm
(Reed and Reed 1997). With TFE it is possible to monitor the percentage of helicity in the
peptide with regard to TFE concentration increase.
Blank measurements were taken in only SPB 10 mM, 400 l in 0.2 l cuvette, for
baseline noise control in order to exclude any background noise. 6.25 l peptide (20 M)
was mixed with 393.75 l of SPB 10 mM and the CD spectrum determined, and then, in
order to distinguish more precisely the amount of the organic solvent needed to induce
peptide folding in the  helix, TFE was gradually added as it can be seen from the Table 4.
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Table 4. Calculation for the volume of TFE to be added to the peptide in order to calculate percentage of 
helix.
% TFE Volume TFEneeded Volume TFE added
Dilution factor of
the peptide
5 21.05 21.05 1.05
10 44.44 23.39 1.11
20 100 55.56 1.25
30 171.43 71.43 1.43
40 266.67 95.24 1.67
50 400 133.33 2
Measurements were performed after each TFE addition from 5% to 50% and for each
peptide. The final volume in the cuvette was 800 l.
2.4.2. Preparation and use of liposomes
Standard procedure most commonly used for understanding how membrane-active
peptides function in living cells is by obtaining information on their structure when bound to
the membrane. Artificial phospholipid bilayers are normally used in biophysical approaches
in that kind of study, although efforts have been made to find a method for the same kind of
studies in native biomembranes, for example solid state NMR (Koch et al., 2012). For the
adepantin study standard procedures were used with CD spectroscopic measurements.
In order to predict ADPs behaviour in membranes two types of model membranes
were chosen, one mimicking bacterial cells with anionic characteristics and other mimicking
host cells that are neutral. Both of the model membranes are liposomes of the large
unilamellar vesicles type (LUV) (Figure 7) prepared as described by Morgera et al., (2009).
Lipid bilayer
LUV
SUV
MLV
Polar head
Nonpolar
Tail
Figure 7. Scheme for vesicles in different sizes; MLV = multi lamellar vesicles are large “onion-like” structures,
SUV = small unilamellar vesicle, 15-30 nm in diameter, unstable and tending to fuse spontaneously at
temperatures below phase transition temperature; LUV = large unilamellar vesicles, 100-200 nm or larger
in diameter, stable on storage.
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Liposome variations used to test ADPs are:
a) Anionic liposomes:
 Phosphatidylglycerol (PG), 380 l = 95%
 Diphosphatidylglycerol (dPG), 20 l = 5%
b) Neutral liposomes:
 Phosphatidylcholine (PC), 100 l = 40%
 Sphingomyelin (SM), 100 l = 40%
 Cholesterol (Ch), 50 l = 20%
The procedure for the preparation of both liposome variations was the same.
Concentration of the liposomes prepared was 4 mM in 1 ml and later diluted to 400 M. For
preparation only glassware were used since Chloroform dissolves some plastics. All lipids
were from Sigma, and all were dissolved in 2:1 Chloroform-Methanol (CHCl3/MeOH) solution
to obtain concentration 10mM for anionic and 20mM for neutral liposomes.
Liposomes solutions were mixed in given ratios in a small round bottom flask. Later,
the solvent was evaporated using dry nitrogen stream while flask was constantly rotated to
avoid any clumps or uneven part in liposome film that was forming on the sides of the flask.
Finally, liposomes were vacuum-dried by placing flask in a Heto vacuum centrifuge for 3
hours. 1 ml of 150 mM Phosphate buffered saline (PBS) was used to resuspend liposomes
while rotating for 1 hour at 40°C in Buchi R110 Rotavapor. Achieved phospholipid
concentration was 4 mM. The conversion from MLV to LUV was achieved by subjecting
vesicles to several (in ADPs case 5) freeze–thaw cycles where thermal shocks were provided
by placing flask alternately in 50°C water and -196°C liquid nitrogen. The final step was the
sizing of the vesicles by passing them 10 times through a mini-extruder (Avanti Polar Lipids,
Alabaster, AL) (Figure 8) using successive polycarbonate filters with 1 m, 0.4 m and 0.1 m
pores.
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Figure 8. Scheme of mini-extruder (Avanti Polar Lipids, Alabaster, AL) (as in Web link [13])
After all the vesicles were reduced to the desired size, both variations of liposomes
were diluted with 150 mM PBS to 400 M in 8 ml. For that purpose 800 l PG/dPG was
dissolved in 7200 l 150 mM PBS and 640 l PC/SM/Ch in 7360 l 150 mM PBS. Once again
CD was measured in 0.2 cm wide cuvette at wavelengths from 200 nm to 240 nm, by adding
each of the peptides to achieve concentration of 20 M. Dimers were used at 10 M peptide
concentration to get a better correlation with dichrographs of the monomers.
Monomers of adepantins, ADP1, ADP2(AM), ADP2(BY), ADP3(AM), ADP3(BY) at 20
M had similar behaviour forming  helices as in the presence of TFE while dimers were
used at 10 M peptide concentration to get good correlation with dichrographs of the
monomers.
2.5. Antimicrobial activity assays
To be able to confirm AMPs as antibiotics, their antimicrobial activity must be tested.
Adepantins are AMPs constructed to have high TI value with to the assumption that MIC
values can be low, especially against Escherichia coli, Gram-negative (G-) bacteria, since
processing data collected for Escherichia coli is used for ADPs design. In order to confirm
assumption that ADPs have low MIC value three tests were performed MIC, MBC and IC50
value testing.
2.5.1.MIC assays
MIC assay or minimum inhibitory concentration assay measures the minimum
concentration of AMP needed to inhibit visible growth of microorganisms after incubation.
Since the assay requires the incubation time of 18 hours it is not known whether peptides
activity is bacteriostatic or bactericidal. MIC values were determined using a broth
microdilution susceptibility test (Benincasa et al., 2004; Juretić et al., 2009; Ilić et al., 2013).
To perform this assay it was necessary to decide on bacteria strains and mediums depending
on goals wanted to be achieved and on expected sensitivity of peptides.
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a) Antimicrobial activity was tested on the reference strains:
 Escherichia coli ATCC25922
 Staphylococcus aureus ATCC25923
 Pseudomonas aeruginosa ATCC27853
 Salmonella typhimurium ATCC14082
 Klebsiella pneumoniae - clinical isolate
b) Medium used:
 Mueller-Hinton agar (MHa) – solid (for bacterial cultivation before experiment)
 Mueller-Hinton broth (MH) – liquid (for the experiment itself)
Preparation of bacteria:
All bacteria strains were stored at -80C while not in use. When needed for testing,
bacteria were routinely grown onto MHa plates and reinseminated in case of overgrowth or
oldness every 20 days. One day before the experiment, two or three bacterial colonies were
dispersed in 5 ml of MH for each bacteria and left overnight in a bacterial incubator at 37°C.
On the day of experiment 500 l of overnight bacterial culture were overseminated in
additional 15 ml MH and put into motion incubator for 2 hours in order to get active cells in
their exponential growth phase.
For the MIC assay, the ideal number of bacterial cells is in range 1x105 – 5x105 so
average is 2.5x105 and that is the desired final concentration for each bacteria in each
microtiter plate well. But since the bacteria and MH are added into microtiter plate well at
ratio 50:50 the bacteria concentration is reduced by half so used concentration needs to be
5x105.
To achieve the exact concentration of bacteria, dilution factor is calculated on the
basis of known ratio between the concentration and the absorbance measured at 600 nm.
The reference ratio used for bacteria was A = 0.031 nm to achieve 4.6x107 (E. coli), 0.100 for
1x108 (S. aureus), 0.039 for 1.45x108 (P. aeruginosa), 0.038 for 1.7x108 (S. typhimutium), and
0.148 for 1.1x109 (K. pneumoniae). Calculation was performed as follows:
r600 : cfur = m600 : x
Where r600 represents the reference absorbance, cfur reference bacterial number,
m600 measured absorbance and x number of bacteria needed. Dilution factor (df) is
calculated as follows:
X / 5 ∙ 105 = df
Vf / df = V (bacteria stock)
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Vf - V (bacteria stock) = V (MH)
The volume of MH needed for bacterial dilution to the final volume (Vf) is calculated
based on the number of wells used for each bacteria and increased by at least 2-3 ml for
easier manipulation (7-10ml was used).
Preparation of the experiment:
Stock peptide concentration used to determine MIC was mostly 1.28 mM. 96-well
polypropylene microtiter plate (Sarstedt, Nümbrecht, Germany) has 8 rows with 12 columns
and in each well the total volume used was 100 l. In each well from 2 – 12, 50 l of MH was
placed, while in the first well 100 l MH – x l of peptide was placed. After placing x l of
peptide in the first well 50 l of MH suspension was transferred to the second and well
stirred, then 50 l from the second well was transferred to the third, and the process was
repeated until the 11th well was reached, while the 12th was the control well not treated with
the peptide. This way, each step effectively dilutes the peptide two times for example 128
M 64 M 32 M 16 M 8 M 4 M 2 M 1 M 0.5 M 0.25 M
 0.125 M (Table 5) and the process is called serial two-fold dilution. Lastly, in each well
50 l of adjusted inoculums of bacteria was added, cowered with a sterile sticker and plastic
cover and incubated overnight 18 hours in a bacterial incubator at 37°C.
Table 5. Example of microtiter plate preparation for MIC assay; a) 100 l MH – x l of peptide; b) 50 l of MH
where peptide was later added; c) 50 l of MH without peptide that serves as a bacterial growth control;
concentrations in B row represents final peptide concentration in those wells achieved by serial two-fold
dilution.
well 1 2 3 4 5 6 7 8 9 10 11 12
A
B 128
M
64
M
32
M
16
M
8 M 4 M 2 M 1 M 0.5
M
0.25
M
0.125
M
0 M
C
D
E
F
G
H
a) b) c)
MIC values were obtained as the mean values of at least 3 independent
determinations where MIC value was taken as the lowest concentration of AMP resulting in
complete inhibition of visible bacteria growth.
2.5.2.MBC assays
Minimal bactericidal concentration (MBC) of the peptide is defined as the minimal
concentration of chosen peptide that will cause 99.9% of reduction of bacterial growth. The
assay was performed as a follow up of the MIC assay to determine whether MIC value was
only bacteriostatic or also bactericidal. The process will be described for only one peptide,
although it was performed for all of them.
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After collecting MIC values, 10 l aliquots of the medium with peptide and bacteria
were taken from the microtiter plate wells with no visible bacterial growth (MIC value) and
from the next two wells with higher concentration, 2x MIC and 4x MIC. To allow colony
growth, taken aliquots were plated on MH agar plates and incubated for 24 hours. Peptide
concentration causing at least a 99.9% reduction of the number of bacteria present at the
beginning of MIC assay was defined as MBC value (Tossi et al., 1994). The experiment was
repeated two times in duplicate.
2.5.3. Effect of AMPs on bacterial growth kinetics and IC50
IC50 value or half maximal inhibitory concentration is the concentration of the AMP
necessary to inhibit given biological process (e.g. cell growth) by 50%, and was extracted
from the data gathered with bacterial growth kinetics (Mattiuzzo et al., 2007). For this assay
the same bacteria and mediums as for MIC assay were used (see 2.5.1 on page 33). Results
from MIC assay were taken as orientation for peptide concentrations in bacterial growth
kinetics.
Preparation of bacteria:
Bacteria were prepared the same way as for the MIC assay when considering storing,
routinely growing and overnight preparation of bacteria. The part of the procedure that
differs was oversemination on the day of the experiment. The aliquot taken was 300 ml of
overnight culture instead of 500 ml. The final concentration of bacteria in microtiter plate
needs to be 1x106 cfu. Therefore, for the assay each bacteria was prepared in 2x106 cfu
since, when put in the microtiter plate they were diluted two times. The number of bacteria
was calculated in the same way as for MIC assay using same referent values.
Preparation of experiment:
Starting peptide concentration used for bacterial growth kinetics was 1.28 mM.
The total volume used in microtiter plate wells (Sarstedt, Nümbrecht, Germany) of
200 l was achieved with 100 l MH – x l of peptide and 100 l of adjusted inoculums of
bacteria. For each peptide there were 3 - 6 different concentrations used for each bacteria,
preformed in triplicates and repeated at least 3 times. The concentrations of peptides were
obtained by two-fold dilution technique used also in MIC assay, but in smaller number of
dilutions (Table 6). MIC values were taken as orientation and the first attempt of this assay
was only for orientation and later assay was repeated with lower concentration of the
peptides in order that bacterial growth was visible.
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Table 6. Example of microtiter plate preparation for bacterial growth kinetic; First column is negative control
containing bacteria with medium without peptide; each peptide has 3-5 concentrations in triplicates; well
12H contains only 200 l 100 % MH as a blank to avoid any possible background noise.
well 1 2 3 4 5 6 7 8 9 10 11 12
A MH + bacteria ADP18 M ADP14 M ADP12 M ADP11 M ADP2(AM)1.6 M ADP2(AM)0.8 M ADP2(AM)0.4 M ADP3(AM)8M ADP3(AM)4 M ADP3(AM)2 M ADP3(AM)1 M
B MH + bacteria -II- -II- -II- -II- -II- -II- -II- -II- -II- -II- -II-
C MH + bacteria -II- -II- -II- -II- -II- -II- -II- -II- -II- -II- -II-
D MH + bacteria [ADP2]20.4 M [ADP2]20.2 M [ADP2]20.1 M [ADP2]20.05 M [ADP2]20.025 M [ADP3]20.4 M [ADP3]20.2 M [ADP3]20.1 M [ADP3]20.05 M [ADP3]20.025 M /
E MH + bacteria -II- -II- -II- -II- -II- -II- -II- -II- -II- -II- /
F MH + bacteria -II- -II- -II- -II- -II- -II- -II- -II- -II- -II- /
G / / / / / / / / / / / /
H / / / / / / / / / / / MH 100%
-II-: repeat of the well above, / : empty well. Wells A1 to F1 are positive controls (bacteria with no
peptide). Well H12 is a negative control (MH broth with no bacteria or peptide), required to test for
contamination.
In vitro monitoring of bacterial growth inhibition was performed on a microtiter plate
reader (Tecan Männedorf, Switzerland) with periodic shaking at 37°C where optical density
(OD) was measured at 620 nm every 10 min for 4 hours. Mean concentration of the peptide
which inhibits bacterial growth by 50% at 210 min was taken as IC50 value.
2.5.4. Barrier effect of outer membrane – permeabilization kinetics
To test the barrier effect of the outer membrane, the E. coli BW 25113 (a K12 strain)
was used with its deletion mutant waaP (Yethon et al., 1998) (Figure 9). The whole assay
was performed as bacterial growth inhibition assay.
To achieve the exact concentration of bacteria, a dilution factor is calculated on the
basis of known ratio in-between concentration and the absorbance measured at 600 nm in 1
ml cuvette in which for blank measurement was 1 ml of MH and for bacteria concentration
measurement 900 l MH + 100 l bacteria. The reference ratio for the used bacteria was
0.031 OD at 600 nm, to achieve 4.6x107. The calculation was performed as described in
equations on page 34. The microtiter plate was prepared as previously described for
bacterial growth inhibition assay only with different positioning of bacteria and peptides
concentrations. Bacterial growth inhibition was also performed on a microtiter plate reader
(Tecan Männedorf, Switzerland) with periodic shaking at 37°C where optical density (OD)
was measured at 620 nm every 10 min for 4 hours.
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Figure 9. Lipopolysaccharide (LPS) structure in E. coli with genes involved in its synthesis; * predicted activity of
the waaP gene product (as in Yethon and Whitfield, 2001).
2.6. Bacterial membrane permeabilization assays
One of the crucial information on peptides mode of action was to determine whether
peptides permeabilize membrane and which one was permeabilized, outer or inner
membrane. The main target for testing permeabilization was Escherichia coli and it’s
genetically altered strains, since adepantins design used data collected for E. coli. Testing the
permeabilization is based on absorbance or florescence when the reagents, which normally
cannot penetrate the cell, come in contact with certain molecules from the cell after
membrane ruptures. Inner membrane permeabilization was determined by measuring the
propidium iodide (PI) and Gal-ONp uptake by bacterial cells, while outer membrane
permeabilization was determined by CENTA® uptake.
*
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2.6.1. Spectroscopic analysis of permeabilization to chromogenic
substrates
PI assay was also used to discover whether adepantins permeabilize membrane and
help find approximate concentration of peptides necessary for that process. To confirm
permeabilization two other assays were performed, one for outer and other for inner
membrane. For both assays adepantins were prepared in concentration 0.25 M to be
easier to handle.
The permeabilization of the outer membrane of E. coli by adepantins was evaluated
by following the unmasking of the periplasmic hydrolytic enzyme β-lactamase, using
extracellular CENTA® as substrate (Jones et al., 1982), while that of the cytoplasmic
membrane by unmasking cytoplasmic β-galactosidase activity using extracellular o-
nitrophenyl-β-D-galactopyranoside (Gal-ONp) as substrate, as described previously (Tiozzo et
al., 1998; Zelezetsky et al., 2005). The β-galactosidase constitutive, lactose-permease
deficient, ampicillin resistant E. coli ML-35 pYC strain was used.
Preparation of bacteria:
In 15 ml of MH broth with 0.05 mg/ml of ampicillin (MW = 349.41 g/mol) bacteria
were sown and left overnight in bacteria incubator at 37°C. The next morning 300 l of
bacterial suspension was added to 15 ml of fresh MH broth with 0.05 mg/ml of ampicillin
and placed in the motion incubator at 37°C for 2 hours. In order to remove MH medium, the
suspension was centrifuged at 3500 rpm for 10 minutes and pellet of bacteria was
resuspended in PBS buffer to concentration of 1x108 cfu/ml. The concentration was
confirmed by measuring absorption at 600 nm on Ultrospec 2100 Pro (Amersham
Bioscience) spectrophotometer. The final concentration of bacteria in microtiter plate well
was 1x107 cfu/ml.
Protocol for outer membrane:
Fresh 50 mM CENTA® (MW = 535.6 g/mol) solution in DMSO was prepared by
dissolving 1.4 mg of CENTA® in 52.27 l of DMSO. CENTA® solution was then brought to 1.5
mM concentration by diluting it 33x in PBS. 156 l pure PBS was placed into each well of the
microtiter plate which were then treated with 4 l of desired peptide, 20 l of prepared
CENTA® solution and 20 l of bacteria dispersed in PBS, so total volume in the well was 200
l. Controls, negative as bacteria suspension without peptide and positive as well treated
with SMAP-29 peptide were also placed to microtiter plate. Later adepantin dimers were
used as positive controls since they permeabilize membranes more than SMAP-29. Plate was
then placed on microtiter plate reader (Tecan Männedorf, Switzerland) for measurement
with periodic shaking at 37°C where optical density (OD) was measured at 405 nm every 10
min for two hours.
Protocol for inner membrane:
15 mM Gal-ONp (MW = 301.3 g/mol) solution in PBS was prepared. 158 l pure PBS
was placed into each well of the microtiter plate which were then treated with 2 l of
desired peptide, 20 l of prepared Gal-ONp solution and 20 l of bacteria dispersed in PBS,
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so the total volume in the well was 200 l. Controls were prepared as described for CENTA®.
The plate was then placed on a microtiter plate reader (Tecan Männedorf, Switzerland) for
measurement with periodic shaking at 37°C where optical density (OD) was measured at 405
nm every 10 min for two hours.
2.6.2. Flow cytometric analysis of permeabilization to PI
The method used for examining and counting number of cells with certain feature is
called flow cytometry. In the first experiment this method was used for testing propidium
iodide (PI) (Figure 10) uptake by bacterial cells after addition of adepantins. PI cannot be
found in living cell due to its inability to pass through cell membrane. Once membrane is
damaged, in this case with AMPs making pores in it, PI enters cell and binds to nucleic acids.
When bound to the DNA, its red fluorescence increases up to 30 times. This fluorescence
increase allows evaluation of the viability of the bacterial cells. Cells that florescence were
counted as dead cells due to their membrane permeabilization. PI is cationic molecule with
the molecular mass 668.3946 Da.
Figure 10. Propidium iodide (IP) molecule (as in Web link [14]).
The bacteria strain used for this procedure was E. coli ATCC25922 and was prepared
in the same way as for the IC50 assay. Two to three colonies of bacteria were dispersed in 5
ml of MH medium and left overnight at 37°C in bacterial incubator. From an overnight
culture, a volume of 300 l was seminated in 15 ml MH medium and put in a motion
incubator for 2 hours (exponential growth phase). The desired final concentration for
bacteria was 1x106 cfu to which 10 g/ml PI and 0.25 M peptides were added (starting
from prepared stock solution of 25 M peptide). This peptide concentration is lower than
that used in other assays so that a useable signal could be obtained.
PI uptake by bacterial cells was measured using flow cytomerty as described in Podda
et al., 2006. 10 l of PI was added to a glass test tube with 1 ml of bacteria, and 10 l of
peptide. Timing started when peptide was added to the mixture. While waiting for
measurement for a given period of time, the tube was placed in a termostated water bath
adjusted to 37°C. Measurements were performed in a FC500 instrument (Beckman Coulter,
Lexington, MA) after the following incubation times: 15, 30, 45, 60 and 90 minutes. Data
analysis was performed with the FCS Express3 software (De Novo Software, Los Angeles, CA)
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and results were expressed as a percentage of PI positive cells for all peptides in each
measured time period.
2.7. Interaction of peptides with host cells
AMPs can have good antimicrobial activity, but in order for them to be useable as
antibiotics they must have a low toxicity. Not all AMPs listed in AMPad database have that
kind of selectivity. Some have low MIC value and are quite toxic to erythrocytes,
representative of host cells. Toxicity in this case was expressed in terms of a HC50 value that
represents peptide concentration required to induce 50% of haemolysis of red blood cells
(RBC). The HC50 value enters in the expression for the therapeutical index TI= HC50/MIC(1))
where MIC is the minimal inhibitory concentration for E. coli. A low HC50 value indicates high
toxicity. If it is also associated with a high MIC (poor antimicrobial potency), this will lead to a
low TI value, so that the respective peptide does not represent good and selective
antimicrobial antibiotic. To test the selectivity of adepantins, as predicted with „Predictor“
algorithm (Juretić et al., 2009) it was thus necessary to obtain haemolysis values so as to
obtain their HC50 value.
2.7.1. Haemolysis assay
Haemolytic activity of the peptides was assessed on freshly isolated human
erythrocytes (RBC), obtained from healthy donors, by monitoring release of haemoglobin at
405 nm.
Preparation required the day before the experiment:
 Scheme for peptide order on microtiter plate used for faster results collecting, taking
into account that each conc. will be performed in triplet,
 Fresh buffers: 1) PBS (10 mM SPB + 139 mM NaCl, pH=7,4), 2) PBS + 1 mM EDTA, 3)
1% TritonX-100 in PBS (final conc. be 0.2%),
 PBS was added to eppendorfs at the volume required for each peptide conc. that
would be added (50 µl - x µl of peptide),
 PBS + Triton X was added to eppendorfs required for total lysis (positive control).
Content of Eppendorfs used on the day of the expereiment:
 TOTAL LYSIS (Triton) - 270 µl PBS + 80 µl 1% Triton X + 50 µl erythrocytes = 400 µl
(x3),
 BLANK: 50% PBS + 50% prepared erythrocytes (50:50 µl) + 300 µl cold PBS added later
to stop reaction = 400 µl (x3),
 PEPTIDE: 50 µl erythrocytes + (50-x) µl PBS + x µl peptide stock + 300 µl cold PBS
added later to stop the reaction = 400 µl (x3).
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Procedure:
a) Before dealing with blood the following preparations were made:
 waste bag for all waste material that comes in contact with blood,
 container with ice,
 balance for the centrifuge,
 protective clothing (lab coat, gloves, cotton mask, safety glasses).
b) Blood washing:
 If the blood was from the blood bank, all information on the bag (serial n°, blood type
etc.) are recorded.
 If the blood is extracted directly from a donor record name and sex.
 Blood was transferred into a falcon tube with anticoagulant (heparin).
 5ml of the treated blood was transferred into a test tube.
 15 ml of the cold (PBS + 1 mM EDTA) was added in order to deactivate the effect of
Ca++.
 The mixture was centrifuged at 1500 rpm for 15 min that depends on centrifuge and
blood. The result had to be sedimentation and to achieve that it was better to put
centrifugation on lower rpm and longer time period. For adepantins the optimal
combination was 15 min on 1500 rpm.
 Supernatant was eliminated with a glass Pasteur pipette and another aliquot of PBS
was added at a 1:1 ratio with blood.
 Washing was repeated 3-5 times with cold PBS and erythrocytes were then
transferred to another test tube avoiding white foamy part on top.
 Another aliquot of PBS in 1:1 ratio with RBC was added.
c) Erythrocytes concentration:
 Different RBC dilutions were prepared from the starting test tube in eppendorfs to
get for example 40x, 50x and 60x (e.g. 50x = 20 µl RBC + 980 µl PBS for a total 1ml).
 The blank cuvette was filled only with 800 µl of PBS.
 A test cuvette was filled with 540 µl PBS + 160 µl 1% Triton X + 100 µl erythrocytes
(previously prepared dilutions) to a total of 800 µlmixture.
 Absorbance was measured at 405 and 415 nm.
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 If the measurement was near 1.3 for 405 nm and 1.8 for 415 nm the RBC
concentration had the correct values, corresponding to 1% RBC, and that dilution
could be used. If the measured values were not in the desired range, the dilution of
RBC was adjusted to achieve them.
d) Haemolysis:
 To the previously prepared eppendorf tubes aliquots of chosen dilution of 50 µl RBC
were added (50:50 µl).
 Peptides were added to the desired concentration (x ml stock) and stirred very
slightly in order not to affect the lysis process.
 The eppendorf tubes were then incubated at 37°C for 30 min without motion.
 To block the reaction 300 µl of cold PBS was added and the eppendorf tubes left for 5
minutes on an ice-bath before centrifuging at 1000 rpm for 5 minutes.
 200 µl from each supernatant was transferred carefully into a microtiter plate well so
as not to take sediment or create bubbles that could disturb absorbance reading.
 Absorbance was measured at 405 nm with a microtiter plate reader (Tecan
Männedorf, Switzerland).
 To extract percentage of haemolysis the following formula was used:
% HAEMOLYSIS = [(Ax – Ab) / (At – Ab)] ∙ 100 (3)
where Ab is absorbance at 405 nm of blank wells, Ax is the absorbance at 405 nm of
wells with peptide, At is the absorbance at 405 nm of wells with TritonX-100 (positive
control corresponding to 100% haemolysis). Experiments were performed three times in
triplicates for each peptide, and mean values of % haemolysis were plotted against peptide
concentration so that HC50 values could be extrapolated for each peptide as the
concentration of the peptide producing 50% haemolysis, taking standard deviation into
account to estimate the error.
Adepantins in concentrations ranging from 5-500 µM were incubated with washed
0.5% RBC in PBS (achieved by mixing 50 µl of 1% RBC and 50 µl PBS with ADPs) for 30
minutes at 37˚C without shaking. A parallel incubation in the presence of 0.2% Triton was
carried out to determine absorbance at 100% haemolysis. HC50 value was taken as the mean
concentration ± SD of the peptide causing 50% haemolysis.
2.7.2. Flow cytometric analysis of cellular AMP uptake
Flow cytometry was also used to monitor surface binding and internalisation of
BODIPY-labelled adepantins with respect to the U937 cell line (human monocytic lymphoma)
at 106 cells/ml. Monocytes were incubated with ADP2(BY) and ADP3(BY) at concentrations
0.1 M and 1 M and treated with PI for 5 minutes at room temperature, after which
florescence was measured at 525 nm (BODIPY) for membrane interaction and at 610 nm (PI)
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for membrane permeabilization at 5, 15, 30 minutes. At the end the, treated cells were
incubated with 0.1% Trypan blue (TB) quencher, to distinguish between surface bound
peptide (quenched) and internalised peptide (unquenched).
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3. Results
3.1. Peptide sets derived from the AMPad database
Construction of the AMPad database was based on a comprehensive literature survey,
mostly using the PubMed-NCBI database (Web link [6]). Relevant articles were found using
keywords like antimicrobial, peptides, MIC, HC50, TI,  helical, amphipathic, rana, frog, etc.
This literature research performed by Prof. Juretić (Juretić et al., 2009) was the basis for all
subsequent work, including the already mentioned construction of the peptide database, the
development of algorithms based on its contents, and the eventual laboratory testing of
novel peptides suggested by these algorithms.
In the AMPad database we included all peptides that to our knowledge were
available in the literature at the time, with the following characteristics:
 Amphibian origin,
  helical in membrane mimetic solvent,
 Natural peptide or peptide with maximum 1 point mutation,
 Available MIC and HC50 values, if possible in the same article (5 peptides do not
follow this rule),
 MIC values determined using the broth microdilution susceptibility test,
 HC50 values determined using freshly isolated human red blood cells from healthy
donors. Many of the peptides found were tested in Conlon’s laboratory, and
therefore can be assumed to have been tested under the same conditions.
All of the peptides had an -helical structure, either experimentally determined or
predicted. For those peptides for which published experimental data was unavailable, the
helix-forming propensity was predicted by using the SPLIT algorithm version 3.5 (Juretić et
al., 1998) (Web link [7]).
The AMPad database consists of a set of 73 amphibian,  helical peptides. For each,
the TI value was calculated from the collected MIC and HC50 data. This set “set of AMPad
peptides” was termed SAP (Appendix 1). SAP was then split into two sets termed the
“training” and “testing” set. The requirements were that peptides in the “training” set
should be non-homologous, i.e. with less than 70% pairwise identity. All the remaining
peptides formed the “testing” set.
To get information on the pairwise identity, the Clustal V (version used in 2008) tool
was used on the whole SAP set of peptides (Higgins et al., 1992). The resulting data were
placed in a triangular matrix, consisting of peptide names and value of identity. All peptides
with identities  70% were then identified and extracted to join the “testing” set while the
ones remaining in the matrix formed the “training” set. An additional peptide set termed
“set of the best peptides” (SBP) included 26 AMPs with TI > 20, 11 from the “training” and 15
from the “testing” set (Table 7).
Results Nada Ilić
46
Table 7. “Set of the best peptides” (SBP) where the first 15 peptides are from the “testing” set and the last 11
peptides from the “training” set, in both cases ordered by descending value of TI.
Peptide name Peptide sequence HC50 MIC TI(exp)
1 Magainin 2 analogue F5W GIGKWLHSAKKFGKAFVGEIMNS 1000,00 8,00 125,00
2 Pseudin 2 analogue K3, K10,K14 GLKALKKVFKGIHKAIKLINNHVQ 330,00 5,00 66,00
3 Magainin-analogue-12W-MG2 GIGKFLHSAKKWGKAFVGEIMNS 550,00 12,50 44,00
4 Pseudin 2 analogue F19 GLNALKKVFQGIHEAIKLFNNHVQ 430,00 10,00 43,00
5 Brevinin-2PRc GLMSVLKGVLKTAGKHIFKNGGSLLDQAKCKISGQC 125,00 3,00 41,66
6 Temporin-1DRa-Lys-7 HFLGTLKNLAKKIL-NH2 330,00 8,00 41,25
7 Esculentin-1ARb GLFPKFNKKKVKTGIFDIIKTVGKEAGMDVLRTGIDVIGCKIKGEC 120,00 3,00 40,00
8 Ranatuerin-2CSa GILSSFKGVAKGVAKGVAKDLAGKLLETLKCKITGC 150,00 4,00 37,50
9 Brevinin-2TSa GIMSLFKGVLKTAGKHVAGSLVDQLKCKITGGC 100,00 3,00 33,33
10 Brevinin-2PRd GLMSVLKGVLKTAGKHIFKNVGGSLLDQAKCKITGQC 100,00 3,00 33,33
11 Brevinin-2PRe GLLSVLKGVLKTAGKHIFKNVGGSLLDQAKCKISGQC 80,00 3,00 26,67
12 Dermaseptin-L1 GLWSKIKEAAKAAGKAALNAVTGLVNQGDQPS 200,00 8,00 25,00
13 Ranatuerin-2BYa GILSTFKGLAKGVAKDLAGNLLDKFKCKITGC 120,00 5,00 24,00
14 Ranatuerin 1 analogue K8 SMLSVLKKLGKVGLGFVACKINKQC 110,00 5,00 22,00
15 Brevinin-2PRb GLMSLFRGVLKTAGKHIFKNVGGSLLDQAKCKITGEC 65,00 3,00 21,67
1 PGLA GMASKAGAIAGKIAKVALKAL-NH2 900,00 8,60 104,65
2 ESCULENTIN-1ARa GIFSKINKKKAKTGLFNIIKTVGKEAGMDVIRAGIDTISCKIKGEC 180,00 2,00 90,00
3 ASCAPHIN 1 GFRDVLKGAAKAFVKTVAGHIAN-NH2 200,00 3,00 66,67
4 DERMASEPTIN 3 ALWKNMLKGIGKLAGKAALGAVKKLVGAES 50,00 0,80 62,50
5 RANATUERIN-2AUa GILSSFKGVAKGVAKNLAGKLLDELKCKITGC 290,00 5,00 58,00
6 XPF GWASKIGQTLGKIAKVGLKELIQPK-NH2 375,40 8,80 42,66
7 ESCULENTIN-1GRA GLFSKFAGKGIKNLIFKGVKHIGKEVGMDVIRTGIDVAGCKIKGEC 210,00 6,00 35,00
8 PEXIGANAN GIGKFLKKAKKFGKAFVKILKK 45,00 1,50 30,00
9 BREVININ-2GRb GVLGTVKNLLIGAGKSAAQSVLKTLSCKLSNDC 180,00 6,00 30,00
10 DERMASEPTIN 1 ALWKTMLKKLGTMALHAGKAALGAAADTISQGTQ 40,00 1,50 26,67
11 MAGAININ 2 GIGKFLHSAKKFGKAFVGEIMNS 1000,00 50,00 20,00
The peptides sequences selected for entry into our database varied in size from 13 to
46 residues, with a distribution as shown in Figure 11. The largest number of peptides
collected and included in the database was in the 20 - 29 AA range. A peptide with a length
of 20 AA can span the membrane of Gram-negative bacteria which may affect the size of
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AMPs, frequently over 20 residues, although for peptides acting by the “carpet mechanism”
(see section 1.1.2 page 4), that interact with the membrane in a parallel manner, the
permeabilization mechanism is not necessarily dependent on peptide size.
Figure 11. Relationship between peptide length and number of peptide entries in the whole AMPad database,
“training” and “testing” sets and “set of the best peptides” (SBP).
This is evident when considering the distribution of the peptides’ TI values in
dependence of their sequence length (Figure 12), which has a very wide length distribution
(13 - 46). This is irrespective of the TI value, so that peptides with TI < 20 range from 13 – 37,
and those with TI > 20 range from 14 – 47, although most of these peptides are > 20.
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Figure 12. Distribution of the peptides in the AMPad database divided in three sets considering peptide length
by number of AA and experimental TI value; SBP („set of the best peptides“) constructed from peptides
included in both sets that have TI greater than 20.
The adepantins proposed by the algorithm all have the length of 23 AA, with the idea
of creating α helical peptides that could span the membrane of the Gram-negative bacteria,
but also corresponding to the lenght of peptides forming the largest cluster of peptides from
AMPad database (Figure 11). From the table given in Figure 11 one can note that the
“training” and the “testing” set have the largest number of peptides in the same cluster as
the ADPad database consisting of peptides with 20-29 AA legth.
Once the AMPad database was created, it was then possible to correlate TI to the
peptides’ position-dependent physicochemical properties. This made use of the concept of
sequence moments as defined by Prof. Davor Juretić (2009), so that for each peptide, the
sequence profiles were converted into vectors (Figure 14; Juretić et al.,2009; Juretić et al.,
2011).
The next step was to create an optimal descriptor, by finding the correlation between
a scalar descriptor extracted from the sequence moments and the measured TI value of each
peptide in the „training“ set.
The correlation with scalar descriptors corresponding to a single scale of AA atributes
was not high, with r2 = 0.52. A better choice of attributes used a triplet consisting of two AA
scales and one smoothing technique, assigning 2700 descriptors to each triplet (see 2.1.3).
Out of 2700 descriptors for each triplet, the best combination, consisting of Janin and Guy
scale and smoothing process that excludes the central AA in the sliding window of length 11
AA, resulted in a correlation coefficient r2 ≥ 0.83 with respect to the “training” data set. The
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comparable correlation was obtained for the simple descriptor found by Prof. Damir
Vukičević, named D-descriptor (see Table 8), defined as the cosine of the angle between
sequence moments obtained using the hydrophobicitiy scales of Guy (Guy 1985) and Janin
(Janin 1979), with the peptide sequence set in an arc of α = π/2, with a smoothing process
that excludes the central AA in the sliding window used to sum all sequence environment
vectors, and using a weighing factor q = 1/3 (see Figure 14) (Juretić et al., 2009; Juretić et al.,
2011). The sliding window is 11 AA long, excludes central AA and while aproaching the
termini of the sequence reduces number of AA simetricaly. For the first AA the value is
calculated as the mean value of the second and the third AA. Simillar is for the last AA where
value is calculated as the mean of two previous AA. The chosen pair of AA atribute scales
were both hydrophobicity scales differing in their classification of three AA residues in
particular, Gly, Ala and His. In Janin scale, Gly is considered to be burried in the membrane
while in the Guy scale it si considered polar. This led to the possibility of forming unusual
sequences, like all Gly, Ala or Hys peptides that are not likely to exist in nature, but are
predicted to have maximal TI value by the D-descriptor. This was one of the limitations of D-
descriptor model, and for this reason, a filter was set to avoid sequences with repeated
residues. Another limitation was the fact that it is trained on frog-derived peptides and is
considered to be reliable only for this type of peptides. Only extended comparisons with
databases of helical AMPs collected from other microorganisms (e.g. insect peptides or
mammalian cathelicidins) (Tossi et al., 2000), will show if it is more universally applicable.
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Table 8. Three descriptors with the highest correlation found by „PredictorSelector“. Although D-descriptor (in
the second row) has slightly lower correlation than the first one, it was chosen because it is much simpler
than the first one. For codes of the used scales see Appendix 5. Correlation is among descriptor values and
experimentally determined TI values for peptides in the “training” set.
Angle between sequence moments: multiply by angle in radians
Scales: 7, 35
Smoothing technique: sliding window of lenght 11 AA that excludes middle AA
Bending angle: /5
Weighting exponent: 1/2
Length of the sequent moment corresponding to scale 7: length in the nominator
Length of the sequent moment corresponding to scale 35: disregard
Correlation= 0.915613
Angle between sequence moments: multiply by cosine of this angle
Scales: 5, 31
Smoothing technique: sliding window of lenght 11 AA that excludes middle AA
Bending angle: /2
Weighting exponent: 1/3
Length of the sequent moment corresponding to scale 5: disregard
Length of the sequent moment corresponding to scale 31: disregard
Correlation= -0.911006
Angle between sequence moments: multiply by angle in radians
Scales: 29, 31
Smoothing technique: sliding window of lenght 11 AA that excludes middle AA
Bending angle: /2
Weighting exponent: 1/2
Length of the sequent moment corresponding to scale 29: length in the nominator
Length of the sequent moment corresponding to scale 31: length in the denominator
Correlation= 0.907174
The best linear fit between predicted TI value and D-descriptor value: TI = 50.126 –
44.803D, was found after the D-descriptor values were calculated for the „training“ set of
peptides. From this, TI values could be predicted from the D parameter of each peptide in
the „testing“ set. The correlation of the measured and predicted TI values for the “testing”
set gave an acceptable indication of correlation expressed as the determination coefficient
(R2 = 0.64). Statistical methods were not used in standard manner (Juretić et al., 2009). The
Pearson r correlation is used on the nonstandard distribution of data in an attempt to
predict which peptides have high TI value, which was achieved. That way D-descriptor was
designed to distinguish between good and mediocre peptide antibiotics, which is indicated
by the angle between sequence moments. The bigger the angle is, the better antibiotic
peptide is supposed to be. Although the chosen D-descriptor was selected out of many other
possible descriptors using only 11 peptides with high TI values (part of the “training” set, see
Table 7), additional tests justified the choice (Juretić et al., 2009).
The “Designer“ algorithm was then constructed using D-descriptor to suggest the
sequence of potential AMPs with high selectivity (high TI), with some additional restrictions
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to lower the number of generated peptides to a workable load. Amphipathicity is one of the
characteristics of AMPs that helps them interact with membranes. The amphipathicity of a
peptide can be visualised by considering a helical wheel projection, such as that of ascaphin
1 shown in Figure 13. Ascaphin 1 is known to be good peptide antibiotic. Using the Virginia
University helical wheel application (Web link [1]) or HydroMCalc tool (Web link [8]), it can
be seen that the AA residues are distributed so as to cluster on different sides (sectors) of
the projection, and this was one of the features included in the „Designer“ algorithm.
The „Designer“ algorithm thus uses recursive algorithm with inbuilt simple
restrictions to greatly reduce the number of sequences, and then the inbuilt TI-predictor,
based on linear D-descriptor model, eliminated 81% of the rest of proposed peptides with
length of 23 AA leaving a workable load of only 7 peptides. The sequence moment vectors
for three of these peptides: adepantin 1, 2 and 3 are shown in Figure 14, where it can be
seen that there is a large angle separating the vectors determined using the Guy and Janins
scales respectively.
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Figure 13. Example of the results given by Virginia university helical wheel application (Web link [1]) and
HydroMCalc tool (Web link [8]); Aschapin1 was used for experimental testing, as very selective
antimicrobial peptide. Separation between hydrophilic and hydrophobic AA is clearly visible.
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Figure 14. Sequence moments for adepantins 1, 2 and 3; small arrows are calculated by using amino acids index
scales (Appendix 2, Appendix 3, Appendix 4), red for Janin’s (Janin 1979) scale and blue for Guy’s (Guy
1985) scale; sum of the small vectors result in sequence moments presented by the large vectors; angle
between sequence moments is used to calculate D-descriptor as the cosine of that angle.
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3.2. From designed to synthesized peptides
Restrictions included in the „Designer“ algorithm (Juretić et al., 2009) produced a
workable load of 7 peptides (Table 9). Restrictions were created in a manner to suggest
peptides with high TI values and to be active against Gram-negative bacteria.
Table 9. Output adepantin sequences from the „Designer“ algorithm.
Peptide name Peptide sequence TI(pred)
Motif
regularity
index
Mean
hydrophobicity
index (H)
Peptide net
positive
charge(1)
Adepantin 3 GLKGLLGKALKGIGKHIGKAQGC 94.841 2.385 -1.061, 5
- GLKGLLGKALGEAKGLLGKHKGC 94.917 2.487 -1.074, 4
- GITQGVLKGIGKHVGKALKGIGC 85.143 2.436 -0.857, 4
Adepantin 2 GIGKHVGKALKGLKGLLKGLGEC 91.101 2.308 -0.891, 4
Adepantin 1 GIGKHVGKALKGLKGLLKGLGES 85.838 2.308 -0.978, 4
- GIGKHVGKALKGVKGLLKGLGEC 91.915 2.410 -1.135, 4
- GIGKHVGKALGELKGLLKGLKGC 94.905 2.410 -0.891, 4
TI(pred) is the value predicted by the D-descriptor model; mean hydrophobicity is based on CCS scale (Web link
[8]); red underlined – “small” motifs in ADPs ([G,S,A]XXX[G,S,A] and GXXGXXXG) (Senes et al., 2000);. (1) Note
that during the peptide design and filtering process, charge was determined assigning +1 to Lys and Arg and -1
to Glu and Asp. His was considered neutral. Both N- and C-termini were considered free and therefore
cancelled each other out.
„Designer“ output proposed 6 peptides ending with Cysteine, while only one ends
with Serine. Cysteine at the C-terminus of the proposed peptides may be the result of the
requirement that three C-terminal AA residues should be the same as in at least one good
natural peptide antibiotic. Cys is present at the C-terminus of many helical AMPs derived
from frogs (Tossi at al. 2000, Simmaco at al. 1998) as it is part of the so-called “Rana-box”
consisting of Cys on the last and 6th from the last position, connected with disulfide bridge. A
single Cys residue in a sequence can be problematic, as it is quite reactive, so adepantin 1
(ADP1), as the only one ending with a Serine, was considered to be the most suitable first
candidate for performing verification tests. With a predicted TI of 86, ADP1 was not the
peptide predicted to be the most selective in the group, but was in any case expected to be
very selective. The „Designer“ algorithm required a net positive charge of 4 or 5 and the
mean hydrophobicity from 0.0 to -1.2 as often found for helical AMPs (Tossi et al., 2000)
using the CCS scale (Tossi et al., 2002).
Three so-called “small” motifs [G,S,A]XXX[G,S,A] are present in the sequence (Table
9), a primary structural feature that indicates a high probability of membrane insertion and
helix-helix interaction in the membrane (Senes et al., 2000), respectively. Furthermore,
when compared to the primary structures of known α helical peptides, ADP1 was less than
50% identical to any of them. As for the reference peptides from the “training” set, it was
decided to test two of these, picking one mediocre peptide, pseudin 2 (PSEU2) (Olson et al.,
2001), and one good peptide antibiotic with high TI, ascaphin 1 (ASC1) (Conlon et al., 2004).
This would not only provide reference data for comparing the activity of ADP1, but would
also confirm the experimental data for at least two of the database peptides, and the
capacity of the algorithm to predict TI that correlate to the real one. These peptides were
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then also used in a first evaluation of the „Mutator“ algorithm, a version of „Designer“ used
to suggest point mutations to improve the selectivity of known peptides.
For the second set of tests, two additional peptides were taken from the „Designer“
set (Table 9), choosing the most and the least similar in primary structure to adepantin 1.
While adepantin 2 (ADP2) differs from the ADP1 only in the last position (Ser  Cys),
alignment using the Clustal W (version used in 2010) showed that adepantin 3 (ADP3)
differed in maximal number of positions (Figure 15). The purpose for additional testing was
to test if other adepantins are as selective as ADP1 and to use reactive sulphydryl group of
the Cys at the C-terminus for additional testing.
Figure 15. Cladogram tree from Clustal W tool showing sequence alignment of 7 resulting peptides from the
„Designer“ algorithm; Seq4 was later called adepantin 2 and is most similar to adepantin 1; Seq1 later
called adepantin 3 and is most different from adepantin 1.
In preparation for the synthesis, peptides sequences were evaluated using different
software programs. Furthermore, it was decided to synthesize the peptides as C-terminal
amides. This would not only increase stability and facilitate syntheses, but also increase the
charge by +1, likely increasing the potency. The online Expasy ProtParam tool provided MW
as well as pI, stability indices, hydropathicities etc. (Web link [15]) for the amidated peptides.
Results for ADP1 are presented below:
Adepantin 1 (ADP1 or DESC1) [2259,79]
GIGKHVGKALKGLKGLLKGLGES-NH2
Number of amino acids: 23
Molecular weight: 2259.7
Theoretical pI: 10.18
Total number of negatively charged residues (Asp + Glu): 1
Total number of positively charged residues (Arg + Lys): 5
Instability index:
The instability index (II) is computed to be -22.25
This classifies the protein as stable.
Aliphatic index: 118.70
Grand average of hydropathicity (GRAVY): -0.013
Next, the Peptide Companion tool (CoshiSoft) was used to predict possible difficult
coupling points in the synthesis. This tool attempts to estimate the aggregation potential of
the peptides and relates this to decreased coupling efficiency due to steric hindrance.
Although it does not take side-chain protecting groups into consideration, it has been quite
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an effective tool in the experience of the Trieste University peptide synthesis lab. The result
presented is for ADP1 (Figure 16):
Figure 16. Prediction of the synthesis difficulty for ADP1 by Peptide companion tool. Most AA are between
upper two lines indicating difficult synthesis.
As is visible from the figure the aggregation potential was high (1 - 1.2) at almost all
positions from the 6th away from the C-terminus (the peptide is synthesised C-term  N-
term), meaning that couplings among AA in adepantin were to be considered generally
difficult. This suggested the use of double-coupling cycles throughout the synthesis. This
procedure ensured that the peptides were synthesized in good yields and in quite high
purity.
The PepDriver software controlling the synthesizer took double-coupling into account
when calculating reagent weights and solvent volumes for chemicals to be used for each
synthesis. Peptides were synthesized individually at a 0.05 mmol scale. The yield was
estimated for the weight of the peptide-resin complex as well as for the weight of cleaved
peptide, and taking into account probable losses during the work-up and purification
process, the yields can be considered good. As an example, yields for the synthesis of
adepantin 2 and 3 are shown in Table 10.
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Table 10. Theoretical and measured yields of ADP2 and ADP3 with and without resin.
compound Theoretical yield (mg) Measured yield (mg) % of theoretical yield
ADP2-resin 324.33 265 82
ADP3-resin 327.19 229 70
ADP2 113.8 102 90
ADP3 112.3 93 83
The theoretical yield for the peptide-resin complex was calculated by multiplying the weight
of the resin by the resin substitution and MW of fully protected peptide and adding this to
the initial resin mass. The resin used was Fmoc-Linker-AM-Champion in an amount of 0.15 g,
resin substitution was 0.34 mmol/g and for ADP2 and ADP3, fully protected MW was 3418.3
and 3474.4 respectively. For ADP3 the lower yield is principally due to technical difficulties
during synthesis. The theoretical yield for cleaved peptide was calculated by multiplying
synthesis scale 0.05 and peptides MW. The yield was  90% (only ADP3 had a loss of
approximately 10% due to technical difficulties), so both peptides were synthesized in
excellent yields.
3.3. High yields and purity of the adepantins and modified analogues
ESI-MS carried out on all peptides confirmed that molecular weights were in good
correspondence with the calculated values (Table 11). The measurements confirmed not
only that the correct peptide was present, but also a high level of purity as only one peak is
present (Figure 17, Figure 18, Figure 19, Appendix 8). Graphs for bodipylated peptides have
two peaks where lower peek represents correct one for bodipylated peptide while higher
one is a “shadow peak” (Figure 20).
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Figure 17. ESI-MS analysis of adepantins, A) ADP2, B) ADP3.
Table 11. Theoretical and measured MW and yields of ADP1, unmodified ADP2 and ADP3, ASC1 and ASC1 I2,
PSEU2 and Pseu2 A9.
Peptide
abbreviation
Theoretical
MW
Measured
MW
Yield
(mg)
ADP1 2259.0 2259.7 25.8
ADP2 2275.8 2275.4 76
ADP3 2246.8 2246.5 66.2
ASC1 2369.8 2369.5 3.2
ASC1 I2 2335.8 2335.6 3.8
PSEU2 2684.2 2683 32.4
PSE2 A9 2608.1 2608 31.2
After preparative RP-HPLC purification, the purity of ADP1, PSEU2 and ASC1
increased to >99%, as confirmed by the analytical RP-HPLC (see Appendix 7 and Appendix 8).
Thanks to the high purity of crude ADP2 and ADP3 these were directly used in modification
reactions (iodoacetamidation, covalent dimerization or BODIPY labelling) and purified by
semipreparative RP-HPLC only after modification (see Figure 2, page 21). Fractions
containing the desired peptide were identified by ESI-MS (see Appendix 6), pooled and
A)
B)
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lyophilised. In this case also, purity >99% was confirmed by RP-HPLC. All peptides were
synthesized in good yields, considering the inevitable losses due to reversed phase
chromatography, including the ADP2 and ADP3 modifications, which were recovered in mg
quantities (Table 12).
Table 12. ADP2 and ADP3 modifications with its theoretical versus measured MW and their yields; for
ADP2(AM) and [ADP2]2 modification reaction was performed twice, therefore, the yields are higher.
Peptide
abbreviation
Theoretical
MW
Measured
MW
Yield
(mg)
ADP2(AM) 2332.87 2332,4 6.3
[ADP2]2 4549.62 4549.3 6.6
ADP2(BY) 2689.82 2689.6 2.3
ADP3(AM) 2303.83 2303.3 3.8
[ADP3]2 4491.54 4491.5 4.6
ADP3(BY) 2660.87 2660.5 3.6
The blocking of cysteine by iodoacetamidation was performed to avoid unwanted
reactions due to the free sulfhydryl in the C-terminal cysteine which could interfere with
structural determination and functional assays. This reaction results in a side chain with
hydrophobicity characteristics similar to those of glutamine. This reaction gave excellent
yields for both peptides. ESI-MS molecular weight analysis coupled with RP-HPLC confirmed
structure and quality of peptides (Table 12, Figure 18, Appendix 6).
Figure 18. ESI-MS molecular weight analysis of A) ADP2(AM) and B) ADP3(AM)
A)
B)
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The possibility of dimer synthesis by formation of an intermolecular disulphide bridge
enabled us to test the effects of peptide aggregation. This may occur at the membrane
surface in particular, and it is believed to have a significant effect on the mode of action and
pore formation. This process can affect antimicrobial activity as well as host cell cytotoxicity
as will be discussed below.
Dimerization proceeded in good yields by simply exposing a sufficient concentration
of the peptide to oxidizing conditions, and monitoring continuously using analytical RP-HPLC
coupled to ESI-MS (Table 12, Figure 19, Appendix 6).
Figure 19. ESI-MS molecular weight analysis of A) [ADP2]2 and B) [ADP3]2
The presence of a C-terminal Cys residue also allowed us to label these peptides with
the fluorescent probe BODIPY. It was chosen for labelling peptides since it is uncharged,
small, stable and strongly fluorescent. This modification was used to follow peptides’
interaction with membranes, as well as to see if it internalized into cells or remained on their
surface, by monitoring its fluorescence at 525 nm, as it will be discussed later.
The bodipylation reaction went well for both peptides, with good yields. ESI-MS
coupled with RP-HPLC confirmed the correct structure and quality of peptides (Table 12,
Figure 20, Appendix 6).
A)
B)
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Figure 20. ESI-MS molecular weight analysis of A) ADP2(BY) and B) ADP3(BY). Graphs contain two peaks where
lower peek represents correct one for bodipylated peptide while higher one is a “shadow peak” that can
often be noticed during MS analysis of fluorescently labelled peptides possibly due to loss of one fluorine
under ESI conditions.
The exact concentration of each peptide was determined by using the following
methods: mass concentration, Waddell method and quantification by molar extinction
coefficient. All peptides were measured on analytical balance after lyophilisation and
dissolved in MilliQ H2O, and concentrations are shown in Table 13. In the second set of
adepantin dilutions, peptides were dissolved in exactly 500 I MilliQ H2O (Table 14) and
concentrations were then double-checked with methods other two methods.
A)
B)
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Table 13. Mass concentration of peptides tested in the first set of tests.
Peptide
abbreviation
Peptide weight
(mg)
Volume
MilliQ H2O
(ml)
Concentration
mg/ml mM
ADP1 12.7 1.27 10 4.4
ASC1 3.8 0.76 5 2.7
ASC1 I2 3.2 0.64 5 3.6
PSEU2 16 1.6 10 3.7
PSEU2 A9 16.2 1.62 10 3.8
Table 14. Results of methods used for determining concentration of adepantins.
PEPTIDE
ABBREV.
WEIGHT WADDELL
MOLAR
EXTINCTION
COEFICIENT
USED VALUE
mg/ml mM mg/ml mM mg/ml mM mg/ml mM
ADP2(AM) 7.26.8
3.1
2.9
6.5
5.7
2.8
2.5
5.1
5.2
2.2
2.2
6.5
5.7
2.8
2.5
ADP3(AM) 7.6 3.3 6.7 2.9 6.7 2.9
[ADP2]2 8.88.8
1.9
1.9
7.9
8.0
1.8
1.8
5.9
7.8
1.3
1.7
7.9
8.0
1.8
1.8
[ADP3]2 9.2 2.1 8.8 2.0 6.0 1.3 8.8 2.0
ADP2(BY) 4.6 1.7 4.4 1.7 4.8 1.8 4.4 1.7
ADP3(BY) 7.2 2.7 5.5 2.1 6.9 2.6 6.9 2.6
ADP1 10 4.4 10 4.4
For ADP2(AM) and [ADP2]2 modification reaction was performed twice, and both measurements are
presented in the table.
In general, the best agreement between mass-calculated concentrations was
obtained using the extinction coefficient of labelled peptides. For unlabelled peptides
concentrations were often underestimated using the extinction coefficients at 214 nm
according to Kuipres and Gruppen 2007, and are generally closer to the weight-calculated
ones using the Waddell method. Using the mean extinction coefficient determined by
Kupres and Gruppen for the peptide bond, the molar extinction coefficient calculated for
adepantins was 26400 ± 1600 mol-1cm-1. For the dimers, it was calculated in terms of helix
numbers, rather than molecule numbers. In conclusion, while not exactly reflecting the
mass-calculated concentrations, spectroscopic methods confirmed the general trend and led
to a slight down correction of values that were generally centred around those measured
using the Waddell method.
3.4. Confirmed secondary structure
All peptides used for creating AMPad database were -helical. The peptides
predicted by the “Designer” algorithm were therefore expected to have amphipathic -
helical structures as well. To confirm this hypothesis, the structure of ADPs was determined
by monitoring their behaviour in different environments using CD spectrometry. Each
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secondary structure (random coil, α helix and  sheet) of AMPs results in characteristic and
quite different looking spectral bands with different magnitudes.
The first CD spectra were intended to observe the behaviour of ADPs in different
solutions, both aqueous and organic.
Aqueous conditions tested were:
 MilliQ H2O
 PBS (SPB + 150mM NaCl)
 SPB (10mM sodium phosphate buffer)
All ADPs remained unstructured in all three conditions (Figure 21, Figure 22 A)), as
spectra conform to the shape and magnitude of a random coil structure. Dimers tested at
concentration 20 M also have random coil structure (Figure 21) but with twice the
magnitude. However, when normalized for number of chains rather than molecules showed
spectra quite similar to the monomeric peptides (Figure 22 A)).
Figure 21. CD spectra of ADPs (20 M of peptide) measured in A) H2O and B) sodium phosphate buffered (SPB,
10 mM); ADP1(); ADP2(AM) (  ); [ADP2]2 (); ADP2(BY) (-----); ADP3(AM) ( - - -); [ADP3]2
(); ADP3(BY) ().
Figure 22. CD spectra of ADPs (20 M of peptide chain) measured in A) phosphate buffered saline (PBS, pH7.4),
B) 50% trifluoroethanol (TFE) and C) 50% isopropanol (iPrOH); ADP1(); ADP2(AM) (  ); [ADP2]2
(); ADP3(AM) ( - - -); [ADP3]2 ().
A) B) C)
B) SPBH2OA)
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Two more organic conditions were also used:
 Isopropanol (iPrOH) in SPB (50:50%)
 Trifluoroethanol (TFE) at increasing concentrations v/v (10-50%), with SPB
In the presence of 50% isopropanol, ADPs clearly formed  helical structure (Figure
22 C)), confirming that ADPs have a propensity for adopting an amphipathic  helical
conformations if an environment is provided that is compatible with the formation of a
hydrophobic sector. The helical conformation of peptides and proteins can in fact be induced
and stabilized with alcohols which favour intrachain H-bond formation (Hirota et al., 1997).
TFE is often used for inducing such an effect as a helix-favouring solvent, and with
adepantins beginning to induce helix formation at about 10% v/v, whereas helix formation is
effectively complete at 30% v/v (Figure 23). Helix formation was not particulary favoured in
the covalent dimers when in contact with these helix-favouring solvent, considering that
spectra in the presence of iPrOH are not markedly different in intensity or shape between
monomers and dimers.
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Figure 23. Helix % with increasing TFE; ADP1 ; ADP2(AM) ; [ADP2]2 : ADP3(AM) ;
[ADP3]2 .
The percentage helicity was determined in aqueous conditions, and in the presence
of TFE and both types of liposomes suspensions (anionic or neutral), after normalizing the
ellipticity per residue at 222 nm to take dimerization into account, using the method of Reed
and Reed 1997. It was however not corrected for the presence of the BODIPY chromophore
(Table 15).
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Table 15. % helicity of ADPs in different environments according to the method of Reed and Reed 1997.
Peptides were 20 M in H2O, 50% trifluoroethanol (TFE), anionic LUV (PG/dPG =
phospatidylglycerol/diphospatidylglycerol; 95:5) and neutral LUV (PC/SM/Ch =
phospatidylcholine/sphingomyelin/cholesterol; 2:2:1) in PBS buffer. Dimerization was taken into account
by normalising ellipticity per residue. (1)No corrections for the presence of the BODIPY chromophore were
made (% helicity shown in parentheses).
Peptide % helical conformation
H2O TFE LUV
(PG/dPG)
LUV
(PC/SM/Ch)
ADP1 <5 35 55 <10
ADP2(BY) (1) (<5) (40) (50) (<10)
ADP2(AM) <5 45 60 <5
[ADP2]2 <5 40 50 <10
ADP3(BY) (1) (<5) (55) (50) (<5)
ADP3(AM) <5 30 53 <10
[ADP3]2 <5 40 45 <10
Peptide structuring in contact with model membranes (LUVs) can provide insight into
the mode of action. Prokaryotic cell membranes were mimicked with anionic LUVs consisting
of PC/dPG liposomes, while eukaryotic cell were mimicked with neutral LUVs consisting of
PC/SM/Ch liposomes. The % helix per residue of all peptides, calculated in the presence of
both types of LUVs is also shown in the Table 15.
All ADPs showed helix formation when in contact with anionic LUVs (see Figure 24
A)), and the monomers behaved very similarly. The dimeric ADPs showed a distinct change in
the shape of their spectra, and in particular the decrease of the 208/222 ratio to <1 is an
indication that the helices are more aggregated when in contact with the membrane. A less
marked decrease in the 208/222 ratio is evident also for monomeric peptides with respect to
helices forming in the presence of TFE, so that covalent dimerization likely enhances this
effect. These results are indication of a strong interaction with anionic membranes and are
in line with the fact that ADPs can easily permeabilize bacterial membranes and likely have a
membranolytic antimicrobial activity, as described later in section 3.5.
When in contact with neutral LUVs (see Figure 24 B)) all ADPs remained substantially
in the random coil form, suggesting that there was no efficient insertion in this type of
membrane, and that ADPs remained unstructured. This behaviour is in the line with a low
capacity to lyse eukaryotic membranes, as shown by a low haemolytic activity, as described
later in section 3.6. Results of haemolysis confirmed low haemolytic activity for monomers,
while dimers showed unexpected increase in haemolysis.
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Figure 24. CD spectra of ADPs (20 M of peptide chain) measured in A) 1:1 phosphatidylglicerol/
diphosphatidtylglicerol LUVs in PBS (PG/dPG) and B) 2:2:1 phosphatidylcholine/ sphingomyelin/cholesterol
LUVs in PBS (PC/SM/Ch); ADP1(); ADP2(AM) (  ); [ADP2]2 (); ADP3(AM) ( - - -); [ADP3]2
().
3.5. Effects of adepantins on bacterial cells
Assessment of antimicrobial activity of adepantins was done by determining MIC and
IC50 values against both Gram-negative and Gram-positive bacteria of interest. Confirmation
of the killing activity against E. coli was provided by performing MBC assay. From Table 16,
Table 17 and Table 18 it is visible that ADPs have a good antimicrobial activity.
Results for MIC assays were determined by examining microtiter plates after 18
hours of incubation at 37°C. The MIC value was taken as the lowest concentration of the
peptide resulting in the complete inhibition of visible growth. Results are mean values of at
least three independent experiments carried out in duplicate, and are summarised for all
peptide tested, as well as for all bacteria of interest in Table 16. MIC values are also
presented for the two natural reference peptides ascaphin 1 and pseudin 2.
Adepantins were designed peptide antibiotics using Escherichia coli, a Gram-negative
bacterium, used as the target microorganism, in the computational approach. This selectivity
was confirmed by the MIC assay (Table 16). There was however some difference in the
activity between the three ADPs, and the activity was also affected by their modifications.
ADP2 was more active than ADP1 and 3, bodipylation increased activity, but in particular,
the dimers were significantly more active than acetamidated monomers of the same peptide
against E.coli (Figure 25). All ADPs showed low activity against the Gram-positive bacterium
S. aeruginosa (Figure 26) underlining that their activity was directed against Gram-negative
bacteria. The reason for that lower activity may be differences in the membrane
composition and/or the presence of a thicker peptidoglycan layer in the Gram-positive
bacteria.
A) B)
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Table 16. MIC values for adepantins, pseudins and ascaphins; (1) assays were carried out in 100% (v/v) MH
broth using 5x105 cells/ml bacteria in the logarithmic phase; each value is the mean of at least 3
independent determinations carried out in duplicate.
PEPTIDE
MIC (M)(1)
E. coli
ATCC 25922
S. aureus
ATCC 25923
P. aeruginosa
ATCC 27853
S. typhimurium
ATCC 14028
K. pneumoniae
(c. i.)
ADP1 2-4 >128 16 - -
ADP2(AM) 1 >128 32 16-32 64
[ADP2]2 0.5-1 128 2 1 1
ADP2(BY) 1 64 - - -
ADP3(AM) 4 >128 - - -
[ADP3]2 0.5 64-128 - - -
ADP3(BY) 1 >64-64 - - -
PSEU2 8 32 >64 - -
PSEU2 A9 8-16 128 >128 - -
ASC1 2 32 16 - -
ASC1 I2 4 32-64 16-32 - -
Figure 25. Example of MIC results for E. coli all ADPs; rows: ADP1, ADP2(AM), [ADP2]2, ADP2(BY), ADP3(AM),
[ADP3]2, ADP3(BY), empty; columns: 1st – 11th peptide + bacteria + MH starting with concentration 128 µM
and decreasing by two-fold dilution method, 12th negative control = bacteria + MH; white dots on the
bottom of the well is grown bacteria.
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ADP2(AM) was the most active peptide and was therefore chosen to be tested on
other Gram-negative bacteria along with its dimer. [ADP2]2 showed a more potent, broad-
spectrum activity than ADP2(AM), that was also less active against P. aeruginosa, S.
typhimurium and K. pneumoniae (Table 16, ) than against E. coli.
In the first set of tests ADP1 was tested on P. aeruginosa and showed moderate
activity as well as ASC1 and ASC1 I2, while PSEU2 and PSEU2 A9 had poor activity. For both
control peptides MIC values against E. coli were in acceptable correlation with literature
data, as ASC1 had a measured MIC = 2 M, against literature value of 3M, while PSEU2 had
measured MIC = 8 M against a literature value of 20 M (Conlon et al., 2004; Olson et al.,
2001). For PSEU2 there was a larger difference that may derive from the presence of the
amidated C-terminus. Peptides with amidated C-terminus have been reported to have a
somewhat stronger antibacterial activity, likely due to the increased cationicity.
Figure 26. Example of MIC results for S. aureus all ADPs; rows: ADP1, ADP2(AM), [ADP2]2, ADP2(BY), ADP3(AM),
[ADP3]2, ADP3(BY), empty; columns: 1st – 11th peptide + bacteria + MH starting with concentration 128 µM
and decreasing by two-fold dilution method, 12th negative control = bacteria + MH; white dots on the
bottom of the well is grown bacteria.
Minimal bactericidal concentration (MBC) assay was performed (Table 17) following
the MIC assays and revealed that the MBC values are consistently two-fold higher than the
corresponding MIC values (Table 16). One can thus conclude that ADPs are bacteriostatic at
subtoxic concentration and become bactericidal at a threshold concentration between 1-8
μM, depending on the peptide. These results were also confirmed with bacterial growth
inhibition assay (Table 18).
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Table 17. MBC (minimal bactericidal concentration), (1) Concentration resulting in no bacterial growth, 2
independent determinations carried out in duplicate.
PEPTIDE
MBC (M)(1)
E. coli
ATCC 25922
ADP1 4
ADP2(AM) 2
[ADP2]2 2
ADP3(AM) 8
[ADP3]2 0.5-1
Bacterial growth kinetics assay with chosen bacteria enabled IC50 value calculation as
a value representing concentration of the peptide which inhibits bacterial cell growth by 50%
at 210 min and was extrapolated from the given graph for each peptide (see Figure 27 B),
Figure 28).
Figure 27. A) Curves from data collected after growth kinetics for E. coli monomers at concentration 1 M and
dimers at concentration 0.5 M; B) inhibition percentage at 210 min extracted from growth curves;
Bacteria control (); adepantins ADP1 (, ); ADP2(AM) (  , ); ADP3(AM) (- - -,
); [ADP2]2 (,); [ADP3]2 (,).
Examining values gathered with this assay (Table 18) and comparing them with MIC
values (Table 16) a similar trend is observed. Dimers of both adepantins were very active
against E. coli and [ADP2]2 was also quite active against other types of bacteria it was tested
on (see Figure 28 B) and Table 19). This behaviour may indicate that helix aggregation
favours the mechanism of action of these peptides, so that covalent linking of two helices
makes them therefore more active. As the monomer ADP2(AM) was the most active, it was
chosen to be tested, together with its dimer on another three species of bacteria (see Figure
28 A) and Table 19). It is remarkable how a single residue modification, from Ser in ADP1 to
acetamidated Cys in ADP2 (similar to glutamine) can considerably alter activity of the
A) B)
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peptide. In any case, for all tested peptides there was a good correlation between the %
growth inhibition (see Figure 27, Figure 28 and Figure 29) with results collected from MIC
assays.
Table 18. IC50 value of peptides; (1) Concentration resulting in 50% growth inhibition of bacteria, calculated
from data in figure (Figure 27).
PEPTIDE
IC50 (M)(1)
E. coli
ATCC 25922
ADP1 1.5 ± 0.3
ADP2(AM) 0.8 ± 0.1
[ADP2]2 0.2 ± 0.05
ADP3(AM) 2.3 ± 0.3
[ADP3]2 0.2 ± 0.05
Figure 28. Effect of A) ADP2(AM) and B) [ADP2]2 on growth kinetics of E. coli (1), P. aeruginosa (2), K.
pneumoniae (3) and S. typhimurium (4), experiments were done three times in triplicates.
A) B)
Results Nada Ilić
72
Table 19. IC50 value of ADP2(AM) and [ADP2]2 measured for the following bacteria: E. coli, P. aeruginosa, K.
pneumoniae and S. typhimurium; (1) Concentration resulting in a 50% growth inhibition of bacteria,
calculated from data in figure (Figure 28).
PEPTIDE IC50 (M)
(1)
E. coli
ATCC 25922
P. aeruginosa
ATCC 27853
K. pneumoniae
(clinical isolate)
S. typhimurium
ATCC 14028
ADP2(AM) 1 3.6 3.8 4
[ADP2]2 0.16 0.49 0.31 0.37
Figure 29. Effect of ASC1, PSEU2 and ADP1 on growth kinetics of E. coli; PSEU2  ; ASC1  ; ADP1
 ; mean of two experiments performed in triplicates (Juretić et al., 2009).
One possible factor affecting the activity of adepantins against E. coli, is the barrier
effect exerted by the outer membrane. To probe this barrier effect, we compared % growth
inhibition with respect to the E. coli BW 25113 strain (a K12 derived strain in which the LPS
lacks the O-antigen polysaccharide) with that against the ATTC strain that has a fully
developed O-antigen. Furthermore, this relatively rapid assay can provide much needed
information by using mutant strains with specifically altered membranes, due to different
modifications of the core oligosaccharide in the outer membrane lipopolysaccharides layer
(LPS), as for example its anionicity due to the presence of phosphate groups, or its stability.
For example, the waaP mutant of E. coli BW 25113 lacks a key kinase necessary for the
phosphorilation of the first heptose in the core oligosaccharide and as a consequence has an
an incompletely formed core saccharide with destabilized outer membrane (Yethon et al.,
1998). The intention was to distinguish whether the changes in outer membrane will affect
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adepantins activity, and therefore indicate to what extent the need to overcome it affects
the subsequent permeabilization of the cytoplasmic membrane, and to this end, the results
of the bacterial growth inhibition assay in the presence of the different peptides is shown in
Figure 30.
Figure 30. Growth kinetics of A) E. coli BW 25113 strain and B) E. coli BW 25113 waaP strain affected by
adepantins (ADP1 ; ADP2(AM) ; [ADP2]2  ; ADP3(AM) ; [ADP3]2 ).
When results for E. coli BW 25113 and its mutant strain were compared to those for
E.coli ATCC 25922, it was evident that the lack of the O-antigen did not influence the
behaviour of adepantins significantly, so that the O-antigen was not obstacle for ADP’s
activity. Again, dimers inhibited bacterial growth best, while for monomers ADP2(AM) was
the most potent, followed by ADP1 and then by ADP3. A similar trend was noticed for
thewaaP mutant, indicating that destabilising LPS layer of outer membrane does not
improve activity, so that this is likely not an obstacle for ADPs reaching the cytoplasmic
membrane. It is a significant result for the ADP dimers in particular, as these are larger
molecules that could be expected to be slowed down by the outer membrane on their
trajectory to the cytoplasmic membrane.
Membrane permeabilization studies were performed on both outer and inner
membranes. These served to gain more insight into the effects of membrane insertion,
which CD spectroscopy indicated was particularly relevant to anionic membranes. This
process could in fact lead to the membrane permeabilization as part of ADPs mode of action.
Permeabilization of both membrane types was tested using the E. coli ML-35 pYC strain that
constitutively produces both a cytoplasmic -galactosidase and a periplasmic -lactamase.
Gal-ONp is used as an extracellular cromogenic substrate for -galactosidase, with
which it can react only when a membrane-active peptide, in this case an adepantin,
permeabilizes the inner membrane. Its hydrolysis by the cytoplasmic galactosidase results in
a product detected by absorption increase to 405 nm. CENTA® is used as a chromogenic
substrate for the periplasmic lactamase, which it can reach only if the outer membrane is
destabilized or permeabilized. Hydrolysis of the -lactam ring results in a change of colour
from 340 nm to 405 nm. Curves showing the variation of absorption at 405 nm with time, in
A) B)
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the presence of Gal-ONp or CENTA® are thus a measure of the permeabilization kinetics for
the cytoplasmic and outer membranes respectively (Figure 31 A) and B)).
Monomeric adepantins resulted in significant hydrolysis of both chromogenic
substrates at a quite low peptide concentration. The dimers however hydrolysed both
membranes more rapidly confirming that dimerization can be related to increasing potency,
as observed in MIC and growth kinetics assays, due to more efficient membrane
permeabilization. It is significant that permeabilization was even faster than with the
cathelilcidin peptide SMAP-29 which is used as a reference for a high rate of outer and
cytoplasmic membrane permeabilization (Skerlavaj et al., 1999). It should also be noticed
that Gal-ONp hydrolysis is almost as fast as CENTA® hydrolysis, indicating that the peptides
move rapidly through the outer membrane and immediately start permeabilizing the
cytoplasmic membrane, in agreement with growth kinetics studies that had indicated that
the outer membrane was not a formidable barrier for these peptides. Bodipylated peptides
were not included in the measurements as the presence of BODIPY interferes with
absorption measurements at 405 nm.
Figure 31. Permeabilization of the inner and outer membrane of E. coli ML-35 pYC by ADPs determined by
following the hydrolysis of the impermeant chromogenic substrate A) Gal-ONp by a cytoplasmic -
galactosidase and B) CENTA® by the periplasmic enzyme -lactamase respectively (no peptide  ;
ADP1 ; ADP2(AM) ; [ADP2]2 ; ADP3(AM) ; [ADP3]2).
Another way of probing membrane permeabilization is to monitor the internalization
of propidium iodide into bacteria using flow cytometry. This assay was performed in
duplicate using only 0.25 µM peptide and the averaged results are shown in Figure 32.
Adepantins monomers at this sub-toxic concentration showed no permeabilization. On the
contrary, dimers reached more than 90% permeabilization within 15 minutes. This was in
agreement with their increased permeabilizing capacity as measured with Gal-ONp uptake,
as well as a greater antimicrobial potency. Bodipylated peptides were also measured by this
assay and have shown higher level of permeabilization than unmodified monomers which
have reached their maximum within 15 - 30 minutes. What was more interesting in the time
Results Nada Ilić
75
range is that after 30 minutes, fluorescence started to drop, an effect we were not able to
explain.
Figure 32. Permeabilization of E. coli ATCC 25922 (106 cells/ml) inner membrane caused by ADPs (0.25 M) and
determined by % of PI-positive bacterial cells by flow cytometric analyses; (ADP1  ; ADP2(AM)
 ; [ADP2]2 ; ADP2(BY) ; ADP3(AM) ; [ADP3]2 ; ADP3(BY)).
3.6. Effects of adepantins on host cells
Adepantins were created to be selective peptides. This means that they need to have
a high TI, due to low MIC values against E. coli (and our MIC assays gave the desired low MIC
values), but also due to high HC50 values. To verify this, haemolysis assays were performed.
These are instrumental in determining the TI, but it is necessary to obtain other evidence for
a low capacity to permeabilize cellular membranes in general. For this reason the capacity of
ADPs to lyse human cells was also tested by monitoring PI internalization by flow cytometric
analysis.
HC50 values for adepantins were determined from the data gathered in human RBC
haemolysis assays based on the activity of increasing peptide concentrations on 0.5% v/v
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fresh erythrocytes. Results were collected from four different experiments carried out in
triplicate and are displayed in Figure 33 as mean values for each peptide concentration, with
errors based on SD. HC50 values were then extrapolated from the curves as peptide
concentration causing 50% haemolysis.
Figure 33. Adepantin-induced haemolysis on 0.5% RBC; ADP1  ; ADP2(AM)  ; [ADP2]2  ;
ADP3(AM) ; [ADP3]2  ; Results are from four experiments carried out in triplicate.
Figure 33 and Table 20 show that monomeric forms of ADPs had very low haemolytic
activities, with HC50 values >400 µM. Activity decreased in the order ADP2(AM), ADP1,
ADP3(AM), so that there was a certain correlation between haemolytic and antimicrobial
activity, even though the antimicrobial concentrations are two orders of magnitude lower.
Dimers instead showed much lower HC50 values than monomers indicating that their toxicity
towards RBC was considerably greater, being significant already at antimicrobial
concentrations. This effect was not predictable from CD in the presence of eukaryotic cell-
like, neutral LUVs, as no structuring of peptides into helices was observed for either
monomers or dimers (Figure 24). If dimers had a greater tendency to insert into neutral
membranes, explaining their greater haemolytic activity, this would have been evident by
CD. Their increased lytic activity to host cells must have an alternative explanation, one
possibility is that it derives from some kind of surface type of interaction, favoured for the
dimeric peptides. Another explanation could be that dimerization slightly shifts the
equilibrium from a random coil to a helical form in dimeric peptides, with respect to
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monomeric ones. The proportion of structured peptides, capable of inserting into the
membrane, would remain too low to be observable by CD, but might be sufficient for lytic
activity. In any case, dimerization, which would favour peptide aggregation, appears to
favour lytic activity against eukaryotic and prokaryotic cells.
Table 20. Haemolytic, MIC and TI values for tested peptides; Haemolytic activity tested for peptides, expressed
as HC50 value; (1) determined from Figure 33 and Figure 34; MIC values from Table 16; TI value calculated
from experimental data (TI calculated) and predicted one (TI predicted); (2) For ADP1, the first value is
from second set of tests together with other ADPs, while the second value is from the first set of tests
when only ADP1 was tested along with PSEU2 and ASC1. (3) Values are for original peptide sequence not
iodoacetamidated one.
Peptide
abbreviation HC50 (µM)
(1) MIC (µM) TI (calculated) TI (predicted)
ADP1 480 ± 60(> 800(2)) 2 - 4 190 ± 90 86
ADP2(AM) 400 ± 100 1 400 ± 100 91(3)
[ADP2]2 16 ± 4 0.5 - 1 16 ± 4 -
ADP3(AM) > 500 4 > 125 95(3)
[ADP3]2 20 ± 4 0.5 40 ± 8 -
PSEU2 50 8 6 7
PSEU2 A9 > 200 8 – 16 > 30 90
ASC1 80 2 40 54
ASC1 I2 > 200 4 > 60 80
It should be pointed out that in the first set of assays (Juretić et al., 2009), the
haemolysis curves presented in Figure 34 and Table 20 are relative to the wild type control
peptides ascaphin 1 and pseudin 2 and point mutations of each, measured together with
ADP1. For both control peptides the HC50 values were less correlated with literature data
than their MIC values. For ASC1 the measured value was 80 against literature value of 200
and for PSEU2 the measured value was 50 against a literature value of 360 (Conlon et al.,
2004; Olson et al., 2001). In any case, as can be seen from Table 20, the haemolytic activity
was decreased for mutated peptides, confirming the ability of the D-descriptor method to
guide variations to improve selectivity. The variability in haemolysis results is due to slightly
different methods used in different laboratories, and also due to the fact that different RBCs
from different donors are used every time. This can be appreciated when comparing the
HC50 value measured for ADP1 in assays performed in different times.
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Figure 34. Pseudin and ascaphin-induced haemolysis on 0.5% RBC; PSEU2  ; PSEU2 A9  ; ASC1
 ; ASC1 I2  ; Results are from two experiments carried out in triplicate.
The results from MIC and HC50 enabled TI value calculation (Table 20) for all peptides.
High TI values indicate a high selectivity for all adepantins as expected by TI prediction from
the “Predictor” algorithm (Juretić et al., 2009). It should be pointed out that the predicted TI
is just indicative, as is limited to a maximum value of 95 by the “Predictor” algorithm. Any
predicted TI approaching this value generally corresponds to much higher measured TI (see
for example ADP1, ADP2(AM) and ADP3(AM) in Table 20). The calculated TI value
significantly lower than the value 95 corresponds to a low measured TI (see, for example,
pseudin 2 in Table 20).
To further correlate the cytotoxicity of peptides by their capacity to interact with and
permeabilize cellular membranes, a flow cytometric study was carried out. This study used
bodipylated ADP2 and 3 to probe interaction with host cells membranes. By using the
impermeant quencher Trypan blue, it was possible to distinguish peptides bound to the
surface of U937 cells, from peptides inserted into the membrane, or that could have been
translocated into the cytoplasm through a pore-mediated self-promoted uptake mechanism.
To probe the capacity of peptides to permeabilize the membrane, PI was used instead, as
any lesions in the membrane would allow it to internalize and bind to the DNA, becoming
fluorescent. Fluorecsently labelled peptides efficiently and rapidly bound to the membrane
surface, as could be seen in the shift to a higher fluorescence value in gate 1 at increasing
peptide concentration, after only a 5 min exposure (see in Figure 35 A) and B)). However,
treatment with Trypan blue significantly decreased the fluorescence, so peptides are just
surface bound (see Figure 35 C) and D)). PI treatment showed that even if peptides attach to
the membrane, they do so without damaging it, as shown by the fact that there is an
increase in fluorescence at 525 nm (fluorescence axis for BODIPY florescence in Figure 36)
whereas there was little shift at 610 nm (fluorescence axis representing PI
fluorescenceFigure 36).
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Figure 35. ADPs interaction with U937 cells, as measured by flow cytometry, presented on monoparametric
histograms; A) ADP2(BY) and B) ADP3(BY) demonstrates the effect after 5 minutes where the black line is
control, the green line is peptide at concentration 0.1M and the red line is peptide at concentration 1M;
C) ADP2(BY) and D) ADP3(BY) where empty curve is for U937 cells in the absence and filled curve in
presence of ADPs (1M) while dashed line represents U937 cells with ADPs and the impermeant,
extracellular quencher Trypan blue added.
Efficient binding of ADP2(BY) and ADP3(BY) to the U937 cell membrane is visible in
the shift of monoparametric peak to a considerably higher position in Figure 35 C) and D).
The effect was noticed within 5 minutes of interacting time and it depends on the
concentration of the peptide Figure 35 A) and B). Peptide fluorescence was reduced by the
trypan blue quencher revealing that ADPs remain bound to the outer side of the cell
membrane.
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Figure 36. Fluorescence dot plots expressing results of monitoring fluorescence at 525 nm (BODIPY) and 610
nm (PI) on the flow cytometer for human leukemic monocytes (U937, 106 cells/ml) treated with peptides (1
M) A) ADP2(BY) or B) ADP3(BY) and PI for 30 min at room temperature before treating cells with Trypan
blue.
The test confirmed that monomeric labelled ADPs interact with the surface of host
cells membrane at antimicrobial concentrations without expressing any cytotoxicity.
A) B)
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4. Discussion
Bacteria are increasingly developing resistance to antibiotics, justifying research
towards finding new anti-infective agents acting with diverse mechanisms (Taubes 2008).
One promising class of anti-infective agents are AMPs, essential components of innate
immunity, produced by all higher organisms. Cationic AMPs have remained effective against
bacteria throughout evolution (Zasloff 2002; Yeaman and Yount 2007), but cannot be
directly used as anti-infective drugs, outside their physiological context used. Therefore,
numerous attempts have been made to modify natural AMPs to improve essential
properties, such as selectivity, expressed as the therapeutic index (TI), and bioavailability.
The need for developing sophisticated methods capable of improving known natural or
synthetic AMPs was the driving force behind the work described in this thesis. The
theoretical research, which provided the foundation for experimental thesis research, can be
described as the knowledge-based computational usage of amino acid hydrophobicity scales
(Juretić et al., 2009; Juretić et al., 2011). All of five amino acid sales used to construct three
best descriptors (producing correlation higher than 0.9 among experimental and theoretical
TI values, Table 8) are hydrophobicity scales (Appendix 5).
Thousands of endogenous AMPs have been reported, extracted from or identified in
many different types of living organisms, as listed in several different databases (Hammami
and Fliss 2010). For our research also, the first step was to collect appropriate data and sort
it in the AMPad database. Our choice fell on AMPs isolated from anuran species, as these
were likely the most abundant and well characterized in the literature. Database
construction is an essential requirement for subsequent work on computational tool
construction, so that a significant effort was expended to manually assemble a functional
database for this purpose. Briefly, AMPad consists of 73 peptides of anuran origin,
characterized by an α-helical active conformation, and with published HC50 and MIC (E. coli)
data, allowing the definition of TI values. The creation of the AMPad database is described in
section 2.1, while the results of the methods used to design novel AMPs based on this
database are described in section 3.1. Briefly, the separation of sequences into three distinct
“training”, “testing” and “set of best peptides“ sets allowed statistical analysis and algorithm
construction and creation of the software tools: i) “PredictorSelector” to select descriptors
associated with correlation higher than 0.90 (positive or negative) among predicted TI values
and experimentally determined TI values from “training” set; ii) “Predictor” to allow
evaluation of an AMP in terms of a predicted TI, based on its sequence; iii) “Designer” to
suggest a limited set of completely novel peptide sequences predicted to have a high TI, and
iv) “Mutator” to suggest one or more point mutations that should increase the selectivity of
a known peptide in terms of an increased predicted TI (Juretić et al., 2009; Juretić et al.,
2011; Kamech et al., 2012).
The guided increase in the “therapeutic index” was the main interest when starting
this research which resulted in the individuation of a one-parameter linear model that
effectively correlates measured and predicted TI value. This parameter, termed the D-
descriptor was selected using the Pearson’s correlation coefficient on a data set with
experimental TI values of non-homologous peptides from the AMPad data base that were
not normally distributed. Exactly this feature gave the greatest weight to peptides with high
TI values. We had actually not expected one parameter model to be effective, as several
interrelated structural and physicochemical parameters such as charge, secondary structure,
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hydrophobicity and amphipathicity were known to be relevant for modulating activity and
specificity (Tossi et al., 2000). It is for this reason that multi-linear models for predicting
peptide activity have been used in most structure-activity studies based on the sets of
homologous antimicrobial peptides (Langham et al., 2008), while still more complex models
were used with limited success on data sets of non-homologous peptides only after the
“Predictor” and “Designer” algorithm were constructed and published (Aoki et al., 2012;
Hammami and Fliss, 2010; Fernandes et al., 2012; Pirogova et al., 2011; Fjell et al., 2012;
Unal et al., 2010).
An essential aspect of predictive bioinformatics tools is the need for a robust
experimental verification. Only experimental data can confirm the accuracy (closeness of
predicted and measured effect) and efficacy (proportion of corrected predictions over total
predictions) of an algorithm or help to further improve the same algorithm. We had decided
to construct peptides 23 AA long, which is the minimal length of an  helical peptide that
can span a bacterial membrane. The “Designer” algorithm proposed a workable load of 7
peptides (Table 9) with the desired characteristics, out of which one was chosen to be
characterized in a first series of assays (Juretić et al., 2009), and the further two in a
subsequent series of similar assays (Ilić et al., 2013). ADP1 was chosen as the only peptide
not having a Cys at the C-terminus, as the reactive sulphydryl group can result in unwanted
side-effects. ADP2 was the ADP1 analogue with Cys instead of Ser at the C-terminus. This
needed to be acetamidated, to block the sulfhydryl, for testing, or the Cys residue was
exploited for dimerization or linking the fluorescent probe BODIPY. ADP3 was instead chosen
as being the most different in sequence to ADP1 and 2, and as it has a C-terminal Cys, ADP3
was treated in a similar manner as ADP2.
A high relative amphipathicity (Zelezetsky et al., 2005) in the ADPs primary structures
suggested a high probability of membrane association, as well as the possibility of helix-helix
interactions in the membrane, leading to channel formation (Senes et al., 2000). Both effects
were confirmed using different types of assays. Membrane insertion as well as
permeabilization of membranes were respectively shown using CD spectroscopy in the
presence of model membranes, and appropriate membrane permeabilization tests on the E.
coli ML-35 pYC strain. Conformational variations observed by CD in the presence of anionic
LUVs suggested insertion of ADPs into this “bacterial-like” membrane (see in 2.4), while in
the presence of neutral LUVs they seemed to remain surface-bound and not inserted into
the membrane. Permeabilization was tested in different ways: a) flow cytometry in the
presence of PI (see section 2.6.2 and Figure 32) indicated that rapid and efficient
permeabilization of both outer and cytoplasmic membrane of E. coli occurred; b) another
permeabilization assay using two chromogenic substrates, Gal-ONp and CENTA®, for a
periplasmic lactamase and cytoplasmic galactosidase respectively, confirmed an efficient
permeabilization first of the outer and then of the cytoplasmic membrane at quite low
concentration (see section 2.6.1 and Figure 31). Dimeric ADPs permeabilized bacterial
membranes with a significantly faster kinetics than monomeric ones, and this correlated
with lower MIC and IC50, suggesting that dimerization can be related with increasing potency
(see in 2.5 and 3.5).
The effect of adepantins on host cells (see sections 2.7 and 3.6) was evaluated by
determining haemolysis and capacity to permeabilize host cell membrane to PI, in order to
confirm the selectivity of ADPs as defined by their measured TI values (ratio of HC50 to MICE.
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coli). ADPs seemed to interact poorly with neutral LUVs (as observed by CD, see section 3.4)
letting us hope that their haemolytic activity could be low. The haemolysis test (see section
2.7.1) in fact revealed that very high concentrations of ADPs monomers were necessary for a
detectable haemolysis in the presence of adepantins, with some difference between
peptides: ADP2(AM) > ADP1 > ADP3(AM). Dimers, on the other hand, had much lower HC50
values than monomers, with a significant toxicity already at antimicrobial concentrations.
Considering the results of CD spectra representing dimer peptide behaviour in the presence
of neutral LUVs, this effect was unexpected, as no structuring was observed, indicating little
insertion into this type of membrane (Figure 24). The membranolytic activity of dimeric
peptides on eukaryotic membranes may either be caused by interaction of surface-type, or
by a slightly shifted equilibrium to a structured form that can insert and exert a lytic effect,
but insufficiently abundant to be visible by CD. In any case, peptide aggregation, which is
obligatory in the dimers, seems to favours lytic activities against both eukaryotic and
prokaryotic membranes. With regard to this hypotheses, flow cytometric analysis of U937
cells treated with bodipylated ADPs confirmed a significant interaction with these eukaryotic
cells (fluorescence channel increase), but these were surface-bound as the fluorescence
could be quenched by Trypan blue. This confirms a strong interaction with the surface, albeit
likely without insertions (as indicated by CD).
An attempt to localize the targets and binding sites of the ADP2(BY) in mammalian
cells is reported by Novković in his thesis (Novković 2010), although the assay he used still
needs adjusting. In the experiment, live NIH 3T3 murine fibroblasts from established tissue
culture were treated with different concentrations of ADP2(BY) with different time
exposures. Cells were then examined with an epifluorescent microscope and binding of
ADP2(BY) to the nuclei of the treated cells was observed, as well as a concentration and time
dependent staining of the cytoplasm. These results appear to contradict the results gathered
with the flow cytometric study on the U937 cells which indicate attachment of the peptides
to the cell without damaging it (cells remained PI negative). However, some questions as to
the integrity of cells membrane in cells studied with the epifluorescent microscope remain,
as the preparation protocol may have damaged them. Further testing with membrane-
specific fluorescent dye is strongly recommended.
After calculating the TI values for all peptides (see Table 20) it is evident that ADP2
was the most selective adepantin of the three tested, although all three tested adepantins
were quite selective, with regard to the natural peptides from the AMPad database
(Appendix 1). Considering the TI values predicted by the “Predictor” algorithm (Juretić et al.,
2009) these mach calculated values nicely, taking into account that predicted TI values can
vary between 5.3 and 94.9. Also noticeable is that as the predicted value gets closer to the
upper limit, the measured one is more likely to be high and very often well over this upper
limit of the linear, one descriptor fit. The algorithm’s result for two reference natural
peptides ascaphin 1, as an example of a selective peptide, and pseudin 2, as an example of a
mediocre peptide, also showed a good match between the predicted and the measured
values. The extensive testing described in this thesis thus confirms the D-descriptor as a
robust and useful tool for estimating peptide’s selectivity in the high TI range or estimating
the direction of the TI changes after point mutations.
Some testing has been performed on very short, 13 AA ADPs (Separovic, private
communication), with the results that are yet to be published. These were however not that
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encouraging as for the 23 AA ADPs. It is probable that there is a lower limit in length for
highly active AMPs, and as this is approached, it may become more difficult to distinguish a
highly selective peptide which is also quite active. There are however still numerous
sequences that the “Designer” algorithm can propose, with just slight changes of the inbuilt
conditions, and further testing of these can be of interest. Furthermore, the success in
constructing an algorithm that predicts selective AMPs against E. coli, suggests as a next step
in the construction of similar types of algorithms predicting AMPs against other kind of
microbes, such as Gram-positive bacteria or fungi. Some references to attempts at peptide
construction can be found in (Hammami and Fliss 2010). The future construction of
algorithm that would propose peptides, with broader spectrum of activity is
recommendable. A limitation that appeared for other types of organisms at the time of
AMPad database construction was the lack of data for the creation of “training” and
“testing” sets with a sufficient number of sequences to be statistically significant. E. coli is
used as a universal test microorganism in the literature reports, and this allowed collecting
sufficient sequences with measured MIC for defining the D-descriptor. S. aureus and C.
albicans are used respectively as Gram-positive and fungal reference microorganism, but
less frequently then E. coli. The use of other microorganisms, such as the Gram-negative P.
aeruginosa, K. pneumoniae or S. thyphimurium, the Gram-positive B. megaterium, S.
epidermidis or E. faecalis, or fungal organisms such as other candidae, criptococci or
aspergilli is considerably more sporadic. A significant effort was made during work for this
thesis to prepare an equivalent database to AMPad with MIC and HC50 values for S. aureus,
possibly the most used microorganisms after E. coli, but for S. aureus it is much more
difficult to find highly active peptides that are not haemolytic, and we failed in our first
attempt to construct a TI-predictor for that organism.
The research also goes in the direction of considering AMPs as cell penetrating
peptides (CPPs) with possibility of cargo delivery into cells (Milletti 2012; Madani et al., 2011;
Chugh et al., 2010). There are also attempts to use AMPs in fighting cancer cells since AMPs
can have a very localized and specific action on this type of cells. Factors leading to
selectivity for neoplastic cells could be the higher membrane potential or division rates, as
well as somewhat different membrane compositions to normal cells.
Peptides used in the research described here were of amphibian origin, but there are
many other similar peptides also found in other kinds of organisms (Tossi et al., 2000).
Genomics and proteomics approaches are oriented at deciphering the genomes and
proteomes of as many species as possible, some of which are endangered. There are, for
example, almost 6000 species of anurans, but only two genomes have been decoded until
now (Li et al., 2007; Yang et al., 2012). This has led us to explore other less direct methods
for finding possible novel AMPs, presently hidden in the proteomes, genomes or data listed
in protein, DNA or cDNA databases. Some of the results have been published in Juretić et al.,
2011 and Tessera et al., 2012. In the end, we can conclude that the field of AMPs offers
many possibilities to explore.
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5. Conclusion
The “Designer” algorithm is capable of proposing selective, amphipathic  helical
antimicrobial peptides, that we have named adepantins (ADPs). Tests performed on ADPs
confirmed the efficacy and robustness of the algorithm, and in particular of the D-descriptor
parameter, to help identify or propose selective AMP sequences, as well as give some insight
into the mode of action of this large and important class of antimicrobial peptides (AMPs).
ADPs are highly selective and quite potent against Gram-negative bacteria, especially E. coli,
as the algorithm was trained on activity data for this type of bacterium. On the other hand, it
is at the moment lacking the necessary features for Gram-positive bacteria. These
characteristics combined with the fact that ADPs express low cytotoxicity against host cells,
make ADPs potential tools for exploring selectivity mechanisms in AMPs.
ADPs are short, linear, 23 AA residue long peptides rich in Gly and Lys. In contact with
anionic membranes ADPs structure into  helical active forms which can insert into and then
permeabilize these membranes. On the other hand, when in the contact with neutral
membranes ADPs remain in random coil conformation, and it appears that they only interact
with the surface of this kind of membranes. Covalently dimerised versions of ADPs showed
that dimerization significantly impacts on both antimicrobial activity and cytotoxicity
towards host cells. Taken together, experiments described in this thesis have confirmed that
the “Designer” algorithm is a valid AMP design method, and suggest possible improvements
in order to design optimized variants that may be developed as useful anti-infective agents.
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Abstracts
Abstract
As an important part of the innate immune system of all organisms, antimicrobial peptides,
are considered as a possible solution for fighting bacteria resistant to standard antibiotics. Crucial
characteristic of peptide antibiotic, as drug candidate is its high selectivity, parameterized as the ratio
of concentration causing 50% haemolysis (HC50) against erythrocytes and the minimal inhibitory
concentration (MIC) against the reference bacterium Escherichia coli. Using the “Designer” algorithm
adepantins were designed - highly selective artificial glycine and lysine rich peptides in predominant
helical conformation, having less than 50% homology of primary sequence to any known sequence
of antimicrobial peptides. The algoritham used our database of anuran antimicrobial peptides with
known selectivity index.
Structure and activity of adepantins were experimentally and computationally tested in their
monomeric, dimeric and fluorescently labelled form. Experimental investigations performed on
different bacteria strains showed high selectivity of adepantins for Gram-negative bacteria (MIC = 0.5
- 4 µM), especially E. coli. In membrane permeabilization measurements, different membrane
models were used and adepantins showed rapid permeabilization of both membranes of E. coli.
These tests provided insight in their mode of action. All monomeric adepantins have exceptionally
low haemolytic activity, while dimers expressed certain toxicity against host cells. It is proven that
adepantins bind efficiently to the cell surface of the host cell membranes without subsequent
membrane damage. Gathered results confirmed that adepantins are indeed highly selective artificial
peptide antibiotics.
Sažetak
Kao važan dio urođenog imunološkog sustava svih živih bića, antimikrobni peptidi, smatraju
se možebitnim riješenjem u brobi protiv bakterija otpornih na standardne antibiotike. Važna osobina
dobrog kandidata za budući lijek njegova je selektivnost, koja se određuje kao omjer koncentracije pri
kojoj se opaža 50%-tna hemolitična aktivnost prema eritrocitima i minimalne inhibitorne
koncentracije pri kojoj se opaža 100%-tna inhibicija rasta bakterije Escherichije coli. Algoritmom
„Designer“ dizajnirani su adepantini – veoma selektivni umjetni peptidi u konformaciji  uzvojnice,
bogati glicinom i lizinom, a sličnost njihovih sekvenci s poznatim antimikrobnim peptidima manja je
od 50%. Algoritam je koristio našu bazu podataka antimikrobnih peptida iz anura s poznatim
indeksom selektivnosti.
Eksperimentalnim i računalnim metodama istražene su strukture i aktivnosti monomera,
dimera i fluorescentno označenih oblika adepantina. Eksperimentalna istraživanja provedena na
različitim sojevima bakterija pokazala su visoku selektivnost adepantina prema Gram-negativnim
bakterijama (MIC = 0.5 - 4 µM), naročito prema E. coli. U mjerenju propusnosti membrana rabljeni su
različiti modeli membrana, a pokazalo se da adepantini vrlo brzo povećavaju propusnost obje
membrane E. coli. Time je dobiven uvid u mehanizme djelovanja adepantina. Svi monomeri
adepantina imaju izrazito malu hemolitičnost prema eritrocitima, dok su dimeri pokazali određenu
toksičnost prema ljudskim stanicama. Dokazano je da se adepantini vežu na staničnu površinu
ljudskih stanica bez popratnog oštećenja membrane. Prikupljeni rezultati potvrdili su adepantine kao
jako selektivne umjetne peptidne antibiotike.
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Appendix 1. “Set of AMPad peptides” (SAP) that forms AMPad
database.
Peptide name Peptide sequence
„testing“ set HC50(M) MIC(M) TI(exp)
1 Magainin 2 analogue F5W GIGKWLHSAKKFGKAFVGEIMNS 1000,00 8,00 125,00
2 Pseudin 2 analogue K3, K10, K14 GLKALKKVFKGIHKAIKLINNHVQ 330,00 5,00 66,00
3 Magainin-analogue-12W-MG2 GIGKFLHSAKKWGKAFVGEIMNS 550,00 12,50 44,00
4 Pseudin 2 analogue F19 GLNALKKVFQGIHEAIKLFNNHVQ 430,00 10,00 43,00
5 Brevinin-2PRc GLMSVLKGVLKTAGKHIFKNGGSLLDQAKCKISGQC 125,00 3,00 41,66
6 Temporin-1DRa-Lys-7 HFLGTLKNLAKKIL-NH2 330,00 8,00 41,25
7 Esculentin-1ARb GLFPKFNKKKVKTGIFDIIKTVGKEAGMDVLRTGIDVIGCKIKGEC 120,00 3,00 40,00
8 Ranatuerin-2CSa GILSSFKGVAKGVAKGVAKDLAGKLLETLKCKITGC 150,00 4,00 37,50
9 Brevinin-2TSa GIMSLFKGVLKTAGKHVAGSLVDQLKCKITGGC 100,00 3,00 33,33
10 Brevinin-2PRd GLMSVLKGVLKTAGKHIFKNVGGSLLDQAKCKITGQC 100,00 3,00 33,33
11 Brevinin-2PRe GLLSVLKGVLKTAGKHIFKNVGGSLLDQAKCKISGQC 80,00 3,00 26,67
12 Dermaseptin-L1 GLWSKIKEAAKAAGKAALNAVTGLVNQGDQPS 200,00 8,00 25,00
13 Ranatuerin-2BYa GILSTFKGLAKGVAKDLAGNLLDKFKCKITGC 120,00 5,00 24,00
14 Ranatuerin 1 analogue K8 SMLSVLKKLGKVGLGFVACKINKQC 110,00 5,00 22,00
15 Brevinin-2PRb GLMSLFRGVLKTAGKHIFKNVGGSLLDQAKCKITGEC 65,00 3,00 21,67
16 Dermaseptin-S4-N-term-derivative ALWKTLLKKVLKA 50,00 4,50 11,11
17 Ascaphin-8 GFKDLLKGAAKALVKTVLF 55,00 6,00 9,17
18 Magainin analog MG-H2 IIKKFLHSIWKFGKAFVGEIMNI 16,00 2,00 8,00
19 Dybowskin-4 VWPLGLVICKALKIC 60,40 9,10 6,64
20 Dermaseptin K4-S4(1-16)a ALWKTLLKKVLKAAAK 15,00 2,50 6,00
21 Temporin-1DRa-Lys-8 HFLGTLVKLAKKIL 38,00 8,00 4,75
22 Ranatuerin 1 analogue A22 SMLSVLKNLGKVGLGFVACKIAKQC 40,00 10,00 4,00
23 Temporin-1DRa HFLGTLVNLAKKIL 70,00 20,00 3,50
24 Temporin-1Va FLSSIGKILGNLL 120,00 40,00 3,00
25 Brevinin-1BYa (Ser18, Ser24) FLPILASLAAKFGPKLFSLVTKKS 80,00 40,00 2,00
26 Temporin-1AR FLPIVGRLISGLL 210,00 125,00 1,68
27 Temporin-1CSd NFLGTLVNLAKKIL 50,00 64,00 0,78
28 Brevinin-Alb FLPLAVSLAANFLPKLFCKITKKC 1,88 2,44 0,77
29 Temporin-1CSb FLPIIGKLLSGLL 95,00 128,00 0,74
30 Brevinin-1SPd FFPIIAGMAAKVICAITKKC 8,00 13,00 0,62
31 Temporin-1CSa FLPIVGKLLSGLL 75,00 128,00 0,59
32 Brevinin-1BYa FLPILASLAAKFGPKLFCLVTKKC 10,00 20,00 0,50
33 Brevinin-1AUa FLPILAGLAAKLVPKVFCSITKKC 5,00 13,00 0,39
34 Brevinin-1AUb FLPILAGLAANILPKVFCSITKKC 7,00 25,00 0,28
35 Brevinin-1BYb FLPILASLAAKLGPKLFCLVTKKC 4,00 16,00 0,25
36 Magainin analogue MG-H1 GIKKFLHIIWKFIKAFVGEIMNS 2,90 16,00 0,18
37 Brevinin-1CSa FLPILAGLAAKIVPKLFCLATKKC 5,00 32,00 0,16
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„training“ set HC50(M) MIC(M) TI(exp)
1 PGLA GMASKAGAIAGKIAKVALKAL-NH2 900,00 8,60 104,65
2 ESCULENTIN-1ARa GIFSKINKKKAKTGLFNIIKTVGKEAGMDVIRAGIDTISCKIKGEC 180,00 2,00 90,00
3 ASCAPHIN 1 GFRDVLKGAAKAFVKTVAGHIAN-NH2 200,00 3,00 66,67
4 DERMASEPTIN 3 ALWKNMLKGIGKLAGKAALGAVKKLVGAES 50,00 0,80 62,50
5 RANATUERIN-2AUa GILSSFKGVAKGVAKNLAGKLLDELKCKITGC 290,00 5,00 58,00
6 XPF GWASKIGQTLGKIAKVGLKELIQPK-NH2 375,40 8,80 42,66
7 ESCULENTIN-1GRA GLFSKFAGKGIKNLIFKGVKHIGKEVGMDVIRTGIDVAGCKIKGEC 210,00 6,00 35,00
8 PEXIGANAN GIGKFLKKAKKFGKAFVKILKK 45,00 1,50 30,00
9 BREVININ-2GRb GVLGTVKNLLIGAGKSAAQSVLKTLSCKLSNDC 180,00 6,00 30,00
10 DERMASEPTIN 1 ALWKTMLKKLGTMALHAGKAALGAAADTISQGTQ 40,00 1,50 26,67
11 MAGAININ 2 GIGKFLHSAKKFGKAFVGEIMNS 1000,00 50,00 20,00
12 PSEUDIN 2 GLNALKKVFQGIHEAIKLINNHVQ 360,00 20,00 18,00
13 PENTADACTYLIN GLLDTLKGAAKNVVGSLASKVMEKL 400,00 25,00 16,00
14 XT-1 GFLGPLLKLAAKGVAKVIPHLIPSRQQ 90,00 6,00 15,00
15 XT-7 GLLGPLLKIAAKVGSNLL 70,00 5,00 14,00
16 NIGROCIN-2GRb GLFGKILGVGKKVLCGLSGMC 40,00 3,00 13,30
17 DRP-PBN2 GLVTSLIKGAGKLLGGLFGSVTGGQS 75,00 6,25 12,00
18 NIGROCIN-2GRa GLLSGILGAGKHIVCGLSGLC 295,00 25,00 11,80
19 RANATUERIN-2PRa GLMDVFKGAAKNLLASALDKIRCKVTKC 150,00 13,00 11,54
20 RANATUERIN-1 SMLSVLKNLGKVGLGFVACKINKQC 150,00 13,00 11,54
21 BREVININ-2GRa GLLDTFKNLALNAAKSAGVSVLNSLSCKLSKTC 140,00 12,50 11,20
22 GAEGURIN 4 D16W GILDTLKQFAKGVGKWLVKGAAQGVLSTVSCKLAKTC 26,00 2,60 10,00
23 BREVININ-2PRa GLMSLFKGVLKTAGKHIFKNVGGSLLDQAKCKITGEC 55,00 6,00 9,17
24 RANATUERIN-2ARb GILDTIKNAAKTVAVGLLEKIKCKMTGC 150,00 17,00 8,82
25 BREVININ-2GRc GLFTLIKGAAKLIGKTVAKEAGKTGLELMACKITNQC 100,00 12,50 8,00
26 KASSINATUERIN-1 GFMKYIGPLIPHAVKAISDLI 30,00 4,00 7,50
27 TEMPORIN-1TGb AVDLAKIANKVLSSLF 250,00 37,50 6,67
28 RV-23 RIGVLLARLPKLFSLFKLMGKKV 35,00 6,00 5,83
29 BREVININ-2 RELATED PEPTIDE GIWDTIKSMGKVFAGKILQNL 70,00 13,00 5,38
30 DERMASEPTIN 5 GLWSKIKTAGKSVAKAAAKAAVKAVTNAV 60,00 35,00 1,71
31 BREVININ-1SPA FFPIIAGMAAKLIPSLFCKITKKC 7,00 13,00 0,54
32 BREVININ-1TSA FLGSIVGALASALPSLISKIRN 12,00 25,00 0,48
33 MELITTIN RELATED PEPTIDE AIGSILGALAKGLPTLISWIKNR 8,00 20,00 0,40
34 DERMASEPTIN 4 ALWMTLLKKVLKAAAKAALNAVLVGANA 1,40 4,30 0,33
35 BREVININ-1E FLPLLAGLAANFLPKIFCKITRKC 0,41 2,33 0,18
36 BREVININ-1PRA FLSLALAALPKLFCLIFKKC 7,00 100,00 0,07
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Appendix 2. Contribution to the sequent moment of each AA for Janin
and Guy scale - ADP1
Adepantin 1 (GIGKHVGKALKGLKGLLKGLGES)
AA x coordinate
Janin scale
y coordinate
Janin scale
x coordinate
Guy scale
y coordinate
Guy scale
G 0.00000 2.53415 0.00000 0.78423
I 0.06699 0.93669 -0.08031 -1.12279
G 0.01009 0.07018 -0.04679 -0.32540
K 0.30871 1.41910 0.11524 0.52976
H 0.15568 0.53020 -0.20187 -0.68752
V -0.04115 -0.11033 -0.27407 -0.73482
G 0.05247 0.11490 -0.16110 -0.35275
K 0.16785 0.30739 -0.02426 -0.04442
A -0.20257 -0.31520 -0.32048 -0.49867
L -0.08964 -0.11975 -0.41354 -0.55243
K 0.42453 0.48993 0.10747 0.12402
G 0.13500 0.13500 -0.01819 -0.01819
L -0.19776 -0.17136 -0.46636 -0.40410
K 0.40193 0.30088 0.15208 0.11384
G 0.25055 0.16102 0.23472 0.15085
L 0.07089 0.03871 -0.35020 -0.19122
L 0.10739 0.04904 -0.25473 -0.11633
K 0.30212 0.11268 0.17389 0.06486
G 0.12105 0.03554 0.03212 0.00943
L -0.28645 -0.06231 -0.61433 -0.13364
G -0.10058 -0.01446 -0.20656 -0.02970
E -0.11491 -0.00822 -0.61610 -0.04406
S -0.30647 0.00000 -0.63323 0.00000
sequent
moment
1.23572 6.43379 -3.86658 -3.47905
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Appendix 3. Contribution to the sequent moment of each AA for Janin
and Guy scale - ADP2
Adepantin 2 (GIGKHVGKALKGLKGLLKGLGEC)
AA x coordinate
Janin scale
y coordinate
Janin scale
x coordinate
Guy scale
y coordinate
Guy scale
G 0.00000 2.53415 0.00000 0.78423
I 0.06699 0.93669 -0.08031 -1.12279
G 0.01009 0.07018 -0.04679 -0.32540
K 0.30871 1.41910 0.11524 0.52976
H 0.15568 0.53020 -0.20187 -0.68752
V -0.04115 -0.11033 -0.27407 -0.73482
G 0.05247 0.11490 -0.16110 -0.35275
K 0.16785 0.30739 -0.02426 -0.04442
A -0.20257 -0.31520 -0.32048 -0.49867
L -0.08964 -0.11975 -0.41354 -0.55243
K 0.42453 0.48993 0.10747 0.12402
G 0.13500 0.13500 -0.01819 -0.01819
L -0.19776 -0.17136 -0.46636 -0.40410
K 0.40193 0.30088 0.15208 0.11384
G 0.25055 0.16102 0.23472 0.15085
L 0.07089 0.03871 -0.35020 -0.19122
L 0.10739 0.04904 -0.25473 -0.11633
K 0.85515 0.31896 0.48051 0.17922
G 0.78723 0.23115 0.40148 0.11788
L 0.55329 0.12036 -0.14874 -0.03236
G 1.05871 0.15222 0.43620 0.06272
E 1.92617 0.13776 0.51555 0.03687
C -0.30647 0.00000 -0.63323 0.00000
sequent
moment
6.49506 7.33101 -0.95061 -2.98160
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Appendix 4. Contribution to the sequent moment of each AA for Janin
and Guy scale - ADP3
Adepantin 3 (GLKGLLGKALKGIGKHIGKAQGC)
AA x coordinate
Janin scale
y coordinate
Janin scale
x coordinate
Guy scale
y coordinate
Guy scale
G -0.00000 -0.44399 -0.00000 -0.18396
L -0.08258 -1.15462 -0.17967 -2.51201
K 0.23250 1.61704 0.16977 1.18073
G 0.19775 0.90902 0.15388 0.70735
L 0.05941 0.20232 -0.15516 -0.52844
L 0.02930 0.07856 -0.16307 -0.43721
G 0.08908 0.19505 -0.01200 -0.02628
K 0.35364 0.64764 0.06866 0.12574
A 0.40164 0.62496 0.04721 0.07346
L 0.13257 0.17709 -0.30241 -0.40397
K 0.24039 0.27743 -0.05085 -0.05868
G 0.10727 0.10727 -0.26510 -0.26510
I -0.07552 -0.06544 -0.50298 -0.43583
G 0.11428 0.08555 -0.28243 -0.21143
K 0.37782 0.24281 -0.11260 -0.07236
H -0.04941 -0.02698 -0.81633 -0.44575
I -0.13051 -0.05960 -0.73813 -0.33709
G 0.46940 0.17508 -0.21504 -0.08021
K 0.50685 0.14882 -0.16827 -0.04941
A 0.70787 0.15399 -0.25876 -0.05629
Q 0.76920 0.11059 -0.27217 -0.03913
G 1.11985 0.08009 0.15402 0.01102
C -0.30647 0.00000 -0.68941 0.00000
sequent
moment
5.26429 4.08268 -4.59085 -4.04486
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Appendix 5. Table of amino acid scales from Split 3.5 algorithm [7] used
for finding D-descriptor
NO ABREVIATION
NAME OF THE
SCALE REFERENCE
1 KYTDO Kyte and Doolittle
Kyte&Doolittle hydropathy values of amino acid residues. Selected (H) as published
in: J. Kyte and R.F. Doolittle: "A Simple Method for Displaying the Hydropathic
Character of a Protein". J. Mol. Biol. 157(1982)105-132.
2 FAUPL Fauchere and Pliska
Fauchere & Pliska scale of solution hydrophobicities for N-acetyl-amino-acid amides
octanol/water distribution. Selected normalized (H) according to published values: J.-
L. Fauchere and V. Pliska: "Hydrophobic parameters pi of amino-acid side chains
from the partitioning of N-acetyl-amino-acid amides". Eur.J.Med.Chem. - Chim. Ther.
18(1983)369-375
3 PONNU Ponnuswamy
Surrounding hydrophobicity scale. Selected normalized values (H) as published in the
Cornette 1987 paper (reference from Cornette (27) scale) based on: P.K.
Ponnuswamy, M. Prabhakaran and P. Manavalan Biochim. Biophys. Acta 623 (1980),
301-316.
4 ENGEL Engelman
Engelman hydrophobicity values. Selected (H) with opposite sign from: D.M.
Engelman, T.A. Steitz and A. Goldman: "Identifying Nonpolar Transbilayer Helices in
Amino Acid Sequences of Membrane Proteins". Ann.Rev.Biophys.Biophys.Chem.
15(1986), 321-353.
5 JANIN Janin
DeltaG-transfer from buried interior to solvent accessible surface. Selected
normalized values (H) as published in the Cornette 1987 paper (reference from
Cornette (27) scale) based on: J. Janin, Nature 277 (1979), 491-492.
6 JONES Jones
Hydrophobicity scale (H)(NOZAKI-TANFORD-JONES). New version normalized
differently and with slight difference in the His value is not taken here but can be
found in: M. Mutter, F. Master & K.-H. Altman (1985) Biopolymers 24, 1057-1074.
Normalized values in Cornette 1987 paper derived from: D.D. Jones: "Amino Acid
Properties and Side-chain Orientation in Proteins: A Cross Correlation Approach".
J.Theor.Biol. 50(1975)167-183.
7 GUY-M Guy
Average of four hydrophobicity scales. Selected normalized values (H) as published in
the Cornette 1987 paper (reference from Cornette (27) scale) based on: H.R. Guy:
"Amino acid side-chain partition energies and distribution of residues in soluble
proteins". Biophys.J. 47 (1985), 61-70.
8 KRIGK
Krigbaum and
Komoriya
Ethanol to H2O interaction parameter (C). Selected normalized values from Cornette
1987 paper are derived from: W.R. Krigbaum and A. Komoriya Biochim. Biophys.
Acta 576(1979)204-228.
9 VHEBL
von Heijne and
Blomberg
Coil in water to helix in membrane values. Selected (H) as published in: G. von Heijne
and C. Blomberg Eur.J.Biochem. 97(1979)175-181.
10 EIMCL
Eisenberg and
McLachlan
Solvation energy (P). Normalized values from Cornette 1987 paper derived from: D.
Eisenberg and A.D. McLachlan: "Solvation energy in protein folding and binding".
Nature 319(1986)199-203. Table 1, third column.
11 LEVIT Levitt
Hydrophobicity values (H) Statistical scale of hydrophobicity based on information
theory of the observed solvent accessibility of residues in proteins of known
structure. M. Levitt, J.Mol.Biol. 104(1976)59-107.
12 GIBRA Gibrat
Distribution of residues toward protein interior. Scale (H) normalized as ax+b with
a=0.02675, b=2a so that glycine is associated with 0.0. For larger positive values
residue is more often in the interior of a protein. J.F. Gibrat: "Modelization by
Computers of the 3-D Structure of Proteins". Ph.D. thesis. Univ. of Paris VI, Paris,
France. Scale collected from: G.D. Fasman: "Prediction of Protein Structure and the
Principles of Protein Conformation", Plenum, New York 1989, page 457, Table XVII.
13 CIDAA Cid
Hydrophobicity scale (H) for proteins of aa class, Ponnuswamy's 1980 procedure was
used. Selected normalized values based on reported values in: H.Cid, M. Bunster, M.
Canales and F. Gazitua: "Hydrophobicity and structural classes in proteins" Protein
Engineering 5 (1992), 373-375.
14 CIDBB Cid
Hydrophobicity scale (H) for proteins of bb class. Published values normalized to
average=0, sigma=1. The same Cid reference as above.
15 CIDA+ Cid
Hydrophobicity scale (H) for proteins of a+b class. Published values normalized to
average=0, sigma=1. The same Cid reference as above
16 CIDAB Cid
Hydrophobicity scale (H) for proteins of a/b class. Published values normalized to
average=0, sigma=1. The same Cid reference as above.
17 PONG1
Ponnuswamy and
Gromiha
Globular protein surrounding hydrophobicity scale. Selected published values (H)
from: P.K. Ponnuswamy and M.M. Gromiha: "Prediction of transmembrane helices
from hydrophobic characteristics of proteins". Int. J. Peptide Protein Res. 42 (1993),
326-341.
18 PONG2
Ponnuswamy and
Gromiha
Membrane protein surrounding hydrophobicity (H) scale from the Ponnuswamy and
Gromiha 1993 reference (above).
19 PONG3 Ponnuswamy and Membrane protein surrounding hydrophobicity (H) scale (combined membrane
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Gromiha scale) from the Ponnuswamy and Gromiha 1993 reference (above).
20 KIDER Kidera
Hydrophobicity-related scale (H). All published values multiplied with -1. A. Kidera, Y.
Konishi, M. Oka, T. Ooi and A. Scheraga "Statistical Analysis of the Physical Properties
of the 20 Naturally Occuring Amino Acids". J. Prot. Chem. 4 (1985), 23-55.
21 ROSEM Roseman
Calculated values (H) for hydrophathy based on the transfer of solutes from water to
alkalane solvents. Free energy changes are corrected for self-solvation. All published
values are multiplied by -1 to associate positive numbers with Phe, Ile, Leu, Val. M.A.
Roseman: "Hydrophilicity of Polar Amino Acid Side-chains is Markedly Reduced by
Flanking Peptide Bonds". J. Mol. Biol. 200 (1988), 513-522.
22 WOLFE Wolfenden
Wolfenden hydrophobicity scale (H) with proline. R.M. Sweet and D. Eisenberg:
"Correlation of Sequence Hydrophobicities Measures Similarity in Three-Dimensional
Protein Structure". J.Mol.Biol. 171(1983)479-488. R.V. Wolfenden, P.M. Cullis and
C.C.F. Southgate Science, 206 (1979) 575-577.
23 CHOTA Chothia
Chothia residue accessible surface area in tripeptide (H). Selected H as published but
surface area in nm squared. C. Chothia: "The Nature of the Accessible and Buried
Surfaces in Proteins". J. Mol. Biol. 105 (1976), 1-14.
24 ROSEB Rose
Array (H) for Rose mean area buried on transfer from the standard state ( extended
tripeptide ) to the folded protein ( proportional to the hydrophobic contribution to
dG(conf)). All values expressed as nm squared. G.D. Rose, A.R. Geselowitz, G.J.
Lesser, R.H. Lee and M.H. Zehfus: "Hydrophobicity of Amino Acid Residues in
Globular Proteins".Science 229 (1985), 834-838.
25 ROSEA Rose
Array for Rose standard state accessibility (H). Selected as published but area
expressed in nm squared. G.D. Rose, A.R. Geselowitz, G.J. Lesser, R.H. Lee and M.H.
Zehfus: "Hydrophobicity of Amino Acid Residues in Globular Proteins". Science
229(1985)834-838. (second column in Table 1.).
26 EISEN Eisenberg
Eisenberg normalized consensus hydrophobicity values. Average of 5 other scales.
Selected (H) normalized values as published in: D. Eisenberg, E. Schwarz, M.
Komaromy and R. Wall: " Analysis of Membrane and Surface Protein Sequences with
the Hydrophobic Moment Plot". J. Mol. Biol. 179 (1984), 125-142.
27 PRIFT Cornette
Optimal amphipathic helixes. Selected normalized values (S) as published in: J.L.
Cornette, K.B. Cease, H. Margalit, J.L. Spouge, J.A. Berzofsky and C. DeLisi:
"Hydrophobicity Scales and Computational Techniques for Detecting Amphipathic
Structures in Proteins". J.Mol.Biol. 196 (1987), 659-685.
28 HOPPW Hopp and Woods
Antigenic determinant scale (B). Normalized values from Cornette 1987 paper
derived from: T.P. Hopp and K.R. Woods: "Prediction of protein antigenic
determinants from amino acid sequences". Proc. Natl. Acad. Sci. USA 78 (1981),
3824-3828.
29 CHOTH Chothia
Proportion of residues that are 95% buried. Selected normalized (H) according to the
paper: C. Chothia: "The Nature of the Accessible and Buried Surfaces in Proteins". J.
Mol. Biol. 105 (1976), 1-14.
30 ROSEF Rose
Mean fractional area loss. Selected normalized values (H) as published in the
Cornette 1987 paper (reference from Cornette (27) scale) based on: G.D. Rose, A.R.
Geselowitz, G.J. Lesser, R.H. Lee and M.H. Zehfus: "Hydrophobicity of Amino Acid
Residues in Globular Proteins". Science 229(1985)834-838.
31 GUYFE Guy
Transfer free energy for 6 layers. Values for Trp, Tyr, Lys and Arg obtained by
summing polar (positive) and apolar (negative) contribution. All values (H)
normalized by Cornette (1987) and multiplied with -1. Original attributes published
in the paper: H.R. Guy: "Amino acid side-chain partition energies and distribution of
residues in soluble proteins". Biophys.J. 47(1985)61-70.
32 SWEET Sweet and Eisenberg
Optimal matching hydrophobicity scale. Selected normalized values (H) as published
in the Cornette 1987 paper (reference from Cornette (27) scale) based on: R.M.
Sweet and D. Eisenberg: "Correlation of Sequence Hydrophobicities Measures
Similarity in Three-Dimensional Protein Structure". J.Mol.Biol. 171(1983)479-488.
33 KUNTZ Kuntz
Hydration (H2O that does not freeze) Selected normalized values (P) as published in
the Cornette 1987 paper (reference from Cornette (27) scale) based on: Selected
normalized values (P) as published in the Cornette 1987 paper (reference from
Cornette (27) scale) based on: I.D. Kuntz, J.Am.Chem.Soc. 93(1971)514-516.
34 BULDG Bull and Bresse
Surface tension of water (P). H.B. Bull and K. Bresse Arch.Biochem.Biophys.
161(1973)665-670.
35 NNEIG Cornette
Eigenvalues of nearest neighbor matrix. Selected normalized values (H) as published
in the Cornette 1987 paper (reference from Cornette (27) scale).
36 COHEN Cohen and Kuntz
Nonpolar area for residues in isolated beta sheets. Selected values (H) are published
values/100. Published values are from Fasman's 1989 book (see above) page 669,
Table IX, column IV. F.E. Cohen and I.D. Kuntz: "Tertiary Structure Prediction", p 647-
705 from Fasman's 1989 book.
37 KIMBE Kim and Berg
Thermodynamic beta-sheet propensities (S) All published values were multiplied
with -1 in order to associate larger positive values with beta forming residues. The
value for Pro was taken to be 0.23 according to: C.K. Smith, J.M. Withka and L.
Regan: "A thermodynamic Scale for the beta-Sheet Forming Tendencies of the Amino
Acids". Biochemistry 33 (1994), 5510-5517. C.A. Kim and J.M. Berg, Nature:
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"Thermodynamic beta-sheet propensities measured using a zinc-finger host
peptide". Nature 362 (1993) 267-270.
38 MINKI Minor and Kim
Beta-sheet propensities (S) D.L.Minor jr.,P.S.Kim, Nature, vol.367,no.6464 (1994)
660-665.
39 MEIRO Meirovitch
Average normalized distance of the alpha-carbon of amino acid X from the center of
the protein. Normalization by the radius of gyration. Normalized values (H) in
Cornette 1987 paper derived from: H. Meirovitch, S. Rackovsky and H.A. Scheraga,
Macromolecules 13 (1980), 1398-1405.
40 JACWH Jacobs and White
Jacobs & White weights from their IFH scale (H): R. Jacobs and S.H. White: " The
nature of the hydrophobic bonding of small peptides at the bilayer interface:
implications for the insertion of transbilayer helices." Biochemistry 28 (1989), 3421-
3437.
41 ZAMYA Zamyatin
Partial specific volume = increase in volume of water after adding one gram of
residue expressed in cubic centimeters per gram. This physical property scale (P) can
be found in: T.E. Creighton: "Proteins. Structural and Molecular Properties".
Freeman, New York 1992, p. 143, Table 4.3 A.A. Zamyatin, Ann. Rev. Biophys. Bioeng.
13 (1984), 145-165.
42 MIJER
Miyazava and
Jernigan
An average contact energy scale (P). Selected normalized values from Cornette 1987
reference are derived from: S. Miyazava and R.L. Jernigan, Macromolecules
18(1985)534-552.
43 KUHLE Kuhn and Leigh
Membrane propensity scale. Selected (S) as published in: L.A. Kuhn and J.S. Leigh: "A
statistical technique for predicting membrane protein structure". Biochim. Biophys.
Acta 828(1985)351-361.
44 DEBER Deber
M/A ratio in membrane transport proteins. Selected (S) as published with 1.0
subtracted from each value. C.M. Deber, C.J. Brandl, R.B. Deber, L.C. Hsu and X.K.
Young:" Amino Acid Composition of the Membrane and Aqueous Domains of Integral
Membrane Proteins". Archives of Biochem. and Biophys. 251(1986) 68-76.
45 WERSC Wertz and Scheraga
Scheraga ratio of in/out residues. Selected normalized values from Cornette 1987
reference are derived from: D.H. Wertz and H.A. Scheraga Macromolecules
11(1978)9-15.
46 NEILD O'Neil and DeGrado
Helix formation parameters (C) - the differences in the free energies of helix
stabilization for each amino acid relative to Gly (in kcal/mol). More negative values
are more helix favoring. Ala is the most helix favoring residue ! One should multiply
each value with -1 and try such scale for the prediction of transmembrane alpha
helices. K.T. O'Neil and W.F. DeGrado: "A Thermodynamic Scale for the Helix-
Forming Tendencies of the Commonly Occurring Amino Acids", Science 250 (1990),
646-651.
47 SCHER Scheraga
Scheraga s values (P). From: J. Wojcik, K.-H. Altmann and H.A. Scheraga, Biopolymers
30 (1990) 12. We took these s values from: K.T. O'Neil and W.F. DeGrado: "A
Thermodynamic Scale for the Helix-Forming Tendencies of the Commonly Occurring
Amino Acids", Science 250(1990), 646-651.
48 JURPE Juretic and Pesic
Statistical (S) scale of beta preferences derived from 8 membrane porins. D. Juretic
and R. Pesic: " A scale of beta- preferences for structure-activity predictions in
membrane proteins". Croatica Chemica Acta 68 (1995) 215-232.
49 HEIJN von Heijne
Scale for transmembrane segments derived with the help of Engelman's scale (4) for
bacterial inner membrane proteins: h=ln(fM/fA). Selected (S) as published in: G. von
Heijne: "Membrane Protein Structure Prediction. Hydrophobicity Analysis and the
Positive-inside Rule. J.Mol.Biol. 225 (1992),487-494.
50 EDEWH Edelman and White
Linear optimization weights. Optimal predictor scale (O) from: J. Edelman and S.H.
White: "Linear Optimization of Predictors for Secondary Structure. Application to
Transbilayer Segments of Membrane Proteins". J. Mol. Biol. 210 (1989), 195-209.
51 EDE31 Edelman-31 Optimal predictors (width 31). Selected (O) as published in Edelman 1993 paper.
52 EDE25 Edelman-25
Optimal predictors (width 25). Selected (O) values are the same as published valuers
except for the Val value of 0.859 instead of 0.559 as in: J.Edelman: "Quadratic
Minimization of Predictors for Protein Secondary Structure. Application to
Transmembrane alpha-Helices". J.Mol.Biol. 232 (1993), 165-191.
53 EDE21 Edelman-21 Selected (O) as published in Edelman 1993 paper.
54 EDE15 Edelman-15 Optimal predictors (width 15). Selected (O) as published in Edelman 1993 paper.
55 FASMA Chou and Fasman
Statistical preferences (S) for the alpha helix conformation in soluble
proteins. Identical values reported in: P.Y. Chou and G.D. Fasman "Prediction of
protein secondary structure" Adv. Enzymol. 47 (1978) 45-148. M. Charton and B.I.
Charton: "The dependence of the Chou-Fasman parameters on amino acid side chain
structure". J. theor. Biol. 102(1983), 121-134.
56 FASMB Chou and Fasman
Beta preferences (S). Reported in the Chou & Fasman review (see above) from Adv.
Enzymol. 47 (1978) 45-148.
57 FASMT Chou and Fasman
Statistical turn preferences (S). Values reported in: P.Y. Chou and G.D. Fasman
"Prediction of protein secondary structure" Adv. Enzymol. 47 (1978) 45-148. M.
Charton and B.I. Charton: "The dependence of the Chou-Fasman parameters on
amino acid side chain structure". J. theor. Biol. 102(1983), 121-134.
58 RICRI Richardson and Middle alpha helix preferences (S): 5-point averages of values N4, N5, Mid, C5 and C4
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Richardson in the Table I from: Richardson & Richardson: Science 240(1988)1648. For full
reference look at scale 60 comment.
59 JURET Juretic
Statistical preferences (S) for alpha and beta conformation averaged for each amino
acid residue. D. Juretic, N. Trinajstic and B. Lucic, "Protein secondary structure
conformations and associated hydrophobicity scales". J. Math. Chem. 14 (1993), 35-
45. Calculated from: G. Deleage and B. Roux: "An algorithm for protein secondary
structure prediction based on class prediction". Protein Engineering 1 (1987), 289-
294. Table I second and fourth column; values from each row averaged. Preference
for alpha and beta conformation reported in: P.Y. Chou and G.D. Fasman "Prediction
of protein secondary structure" Adv. Enzymol. 47 (1978) 45-148.
60 RICH1
Richardson and
Richardson
Mid-alpha preference values (S) from: J.S. Richardson and D.C. Richardson: "Amino
Acid Preferences for Specific Locations at the Ends of alpha Helices. Science 240
(1988), 1648-1652. Same P-mid values are used in the O'Neil & DeGrado 1990
reference.
61 CHOU1 Chou
Statistical preferences (S) for the alpha helix conformation in alpha class soluble
protein. Values from Fasman's 1989 book: G.D. Fasman: "Prediction of Protein
Structure and the Principles of Protein Conformation", Plenum, New York 1989. Page
568 from the chapter: P.Y. Chou: "Prediction of Protein Structural Classes from
Amino Acid Compositions". p 549-586.
62 CHOU2 Chou
Statistical preferences (S) for beta conformation in beta class proteins. Values taken
from the Fasman's 1989 book as for the Chou 66 scale (above).
63 CHOU3 Chou
Statistical (S) preferences for alpha conformation in alpha+beta class
proteins. Values taken from: P.Y. Chou: "Prediction of Protein Structural Classes from
Amino Acid Compositions". p 549-586 in the Fasman's 1989 book: G.D. Fasman:
"Prediction of Protein Structure and the Principles of Protein Conformation",
Plenum, New York 1989.
64 CHOU4 Chou
Statistical preferences (S) for the alpha helix conformation in alpha/beta class
soluble proteins) Fasman's book (see above), page 568.
65 CHOU5 Chou
Statistical (S) preferences for beta conformation in alpha+beta class proteins. Values
taken from: P.Y. Chou: "Prediction of Protein Structural Classes from Amino Acid
Compositions". p 549-586 in the Fasman's 1989 book: G.D. Fasman: "Prediction of
Protein Structure and the Principles of Protein Conformation", Plenum, New York
1989.
66 CHOU6 Chou
Statistical preferences (S) for the alpha helix conformation in soluble alpha/beta
class proteins. class proteins. Values taken from: P.Y. Chou: "Prediction of Protein
Structural Classes from Amino Acid Compositions". p 549-586 in the Fasman's 1989
book: G.D. Fasman: "Prediction of Protein Structure and the Principles of Protein
Conformation", Plenum, New York 1989.
67 MEEKR Meek
Retention times at HPLC (C). J.L. Meek, Proc. Natl. Acad. Sci., USA 77 (1980), 1632-
1636. J.L. Meek
68 KARPL Karplus and Schulz
Karplus flexibility scale (P) from his FIGURE 1a in: P.A. Karplus and G.E. Schulz:
"Prediction of Chain Flexibility in Proteins". Naturwissenschaften 72 (1985), 212-213.
69 MATPO
Mathusamy and
Ponnuswamy
Mean rms fluctational displacements F1 (P). R. Mathusamy and P.K. Ponnuswamy:
"Variation of amino properties in protein secondary structures, alpha- helices and
beta-strands." Int. J.Peptide Protein Res. 35 (1990), 378-395.
70 WOESE Woese
Polarity values (P). All reported values subtracted from number 8 in order to obtain
positive values for less polar residues. M. Di Giulio, M.R. Capobianco and M,
Medugno: "On the Optimization of the Physicochemical Distances between Amino
Acids in the Evolution of Genetic Code". J. theor. Biol. 168 (1994), 43-51 C.R. Woese,
D.H. Dugre, S.A. Dugre, M. Kondo and W.C. Saxinger: "On the fundamental nature
and evolution of the genetic code". Cold Spring Harbor Symp. Quant. Biol. 31 (1966)
723-736.
71 GRANT Grantham
Polarity values (P). Normalized values derived from: R.Grantham: "Amino Acid
Difference Formula to Help Explain Protein Evolution", Science, 185 (1974) 862-864.
72 ZIMMP Zimmerman
Polarity values (P). Published values are divided with 10. D.D. Jones: "Amino Acid
Properties and Side-chain Orientation in Proteins". J. Theor. Biol. 50 (1975), 167-183.
Collected by: J.M. Zimmerman, N. Eliezer and R. Simha: "The Characterization of
Amino Acid Sequences in Proteins by Statistical Methods". J. Theor. Biol. 21 (1968)
170-201. Table 3 third column.
73 MCMER McMeekin
Refractivity values (P). All values from Jones paper divided with 10. D.D. Jones:
"Amino Acid Properties and Side-chain Orientation in Proteins". J. Theor. Biol. 50
(1975), 167-183. Collected by: T.L. McMeekin, M.L. Groves and N.J. Hipp (1964) In
"Amino Acids and Serum Proteins" (J.A. Stekol, ed) p. 54, Washington, D.C.:
American Chemical Society.
74 FAUCH Fauchere
Graph shape index (M). J.-L. Fauchere, M. Charton, L.B. Kier, A. Verloop and V. Pliska:
"Amino acid side chain parameters for correlation studies in biology and
pharmacology". Int. J. Peptide Protein Res. 32 (1988), 269-278.
75 KUBOT Kubota
Relative mutability factor (B). Reported values divided with 100. Y. Kubota, H.
Takahashi, K. Nishikawa and T. Ooi, J. Theor. Biol. 91 (1981), 347.
76 URRY1 Urry The temperature T1 of inverse temperature transition (P). Selected values are 1-
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T1/100. Reported T1 values in: D.W. Urry: "Free energy transduction in polypeptides
and proteins based on inverse temperature transitions" Progress Bioph.& Mol. Biol.
57 (1992), 23-57. Table 1,. column 2.
77 URRY2 Urry
The temperature T1 of inverse temperature transition (P). Selected values are
T1/100. Reported T1 vales from the reference cited above.
78 CASSI Casari and Sippl
Structure-derived hydrophobicity scale (H) G. Casari and M. Sippl: "Structure-derived
Hydrophobic Potential. Hydrophobic Potential Derived from X-ray Structures of
Globular Proteins is able to Identify Native Folds". J. Mol. Biol. 224 (1992), 725-732.
79 MARTI Landolt-Marticorena
Positional preferences for occurrence of residues in the middle segment of single
helix transmembrane spanning segments. Selected (S) as published in: C. Landolt-
Marticorena, K.A. Williams, C.M. Deber, and R.A.F. Reithmeier: 'Non-random
distribution of amino acids in the transmembrane segments of human type I single
span membrane proteins'. J. Mol. Biol. 229 (1993), 602-608.
80 MDK0 Juretic
Scale (H) derived from # 1 (Kyte-Doolittle) in an iterative procedure as described for
Juretic (86).
81 MDK1 Juretic
Scale (H) derived from # 1 (Kyte-Doolittle) in an iterative procedure as described for
Juretic (86).
82 MKD2 Juretic
Scale (H) derived from # 1 (Kyte-Doolittle) in an iterative procedure as described for
Juretic (86).
83 MODKD Juretic
Modified Kyte-Doolittle scale in an iterative procedure. Selected (H) as published in
reference 1. Iterative procedure described in: D. Juretic, B. Lucic and N. Trinajstic,
"Predicting membrane protein secondary structure. Preference functions method for
finding optimal conformational preferences" Croatica Chemica Acta 66 (1993), 201-
208.
84 MKD4 Juretic
Scale (H) derived from # 1 (Kyte-Doolittle) in an iterative procedure as described for
Juretic (86).
85 OSMP1 Juretic
Optimal scale for memb. proteins with one transmembrane helix. Obtained in an
iterative procedure described in: D. Juretic, B. Lucic and N. Trinajstic, "Predicting
membrane protein secondary structure. Preference functions method for finding
optimal conformational preferences" Croatica Chemica Acta 66 (1993), 201-208.
86 OSMP Juretic
Optimal scale (S) for memb. proteins with more than one transmembrane helical
segment. Obtained in an iterative procedure described in: D. Juretic, B. Lucic and N.
Trinajstic, "Predicting membrane protein secondary structure. Preference functions
method for finding optimal conformational preferences" Croatica Chemica Acta 66
(1993), 201-208.
87 JACWH2 Jacobs and White Jacobs & White IFH(0.5) scale (H). Table V in the above reference.
88 CPREF Juretic
Scale of constant preference values extracted from the reference data set of 168
integral membrane proteins. Selected (S) as published in the Juretic at al. reference 1
(see above), but the code number 88 instead of 100 is used by the server.
Appendices Nada Ilić
115
Appendix 6. Preparative RP-HPLC spectra for ADP2(AC) (both synthesis),
[ADP2]2 (both synthesis), ADP2(BY), ADP3(AC), [ADP3]2, ADP3(BY)
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Appendix 7. Analytical RP-HPLC for ADP1 (first testing name was DESC1)
ADP2(AC), [ADP2]2, ADP2(BY), ADP3(AC), [ADP3]2, ADP3(BY), all graphs
overlapped for comparison.
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Appendix 8. ESI - MS and Analytical RP-HPLC for ADP1 (first testing
name was DESC1), PSEU2 (first testing name was PSEU2B), PSEU2 A9
(first testing name was PSEU2A), ASC1 (first testing name was ASC1B),
ASC1 I2 (first testing name was ASC1A).
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